Document:

EX-10.28

 Exhibit 10.28 

THIS ADVANCE is made on 8 March 2022 and effective as of 8 March 2022 

BETWEEN 
  

	(1)	 Aztiq Pharma Partners S.à r.l., a
société à responsabilité limitée incorporated and existing under the laws of the Grand Duchy of Luxembourg, registered with the
Luxembourg Trade and Companies Register under number B147728, having its registered office at 5, rue Heienhaff, L-1736 Senningerberg, Grand Duchy of Luxembourg, (the “Lender”);

 AND 
  

	(2)	 Alvotech Holdings S.A., a société anonyme
incorporated and existing under the laws of the Grand Duchy of Luxembourg, registered with the Luxembourg trade and Companies Register under number B229193, having its registered office at 9 rue de Bitbourg,
L-1273 Luxembourg, Grand Duchy of Luxembourg, (the “Borrower”); 

 each a
“Party” and together the “Parties” to this Advance. 
 RECITALS 

 

	(A)	 The Lender made an interest free advance to the Borrower of an amount of up to USD 25,000,000 on the following
terms (the “Advance”): 

  

	(B)	 The Parties now wish to document the terms of such Advance. 

THE PARTIES HEREBY agree as follows: 
  

	1.	 CONSTRUCTION 

  

	1.1	 Definitions 

When used in this Advance, the following terms have the following meanings: 

“Borrower” has the meaning set out in the above parties section. 

“BCA” means the business combination agreement dated 7 December 2021, entered into, inter alios, by the Borrower and
Oaktree Acquisition Corp. II, a Cayman Island exempt company, registered with the Cayman Islands Companies Register under number 364940. 

“Business Day” means any day on which banks are open for general business in Luxembourg. 

“Lender” has the meaning set out in the above parties section. 

“Party” and “Parties” have the meaning set out in the above parties section. 

  
 1/8 

 “Repayment Date” means (i) the date falling 30 Business Days after the
Second Merger Effective Time under and as defined in the BCA or (ii) in the event that the Second Merger Effective Time (under and as defined in the BCA) does not occur, on the second anniversary of the date on which the Advance was made
available to the Borrower. 
 “Second Merger Effective Time” has the meaning given to that terms in the BCA. 

“TopCo” means Alvotech S.A.S., a simplified joint stock company (société par actions simplifiée)
incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its registered office at 9, rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg and registered with the Luxembourg
Trade and Company Register (Registre de Commerce et des Sociétés, Luxembourg) under number B258884. 
  

	1.2	 Interpretation 

In this Advance: 
  

	 	(a)	 any reference to any agreement is to be construed as a reference to such agreement as it may be amended,
supplemented, modified or extended from time to time, whether before or after the date hereof; 

  

	 	(b)	 a reference to a person or persons is, where relevant, deemed to be a reference to or to include their
respective successors, permitted assignees or transferees, as appropriate; 

  

	 	(c)	 reference to clauses are references to, respectively, clauses of this Advance and reference to this Advance
includes its annexes; 

  

	 	(d)	 a reference to a law or regulation or any provisions thereof is to be construed as a reference to such law,
regulation or provisions as the same may have been, or may from time to time hereafter be, amended or re-enacted; and 

  

	 	(e)	 words denoting the singular include the plural and vice versa; 

 

	 	(f)	 words denoting a gender also include the other gender; 

 

	 	(g)	 words denoting persons include bodies corporate, partnerships, associations and any other organised groups of
persons or entities whether incorporated or not. 

  

	1.3	 Clause headings 

Clause headings are for ease of reference only and shall not affect interpretation. 

  
 2/8 

	2.	 THE ADVANCE 

  

	2.1	 Advance 

Subject to the terms and conditions hereinafter set forth, the Lender agrees to make available to the Borrower as of the date hereof, an
advance (the “Advance”) of up to a maximum amount of twenty-five million U.S. Dollar (USD 25,000,000), on the terms set out in this Agreement. The Borrower may utilise the Advance by making no more than two requests,
substantially in the form set out in the Annex 1, to the Lender (each a “Drawdown Request”) or without any Drawdown Request as mutually agreed by the Parties. Save as otherwise agreed between the Parties, the Lender shall make
available an advance to the Borrower within two (2) Business Days upon receiving a Drawdown Request. 
  

	2.2	 Interest 

The Advance shall bear no interest. 
  

	2.3	 Repayment 

Subject to the terms hereof, the Borrower shall repay the Advance to the Lender in cash and in full on the Repayment Date. 

 

	3.	 MERGER  

  

	3.1	 It is acknowledged by the Parties that at the Second Merger Effective Time, the Borrower will merge with and
into TopCo, with TopCo as the surviving company (as universal successor) in the merger and shall succeed to and assume all the rights and obligations of the Borrower (including rights and obligations hereunder), as details of which are set out in
the BCA. 

  

	3.2	 Unless the context otherwise requires, where there is a reference in this Agreement to the Borrower, on and
after the Second Merger Effective Time, it shall be deemed to include a reference to the TopCo. 

  

	4.	 REPRESENTATIONS 

 

	4.1	 The Lender (i) is a validly organised and existing company under the laws of the Grand-Duchy of
Luxembourg, (ii) has not ceased making, or is not unable to make, payments when they fall due (en état de cessation des paiements) and is not subject to any Insolvency Proceeding and (iii) has the corporate power and
authority to enter into this Agreement and to carry out its obligations hereunder. 

  

	3.1	 The Borrower (i) is a validly organised and existing company under the laws of the Grand-Duchy of
Luxembourg, (ii) has not ceased making, or is not unable to make, payments when they fall due (en état de cessation des paiements) and is not subject to any Insolvency Proceeding and (iii) has the corporate power and
authority to enter into this Agreement and to carry out its obligations hereunder. 

  

	5.	 NO WAIVER 

No failure or delay of a Party to exercise any right or remedy under this Advance shall be considered, or operate as, a waiver thereof, nor
shall any single or partial exercise of any right or remedy preclude any other or further exercise thereof or the exercise of any other right or remedy. 

  
 3/8 

	6.	 AMENDMENTS 

This Advance may only be amended or supplemented by a written agreement signed by all of the Parties. 

 

	7.	 ASSIGNMENT 

The Lender may assign and/or pledge any of its rights under this Advance without the consent of the Borrower. The Lender shall notify any such
assignment to the Borrower. The Borrower may assign any of its rights under this Advance with the prior written consent of the Lender only. 
  

	8.	 NOTICES 

All notices and other communications under this Advance shall be in writing and shall be deemed to have been duly given (i) on the date of
delivery if delivered personally to the Party to whom notice is to be given, or (ii) on the first Business Day after delivery to an international courier service, if properly addressed and all costs prepaid, to the Parties as follows: 

 

					
		  	For the Lender:	  	 Aztiq Pharma Partners S.à r.l.
 5, rue
Heienhaff, L-1736 Senningerberg
 Grand Duchy of Luxembourg

			
		  	For the Borrower:	  	 Alvotech Holdings S.A.
 9, rue de Bitbourg, L-1273 Senningerberg
 Grand Duchy of Luxembourg

 Either Party may change its address for the purpose of this clause by giving the other Party written notice of
its new address. 
  

	9.	 SEVERABILITY 

If one or more of the provisions of this Advance is or becomes invalid, illegal or unenforceable in any respect under any applicable law, the
validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected and any invalid provision shall be deemed to be severable. Each of the Parties agrees in such case to use its best efforts to
negotiate in good faith a legally valid and economically equivalent replacement provision. 
  

	10.	 COSTS 

Each Party shall bear its own costs, fees and expenses incurred in connection with the preparation, negotiation, execution and performance of
this Advance. 
  

	11.	 COUNTERPARTS 

this Advance may be executed in any number of counterparts and by the Parties on separate counterparts, all of which shall together constitute
one instrument. 

  
 4/8 

	12.	 GOVERNING LAW AND JURISDICTION 

This Advance shall be governed by and construed in accordance with the laws of the Grand Duchy of Luxembourg. The Parties irrevocably agree
that any disputes arising out of or in connection with this Advance shall be submitted exclusively to the courts of the City of Luxembourg, Grand Duchy of Luxembourg. 

The Parties have executed this Advance in counterparts, each Party acknowledging receipt of one copy on the date first above written. 

[Remainder of page remains intentionally blank and signature page follows] 

  
 5/8 

 [Signature page - Advance] 

 

			
	THE LENDER	  	
		
	Aztiq Pharma Partners S.à r.l.	  	
		
	/s/ Arni Hardarson	  	/s/ Danny Major
		
	By: Arni Hardarson	  	By: Danny Major
		
	Title: Manager and authorized signatory	  	Title: Manager and authorized signatory

  

			
	THE BORROWER	  	
		
	Alvotech Holdings S.A.	  	
		
	/s/ Robert Wessman	  	/s/ Faysal Kalmoua
		
	By: Robert Wessman	  	By: Faysal Kalmoua
		
	Title: Director and authorized signatory	  	Title: Director and authorized signatory

  
 6/8 

 ANNEX 1 

FORM OF DRAWDOWN REQUEST 
 From:
Alvotech Holdings S.A., a société anonyme incorporated and existing under the laws of the Grand Duchy of Luxembourg, registered with the Luxembourg trade and Companies Register under number B229193, having its
registered office at 9 rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg (the “Borrower”), 

To: Aztiq Pharma Partners S.à r.l., a société à responsabilité limitée incorporated and
existing under the laws of the Grand Duchy of Luxembourg, registered with the Luxembourg Trade and Companies Register under number B147728, having its registered office at 5, rue Heienhaff, L-1736
Senningerberg, Grand Duchy of Luxembourg (the “Lender”). 
 Dated: [date] 

Dear Sirs, 
 Interest-Free Advance Agreement dated [***] made
between us as Borrower and you as Lender 
 Reference is made to the interest-free advance agreement dated [DATE] and made by and between the
Borrower and the Lender, whereby the Lender has agreed to make available to the Borrower an advance of up to a maximum aggregate amount of twenty-five million U.S. Dollar (USD 25,000,000) (the “Agreement”). 

In accordance with Clause 2.1 of the Agreement, we hereby send you a Drawdown Request to confirm that we wish to draw the amount of [***] with effect
as of [***]. 
 We request you to credit the amount of [***] to the bank account with IBAN [***]. 

Capitalised terms not defined in this Drawdown Request have the meaning ascribed to such terms in the Agreement. 

This Drawdown Request shall be governed by and construed in accordance with the laws of the Grand Duchy of Luxembourg. The Parties irrevocably agree that any
disputes arising out of or in connection with this Drawdown Request shall be submitted exclusively to the courts of the city of Luxembourg, Grand Duchy of Luxembourg. 

THE BORROWER 
 Alvotech Holdings S.A. 

 

									
			
	 	 		 	 
					
	 By:
	 		 		 	 By:
	 	
					
	 Title:
	 		 		 	 Title:
	 	

  
 7/8 

 THE LENDER 

Aztiq Pharma Partners S.à r.l. 
  

									
			
	 	 		 	 
					
	 By:
	 		 		 	 By:
	 	
					
	 Title:
	 		 		 	 Title:
	 	

  
 8/8EX-10.29

 Exhibit 10.29 

Execution Version 
 FRE 408 / Confidential 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, 

MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT 

MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS 

PRIVATE OR CONFIDENTIAL. 

SETTLEMENT AND LICENSE AGREEMENT 

THIS SETTLEMENT AND LICENSE AGREEMENT (“Agreement”), effective March 8, 2022
(“Effective Date”), is entered into by and among AbbVie Inc., a corporation organized and existing under the laws of Delaware, having its corporate headquarters at 1 North Waukegan Road, North
Chicago, Illinois 60064, on behalf of itself and its Affiliates, and AbbVie Biotechnology Ltd, a corporation organized and existing under the laws of Bermuda with a place of business at Harbour Fiduciary Services Limited, Thistle House, 4 Burnaby
Street, Hamilton, Pembroke, HM 11, Bermuda (collectively and including their Affiliates, “AbbVie”); and Alvotech hf., a corporation organized and existing under the laws of the Republic of Iceland,
with its corporate headquarters at Saemundargata 15-19, 101 Reykjavik, Iceland (collectively and including their Affiliates “Alvotech”).  

WHEREAS, AbbVie manufactures and markets a fully human anti-TNFα monoclonal antibody with the
brand name HUMIRA® and international non-proprietary name adalimumab (the “Humira Product”), which was invented by AbbVie (or
its predecessors); 
 WHEREAS, AbbVie Inc. owns or has exclusively licensed from AbbVie Biotechnology Ltd more than 100 issued U.S. Patents
related to the Humira Product, the last of which will expire in 2034; 
 WHEREAS, AbbVie Biotechnology Ltd owns or has licensed from AbbVie
Inc. more than 100 issued U.S. Patents related to the Humira Product, the last of which will expire in 2034; 
 WHEREAS, AbbVie markets the
Humira Product in the Territory pursuant to Biologics License Application No. 125057 (together with any replacements or supplements thereto, as amended now or in the future, the “Humira BLA”); 

WHEREAS, Alvotech seeks to market a biosimilar version of the Humira Product pursuant to a marketing authorization to be obtained under the
Biologics Price Competition and Innovation Act (“BPCIA”); 
 WHEREAS, Alvotech has filed two Biologics License
Applications Nos. 761205 and 761299 pursuant to 42 U.S.C. § 262(k) of the BPCIA seeking approval to market a biosimilar, including one designated as interchangeable, of the Humira Product (together with any supplements and replacement thereto,
as amended now or in the future, and any new or supplemental BLA(s) filed for additional presentations, the “Alvotech BLAs”) prior to the expiration of at least one of the U.S. Patents related to the Humira Product;

  

  
 1 

 Execution Version 

FRE 408 / Confidential 
  

 WHEREAS, the patent identification provisions of the BPCIA in connection with the filing of
Biologics License Applications No. 761205 resulted in a list of 65 patents (including those noticed under 42 U.S.C. § 262(l)(7)); 

WHEREAS, on April 27, 2021, pursuant to 42 U.S.C. § 262(l)(6)(B) of the BPCIA, AbbVie brought an action for patent infringement
under the caption AbbVie Inc. et al v. Alvotech hf., C.A. No. 1:21-cv-2258 (N.D. IL) (the “BPCIA (l)(6) Case”) for infringement by the
product in Biologics License Applications No. 761205 of four patents identified pursuant to the procedures of 42 U.S.C. § 262(l)(5) of the BPCIA; AbbVie’s complaint, attached hereto as Exhibit B, summarizes the BPCIA (l)(6) Case; 

WHEREAS, on May 11, 2021, Alvotech served a commercial notice for the product to be manufactured and sold under BLA No. 761205; 

WHEREAS, on May 28, 2021, pursuant to 42 U.S.C. § 262(l)(8) of the BPCIA, AbbVie brought an action for patent infringement under the
caption AbbVie Inc. et al v. Alvotech hf., C.A. No. 1:21-cv-2899 (N.D. IL) (the “BPCIA (l)(8) Case”) (together the BPCIA(l)(6)
Case and the BPCIA (l)(8) Case are defined as “the BPCIA Litigation”) for infringement by the product in Biologics License Applications No. 761205 of 58 additional patents identified pursuant to the
procedures of 42 U.S.C. § 262(l)(5) of the BPCIA; 
 WHEREAS, the complaint in the BPCIA (l)(8) Case was twice amended to add three
additional patents for a total of 61 patents; AbbVie’s second amended complaint, attached hereto as Exhibit C, summarizes the BPCIA (l)(8) Case; 

WHEREAS, the patents asserted in the BPCIA(l)(6) Case and the BPCIA(l)(8) Case are listed on Exhibit A and are defined as the
“BPCIA Litigation Patents”; 
 WHEREAS, on March 19, 2021, AbbVie brought an action for trade secret
misappropriation under the caption AbbVie Inc. et al v. Alvotech hf., C.A. No. 1:21-cv-1530 (N.D. IL); whereas that action was dismissed for lack of personal
jurisdiction on October 6, 2021, which dismissal AbbVie has appealed to the Court of Appeals for the Seventh Circuit, which appeal was docketed as No. 21-3052, which remains pending (“the
7th Circuit Appeal”); 
 WHEREAS, on
December 17, 2021, AbbVie filed a complaint with the United States International Trade Commission (“ITC”) under the caption Certain Adalimumab, Processes for Manufacturing or Relating to Same, and Products Containing
Same; whereas the ITC instituted an investigation against all named respondents (Inv. No. 337-TA-1296), which remains pending (“the ITC Action”);

 WHEREAS, the biosimilar of the Humira Product that is the subject of the Alvotech BLAs may be labeled for indications including, but not
limited to, rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and ankylosing spondylitis and for each indication will have the same route of administration and dosing regimen as the Humira Product; 

WHEREAS, the biosimilar of the Humira Product that is the subject of the Alvotech BLAs may be labeled as interchangeable; 

  
 2 

 Execution Version 

FRE 408 / Confidential 
  

 WHEREAS, AbbVie previously asserted in litigation pursuant to the BPCIA 10 U.S. Patents
related to the Humira Product that AbbVie asserted were infringed by biosimilar products of adalimumab sought to be marketed by Amgen Inc. and Amgen Manufacturing Limited (collectively and including their respective Affiliates,
“Amgen”) and reserved the right to assert at least an additional 51 patents if and when Amgen provided commercial notice of its intent to market its biosimilar adalimumab product; 

WHEREAS, AbbVie and Amgen resolved all pending BPCIA and future patent litigation related to its biosimilar adalimumab product in the U.S. via
a settlement announced publicly on September 28, 2017; 
 WHEREAS, Samsung Bioepis Co., Ltd. (including its Affiliates
“Samsung”) intends to market a biosimilar version of the Humira Product pursuant to the BPCIA, which it identifies as SB5; AbbVie and Samsung resolved all BPCIA disputes related to Samsung’s biosimilar adalimumab product
in the U.S. via a settlement announced publicly on April 5, 2018; 
 WHEREAS, Mylan Pharmaceuticals, Inc. (including its Affiliates
“Mylan”) intends to market a biosimilar version of the Humira Product pursuant to the BPCIA; AbbVie and Mylan resolved all BPCIA disputes related to the Mylan biosimilar adalimumab product in the U.S. via a settlement
announced publicly on July 17, 2018; 
 WHEREAS, AbbVie previously asserted in litigation pursuant to the BPCIA two U.S. Patents
related to the Humira Product that AbbVie asserted were infringed by biosimilar products of adalimumab sought to be marketed by Sandoz Inc., Sandoz International GmbH, and Sandoz GmbH (collectively and including their Affiliates
“Sandoz”) and reserved the right to assert at least an additional 82 patents if and when Sandoz provided commercial notice of its intent to market its biosimilar adalimumab product; 

WHEREAS, AbbVie and Sandoz resolved all pending BPCIA litigation, any pending inter partes review proceedings, and future patent litigation
related to its biosimilar adalimumab product in the U.S. via a settlement announced publicly on October 11, 2018; 
 WHEREAS, Fresenius
Kabi Deutschland GmbH (including its Affiliates “Fresenius”) intends to market a biosimilar version of the Humira Product pursuant to the BPCIA; AbbVie and Fresenius resolved all BPCIA disputes related to the Fresenius
biosimilar adalimumab product in the U.S. via a settlement announced publicly on October 18, 2018; 
 WHEREAS, Momenta Pharmaceuticals,
Inc. (including its Affiliates “Momenta”) intends to market a biosimilar version of the Humira Product pursuant to the BPCIA; AbbVie and Momenta resolved all BPCIA disputes related to the Momenta biosimilar adalimumab product
in the U.S. via a settlement announced publicly on November 6, 2018; 
 WHEREAS, Pfizer Inc. (including its Affiliates
“Pfizer”) intends to market a biosimilar version of the Humira Product pursuant to the BPCIA; AbbVie and Pfizer resolved all BPCIA disputes related to the Pfizer biosimilar adalimumab product in the U.S. via a settlement
announced publicly on November 30, 2018; 

  
 3 

 Execution Version 

FRE 408 / Confidential 
  

 WHEREAS, Coherus BioSciences, Inc. (including its Affiliates,
“Coherus”) intends to market a biosimilar version of the Humira Product pursuant to the BPCIA; AbbVie and Coherus resolved all BPCIA disputes related to the Coherus biosimilar adalimumab product in the U.S. via a settlement
announced publicly on January 25, 2019; 
 WHEREAS, AbbVie previously asserted in litigation pursuant to the BPCIA eight U.S. Patents
related to the Humira Product that AbbVie asserted were infringed by biosimilar products of adalimumab sought to be marketed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals, Inc., and Boehringer Ingelheim Fremont,
Inc. (collectively and including their respective Affiliates, “BI”) and reserved the right to assert at least an additional 66 patents if and when BI provided commercial notice of its intent to market its biosimilar
adalimumab product; 
 WHEREAS, AbbVie and BI resolved all pending BPCIA and future patent litigation related to its biosimilar adalimumab
product in the U.S. via a settlement announced publicly on May 13, 2019; 
 WHEREAS, Celltrion Inc. (including its Affiliates,
“Celltrion”) intends to market a biosimilar version of the Humira Product pursuant to the BPCIA; AbbVie and Celltrion resolved all BPCIA disputes related to the Celltrion biosimilar adalimumab product in the U.S. via a
settlement dated December 10, 2020; 
 WHEREAS, Amgen filed two petitions seeking inter partes review of U.S. Patent Nos.
8,916,157 and 8,916,158, which cover formulations comprising adalimumab; and on January 14, 2016 the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (“PTAB”) denied institution, holding that Amgen
failed to establish a reasonable likelihood that any challenged claim would be held unpatentable; 
 WHEREAS, Coherus Biosciences Inc. filed
a petition seeking inter partes review of U.S. Patent No. 9,114,166, which covers formulations comprising adalimumab; and on November 7, 2016 the PTAB denied institution, holding that Coherus failed to establish a reasonable
likelihood that any challenged claim would be held unpatentable; 
 WHEREAS, Coherus Biosciences Inc. filed four petitions seeking inter
partes review of U.S. Patent No. 9,085,619, which covers formulations comprising adalimumab and which patent is infringed by the biosimilar that is the subject of the Alvotech BLAs; and on September 7, 2017 the PTAB denied institution
of all four petitions, holding that Coherus failed to establish a reasonable likelihood that any challenged claim would be held unpatentable; 

WHEREAS, Sandoz Inc. filed a petition seeking inter partes review of U.S. Patent No. 8,802,100, which covers formulations
comprising adalimumab; and on February 9, 2018 the PTAB denied institution, holding that Sandoz failed to establish a reasonable likelihood that any challenged claim would be held unpatentable; 

WHEREAS, Sandoz Inc. filed two petitions seeking inter partes review of U.S. Patent No. 9,512,216, which covers methods of
treating chronic plaque psoriasis with adalimumab, which method would be included in the instructions for use for the biosimilar of the Humira Product that will be the subject of the Alvotech BLAs; and on February 9, 2018 and May 3, 2018
the PTAB denied institution, holding that Sandoz failed to establish a reasonable likelihood that any challenged claim would be held unpatentable; 

  
 4 

 Execution Version 

FRE 408 / Confidential 
  

 WHEREAS, Sandoz Inc. filed a petition seeking inter partes review of U.S. Patent
No. 8,974,790, which covers methods of treating ulcerative colitis with adalimumab, which methods would be included in the instructions for use for the biosimilar of the Humira Product that will be the subject of the Alvotech BLAs; and on
March 9, 2018 the PTAB denied institution, holding that Sandoz failed to establish a reasonable likelihood that any challenged claim would be held unpatentable; 

WHEREAS, Sandoz Inc. filed a petition seeking inter partes review of U.S. Patent No. 8,911,737, which covers methods of treating
Crohn’s disease with adalimumab, which method would be included in the instructions for use for the biosimilar of the Humira Product that will be the subject of the Alvotech BLAs; and on March 9, 2018 the PTAB denied institution, holding
that Sandoz failed to establish a reasonable likelihood that any challenged claim would be held unpatentable; 
 WHEREAS, Sandoz Inc. filed
a petition seeking inter partes review of U.S. Patent No. 9,187,559, which covers methods of treating Crohn’s disease and ulcerative colitis with adalimumab, which method would be included in the instructions for use for the
biosimilar of the Humira Product that will be the subject of the Alvotech BLAs; and on June 5, 2018 the PTAB denied institution, holding that Sandoz failed to establish a reasonable likelihood that any challenged claim would be held
unpatentable; 
 WHEREAS, Alvotech intends to begin offering for sale and selling the biosimilar of the Humira Product that will be the
subject of the Alvotech BLAs on July 1, 2023; 
 WHEREAS, the Parties wish to settle the BPCIA Litigation, the 7th Circuit Appeal and the ITC Action between them in the Territory; 
 WHEREAS, no Party has
received any consideration from the other Party for its entry into this Agreement other than that which is described in this Agreement. 

NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Agreement and for other good and valuable
consideration, the receipt of and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
 ARTICLE 1: DEFINITIONS

 Terms when used herein with initial capital letters shall have the meanings set forth below or as otherwise defined in this
Agreement. 
 1.1 “AbbVie” has the meaning set forth in the introductory paragraph of this Agreement. 

1.2 “AbbVie Releasees” has the meaning set forth in Section 3.2. 

1.3 “AbbVie Releasors” has the meaning set forth in Section 3.1. 

  
 5 

 Execution Version 

FRE 408 / Confidential 
  

 1.4 “Affiliate” means, with respect to a Person, any Person that,
directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such Person, provided however, that in each case any such other Person shall be considered to be an Affiliate only during the
time period during which such control exists. For purposes of this definition, “control” means ownership, directly or through one or more Affiliates, of (a) more than fifty percent (50%) of the shares of stock entitled to vote for the
election of directors, in the case of a corporation, or (b) more than fifty percent (50%) of the equity interests in the case of any other type of legal entity or status as a general partner in any partnership, or (c) any other arrangement
whereby a Person controls or has the right to control the Board of Directors or equivalent governing body of a corporation or other entity. For purposes of clarity, if a Person loses its status as an Affiliate, such Person thereafter will not
benefit from rights granted in this Agreement. 
 1.5 “Agreement” has the meaning set forth in the introductory
paragraph of this Agreement. 
 1.6 “Alvotech” has the meaning set forth in the introductory paragraph of this
Agreement. 
 1.7 “Alvotech Biosimilar Product” means [***]. 

1.8 “Alvotech BLAs” has the meaning set forth in the WHEREAS clauses. 

1.9 “Alvotech Releasees” has the meaning set forth in Section 3.1. 

1.10 “Alvotech Releasors” has the meaning set forth in Section 3.2. 

1.11 “Amgen” has the meaning set forth in the WHEREAS clauses. 

1.12 “BI” has the meaning set forth in the WHEREAS clauses. 

1.13 “BLA” means a Biologic License Application as defined in the U.S. Public Health Service (PHS) Act and the U.S.
Federal Food, Drug, and Cosmetic Act. 
 1.14 “BPCIA” has the meaning set forth in the WHEREAS clauses. 

1.15 “BPCIA (l)(6) Case” has the meaning set forth in the WHEREAS clauses. 

1.16 “BPCIA (l)(8) Case” has the meaning set forth in the WHEREAS clauses. 

1.17 “BPCIA Litigation” has the meaning set forth in the WHEREAS clauses. 

1.18 “BPCIA Litigation Patents” has the meaning set forth in the WHEREAS clauses; and the list of BPCIA
Litigation Patents is attached as Exhibit A. 
 1.19 “Celltrion” has the meaning set forth in the WHEREAS clauses.

 1.20 “Coherus” has the meaning set forth in the WHEREAS clauses. 

  
 6 

 Execution Version 

FRE 408 / Confidential 
  

 1.21 “Commercialization Partner(s)” means [***]. 

1.22 “Effective Date” means the date on which this Agreement was executed by the latest-signing Party, which date is
memorialized on page one (1) of this Agreement. 
 1.23 “Fresenius” has the meaning set forth in the WHEREAS
clauses. 
 1.24 “Humira Biosimilar Product” means any biologic product for which marketing approval was sought by
means of a BLA filed pursuant to 42 U.S.C. § 262(k) that lists the Humira Product or any product containing adalimumab as the sole active pharmaceutical ingredient (including all strengths/concentration) as the reference product. 

1.25 “Humira BLA” has the meaning set forth in the WHEREAS clauses. 

1.26 “Humira Product” has the meaning set forth in the WHEREAS clauses. 

1.27 “IPR” means Inter Partes Review pursuant to 35 U.S.C. § 311 et seq. 

1.28 “ITC” has the meaning set forth in the WHEREAS clauses. 

1.29 “ITC Action” has the meaning set forth in the WHEREAS clauses. 

1.30 “License Entry Date” has the meaning set forth in Section 6.1. 

1.31 “Licensed Humira Patents” means, collectively, [***]. 

1.32 “License Term(s)” has the meaning set forth in Section 5.5. 

1.33 “Momenta” has the meaning set forth in the WHEREAS clauses.  

1.34 “Mylan” has the meaning set forth in the WHEREAS clauses. 

1.35 “Net Sales” means, with respect to an Alvotech Biosimilar Product sold in the Territory, [***]: 

(a) [***]; 
 (b) [***]; 

(c) [***]; 
 (d) [***]; 

(e) [***]; and 
 (f) [***]. 

[***]. 

  
 7 

 Execution Version 

FRE 408 / Confidential 
  

 1.36 “Party” means AbbVie or Alvotech, and “Parties”
means all of the foregoing. 
 1.37 “Person” means an individual, a corporation, a partnership, an association,
a trust or other entity or organization, including a government or political subdivision or an agency or instrumentality thereof. 
 1.38
“Pfizer” has the meaning set forth in the WHEREAS clauses. 
 1.39 “PGR” means
post-grant review pursuant to 35 U.S.C. § 321 et seq. 
 1.40 “PTAB” has the meaning set forth in the
WHEREAS clauses. 
 1.41 “Royalty Rate” has the meaning set forth in Section 5.4. 

1.42 “Royalty Termination Date” has the meaning set forth in Section 5.6. 

1.43 “Samsung” has the meaning set forth in the WHEREAS clauses. 

1.44 “Sandoz” has the meaning set forth in the WHEREAS clauses. 

1.45 “Selling Entity” has the meaning set forth in Section 1.35. 

1.46 “7th Circuit Appeal” has
the meaning set forth in the WHEREAS clauses. 
 1.47 “Sublicensee(s)” means Teva, upon fulfillment of the condition
set out in Section 9.2, and any Person that is party to a valid sublicense with Alvotech pursuant to Section 9.3 upon fulfillment of the conditions set out in Sections 9.3(c) and (d). [***] For the avoidance of doubt, no Sublicensee under
Sections 9.2 or 9.3 has any rights under this Agreement until the conditions set out in Sections 9.2 and 9.3, respectively, are met. 
 1.48
“Territory” means the United States of America, and its territories, districts, and possessions, including the District of Columbia and the Commonwealth of Puerto Rico. 

1.49 “Teva” means Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals International GmbH,
individually or collectively, and including their Affiliates. 
 1.50 “Third Party” means a Person or entity that is
not a Party, a Sublicensee, or an Affiliate of a Sublicensee. 
 1.51 “Third Party Humira Biosimilar Product” means
[***]. 
 1.52 “Third Party License” means [***]. 

ARTICLE 2: TERMINATION OF LITIGATION 

2.1 Stipulation of Dismissal of BPCIA Litigation. The Parties agree to stipulate to the dismissal of all claims, counterclaims,
potential claims and counterclaims in the BPCIA Litigation without prejudice, with each Party to bear its own fees and costs. Within three (3) business days of the Effective Dates, Alvotech and AbbVie shall, as applicable, file a stipulation of
dismissal substantially in the form attached as Exhibit D, with the United States District Court for the Northern District of Illinois, so that the Parties’ respective claims and counterclaims in the BPCIA (l)(6) Case and the BPCIA (l)(8) Case
are dismissed without prejudice in accordance with Federal Rule of Civil Procedure 41(a)(1). 

  
 8 

 Execution Version 

FRE 408 / Confidential 
  

 2.2 Stipulation of Dismissal of
7th Circuit Appeal. The Parties agree to jointly move for dismissal of the 7th Circuit Appeal with each Party to bear its own
fees and costs. Within three (3) business days of the Effective Dates, Alvotech and AbbVie shall, as applicable, file the consent motion and stipulation of dismissal substantially in the form attached as Exhibit E. 

2.3 Stipulation of Dismissal of the ITC Action. The Parties agree that they will jointly seek dismissal of the ITC Action for all
respondents with each respondent to bear its own fees and costs. Alvotech represents that it will procure the consent of all other respondents, including Teva and Ivers-Lee AG. Within three (3) business
days of the Effective Date, the Parties shall file their motion for dismissal substantially in the form attached as Exhibit G and that their attorneys will cooperate to jointly prepare any additional materials required. In seeking to dismiss the ITC
Action, the Parties further agree that they will seek confidential treatment for this Agreement to the extent reasonable under ITC rules and regulations. 

2.4 If the dismissals of the BPCIA Litigation, the ITC Action or the 7th Circuit Appeal
are not accepted and entered by the respective courts and/or administrative tribunals, then the Parties will work together in good faith to effectuate the dismissal of each action as appropriate. 

ARTICLE 3: RELEASE 
 3.1
AbbVie Release. In settlement of the BPCIA Litigation, the 7th Circuit Appeal, and the ITC Action and in consideration of the releases, representations, warranties, and covenants contained
in this Agreement and subject to execution by the Parties of this Agreement, as of the Effective Date, AbbVie and its related companies and predecessors, successors, and assigns, [***]. 

3.2 Alvotech Release. In settlement of the BPCIA Litigation, the 7th Circuit
Appeal and the ITC Action, and in consideration of the releases, representations, warranties, and covenants (including the license) contained in this Agreement and subject to execution by the Parties of this Agreement, as of the Effective Date,
Alvotech and its Sublicensees, related companies and predecessors, successors, and assigns, [***]. 
 3.3 Acknowledgements. It is
expressly understood and agreed that the Parties hereby waive any statutes or common law doctrines under which a general release would not extend to claims which the party releasing such claim does not know or suspect to exist in its favor at the
time of executing the release, including but not limited to any and all rights and benefits conferred by § 1542 of the California Civil Code (if and to the extent applicable). Each Party represents, warrants, and covenants that it has not
heretofore assigned or transferred, and will not assign or otherwise transfer, to any Person any matters released by such Party in this Section 3, and such Party agrees to indemnify and hold harmless the other Parties from and against all such
released matters arising from any such alleged or actual assignment or transfer. This Agreement may be pleaded as a full and complete defense to, and used as a basis for injunction against, any proceeding that may be instituted, prosecuted or
attempted in breach hereof. 

  
 9 

 Execution Version 

FRE 408 / Confidential 
  

 3.4 [***]. 

3.5 [***]. 
 3.6
Exceptions. Nothing in this Section 3 shall prevent (a) either Party from seeking any remedy for breach of this Agreement, (b) any AbbVie Releasor from enforcing the Licensed Humira Patents in the event of such breach or
(c) any Alvotech Releasor from asserting any and all affirmative defenses, counterclaims, and the like in response to an AbbVie Releasor seeking to enforce the Licensed Humira Patents in the event of such a breach and termination. 

ARTICLE 4: PATENT ENFORCEABILITY 

4.1 [***]. 
 (a) [***].

 (b) [***]. 
 4.2
Enforceability of Licensed Humira Patents. Alvotech admits that the BPCIA Litigation Patents are valid, enforceable and infringed by the Alvotech BLAs and Alvotech Biosimilar Product. 

4.3 [***]. 
 ARTICLE 5: GRANT
OF LICENSE AND ROYALTIES 
 5.1 License Grant. AbbVie hereby grants to Alvotech, effective on and from the License Entry Date as
described in Section 6.1 of this Agreement, a nonexclusive, royalty-bearing (as set forth in Section 5.4 below), non-transferable (except as expressly permitted by Sections 9.2, 9.3 and 9.5) license
under the Licensed Humira Patents to make, import, use, distribute, sell and offer for sale the Alvotech Biosimilar Product in the Territory. 

5.2 Alvotech Restrictions. In return for AbbVie’s grant of a license, and for other good and valuable consideration, including the
release of AbbVie’s claims that the making, having made, importing, using, marketing, distributing, having distributed, selling or offering to sell the Alvotech Biosimilar Product or any biosimilar version of the Humira Product in the Territory
infringes one or more claims of the Licensed Humira Patents, and the dismissal of the 7th Circuit Appeal and the ITC Action, except as expressly set forth in Section 5.3, [***]. 

5.3 Additional Licenses. In addition to the above, AbbVie hereby grants Alvotech a nonexclusive,
non-transferable (except as expressly permitted by Sections 9.2, 9.3 and 9.5) license under the Licensed Humira Patents to manufacture, import and store a reasonable amount of the Alvotech Biosimilar Product
in the Territory beginning [***] prior to the License Entry Date in anticipation of the License Entry Date. 

  
 10 

 Execution Version 

FRE 408 / Confidential 
  

 5.4 Royalties. Alvotech hereby agrees to pay a royalty to AbbVie of [***] (the
“Royalty Rate”) of the Net Sales of the Alvotech Biosimilar Product in the Territory. For each calendar quarter, Alvotech shall pay such royalties to AbbVie within [***] days of the end of such calendar quarter. For the
avoidance of doubt, the royalty provisions of this Section 5.4 do not apply to the transfer of Product between any of the Selling Entities, but only to the Net Sales. 

5.5 [***]. 
 5.6
Termination of Royalty Payments. The obligations of Alvotech to pay royalties under this Section 5 shall terminate on the earlier of (i) February 11, 2025; or (ii) a decision by the United States Court of Appeals for the
Federal Circuit holding that all unexpired claims of each of the Licensed Humira Patents are invalid or unenforceable (the “Royalty Termination Date”), at which time the non-exclusive, non-transferable (except as permitted by Sections 9.2, 9.3 and 9.5) license granted hereunder will be deemed fully paid up and irrevocable. 

5.7 Quarterly Statements. Not later than [***] days after the end of each calendar quarter, Alvotech will provide AbbVie with
statements setting forth the gross sales of the Alvotech Biosimilar Product in the Territory for such calendar quarter, Net Sales of the Alvotech Biosimilar Product in the Territory for such calendar quarter, the royalty amount payable for such
calendar quarter, the calculation used to determine the royalty amount, all information necessary to calculate the royalty amount, and any other details or particulars that AbbVie may reasonably request. 

5.8 Record Retention and Audit Rights. Alvotech and its Sublicensees will retain their books and records pertaining to the Net Sales of
the Alvotech Biosimilar Product in the Territory for each calendar quarter for at least [***] from the end of such calendar quarter. Until the later of [***] after the Royalty Termination Date or [***] after the provision of the [***], AbbVie may
provide Alvotech with reasonable notice of its request to have an independent public accounting firm audit records required to determine the Net Sales of the Alvotech Biosimilar Product in the Territory and the royalty due under this Agreement.
Alvotech and its Sublicensees will accommodate such an audit and use reasonable efforts to accommodate such request within [***] of AbbVie’s request; provided however, any audit under this Section 5.8 shall be conducted during normal
business hours of Alvotech and its Sublicensees. The audit will be at AbbVie’s sole expense unless the audit shows an underpayment in the royalties due to AbbVie of [***] or more in any calendar quarter in which case Alvotech will pay for the
audit. In the event that an audit reveals any underpayment in royalties due to AbbVie, Alvotech shall promptly, but in no event later than [***] days after receipt of written notice thereof, pay such underpayment to AbbVie. AbbVie’s audit
rights may only be exercised once during any [***] period. Notwithstanding any provision herein to the contrary, Alvotech and its Sublicensees shall not have the right to audit any books and records of AbbVie or any of its agents. 

5.9 [***] 
 5.10 FDA
Approval. [***] Nothing in this Section 5.10 shall restrict AbbVie from communicating with the FDA regarding any actual good faith legal, regulatory, safety or efficacy issue affecting any Humira Biosimilar Product including issues specific
to the Alvotech Biosimilar Product. 

  
 11 

 Execution Version 

FRE 408 / Confidential 
  

 ARTICLE 6: LICENSE ENTRY DATE FOR THE 

ALVOTECH BIOSIMILAR PRODUCT 

6.1 License Entry Date. The “License Entry Date” for the Alvotech Biosimilar Product will be July 1, 2023.

 ARTICLE 7: ADDITIONAL COVENANTS 

7.1 Certain Remedies. Each Party acknowledges and agrees that the restrictions and other terms and conditions set forth herein
regarding the use, sale, offer for sale, marketing, manufacture or importation of the Alvotech Biosimilar Product by Alvotech and its Sublicensees are reasonable and necessary to protect the respective legitimate interests of AbbVie and Alvotech,
and that in the event of a breach or threatened breach of those restrictions or other terms or conditions by either Party or Sublicensees, the other Party shall have the right to seek from any court of competent jurisdiction injunctive relief,
whether temporary, preliminary, or permanent, and specific performance, which rights shall be cumulative and in addition to any other rights or remedies to which such Party may be entitled in law or equity. [***] Nothing in this Section 7.1 is
intended, or shall be construed, to limit the Parties’ rights to equitable relief or any other remedy for a breach of any provision of this Agreement. [***] 

7.2 Confidentiality. Except as set forth below in Section 7.3, the Parties shall keep the terms of this Agreement and the
underlying settlement confidential using at least the level of care they use for their own proprietary information, and shall not disclose the terms of this Agreement to any Third Party (other than the Parties’ respective financial advisors,
legal advisors, and insurers, or in connection with a potential or actual sublicense pursuant to Section 9.2 or 9.3 or in connection with a potential or actual assignment pursuant to Section 9.5, in each such case subject to appropriate
confidentiality protections). 
 7.3 Exceptions to Confidentiality. Notwithstanding Section 7.2, a Party may upon the execution
of this Agreement and without prior written consent, publicly disclose: (a) that the Parties have settled the BPCIA Litigation, the 7th Circuit Appeal and the ITC Action, that this Agreement
exists, and that the Agreement includes the license set forth in Section 5.1; (b) the information contained in Sections 1.48, 4.2 and 6.1; (c) any information required to be so disclosed by a court, governmental agency, or other regulatory
authority; and (d) any information that is, in the opinion of the disclosing Party’s counsel, required by law or the rules of a stock exchange on which the securities of the disclosing Party are listed (including, without limitation,
Alvotech’s listing process); provided, however, that in the event that a disclosure under Section 7.3(c) or 7.3(d) is made, the disclosing Party shall submit the proposed disclosure in writing to the other Party as far in advance as
reasonably practicable so as to provide reasonable notice and an opportunity to provide comments. A Party receiving a request, subpoena, or order for the disclosure of the terms or conditions of this Agreement shall notify the other Party as soon as
practicable and, if at all possible, in sufficient time to allow the other Party to oppose disclosure or seek an appropriate protective order. Alvotech further agrees that to the extent this agreement needs to be disclosed to the U.S. Securities and
Exchange Commission by Alvotech, Alvotech will seek confidential treatment for this Agreement to the extent reasonable under SEC rules and regulations. 

  
 12 

 Execution Version 

FRE 408 / Confidential 
  

 7.4 Press Release: Prior to releasing any press release that references this
Agreement, the Party issuing the press release shall provide the draft press release to the other Party for review and consent, not to be unreasonably withheld. 

7.5 Legal Compliance  

(a) Within 10 days following the Effective Date, the Parties shall each file or cause to be filed with the U.S. Federal Trade
Commission, Bureau of Competition (“FTC”) and Antitrust Division of the U.S. Department of Justice (“DOJ”) this Agreement and any notifications to be filed pursuant to section 1112 of the Medicare
Prescription Drug Improvement, and Modernization Act of 2003, Pub. L. No. 108-173 (the “MMA”), as amended by section 3 of the Patient Right to Know Drug Prices Act, Pub. L. No. 115-263, and any other applicable law. The Parties agree that if the FTC or the DOJ raises objections as to any of the provisions of the Agreement, the Parties will use all commercially reasonable efforts
to: (i) respond promptly and in good faith to any requests for additional information made by either of such agencies; (ii) coordinate any necessary joint presentation; and (iii) if possible amend the Agreement to address any such
objections in a way that keeps the economics the same and is consistent with the Parties’ intent. 
 (b) Each Party
reserves the right to communicate with the FTC or DOJ regarding such filings as it believes appropriate. Each Party shall keep the other Party reasonably informed of such communications and, subject to Sections 7.2 and 7.3 above shall not disclose
any confidential information of any other Party without such other Party’s consent, which shall not be unreasonably withheld or delayed. 

ARTICLE 8: REPRESENTATIONS AND WARRANTIES 

8.1 Representations and Warranties. Each Party represents, warrants, and covenants to the other Parties that as of the Effective Date:

 (a) it has the corporate power and authority to enter into this Agreement and to perform its obligations and bind itself and its
Sublicensees to perform their obligations hereunder, and that the persons executing this Agreement on behalf of each of the Parties are authorized to do so; 

(b) the execution and delivery of this Agreement and the performance of the transactions contemplated hereunder have been duly authorized by
all necessary corporate actions of the Party; 
 (c) this Agreement has been duly executed and delivered by it and is a binding obligation of
it, enforceable against it and its Sublicensees in accordance with its terms; and 
 (d) the execution and delivery of this Agreement and the
performance by the Party or its Sublicensees of any of its obligations hereunder do not and will not conflict with (i) any judgment of any court or governmental body applicable to the Party or its respective properties, or (ii) any other
agreements to which it may be a party, or (iii) to the Party’s knowledge, any statute, decree, order, rule or regulation of any court or governmental agency or body applicable to the Party or its properties. 

  
 13 

 Execution Version 

FRE 408 / Confidential 
  

 8.2 Additional AbbVie Representations and Warranties. 

(a) AbbVie further represents and warrants that it has the necessary rights, title, interest, and authority to grant Alvotech the license to
the Licensed Humira Patents contained herein. 
 (b) [***]. 

(c) [***]. 
 8.3 Additional
Alvotech Representations and Warranties. 
 (a) [***]. 

(b) As of the Effective Date, Alvotech represents and warrants that it has filed Biologics License Applications Nos. 761205 and 761299. 

(c) [***]. 
 (d) [***]. 

8.4 Limitations. Except as expressly provided in this Agreement, neither Party makes any representations or warranties, express or
implied, either in fact or by operation of applicable law. Specifically, AbbVie makes no representation that, as of the License Entry Date, Alvotech or its Sublicensees will be able to launch the Alvotech Biosimilar Product. The Parties herein
acknowledge that the ability of Alvotech or its Sublicensees to launch the Alvotech Biosimilar Product may be limited by (a) the FDA’s failure to finally approve, or revocation of approval of, the Alvotech Biosimilar Product; (b) the
inability of Alvotech or its Sublicensees to manufacture, package, and otherwise prepare a sufficient amount of the Alvotech Biosimilar Product by the License Entry Date; or (c) other situations not currently within the Parties’
contemplation. Without limiting any other provision of this Agreement, AbbVie therefore makes no warranty and no representation with respect to the actual date that the Alvotech Biosimilar Product will be available for sale. 

ARTICLE 9: SCOPE OF THE PARTIES’ AGREEMENT 

9.1 Right to Prosecute Licensed Humira Patents. AbbVie shall have the sole right to prosecute, maintain, enforce, and defend any of the
Licensed Humira Patents. 
 9.2 Sublicensing to Teva as a Commercialization Partner. 

(a) Alvotech may sublicense its rights under both Section 5.1 and 5.3 of this Agreement to Teva. 

  
 14 

 Execution Version 

FRE 408 / Confidential 
  

 (b) Teva has agreed to be bound by the terms and conditions of this Agreement and will
execute an undertaking memorializing its agreement to the terms and conditions of this Agreement substantially in the form of Exhibit F. Teva’s sublicense is conditional on its undertaking to be bound by each and every term of this Agreement
that binds Alvotech, its undertaking that AbbVie is an intended third party beneficiary of its sublicense from Alvotech of the rights in this Agreement, and its undertaking that AbbVie will have the right to enforce the terms of the sublicense in
addition to the terms of this Agreement to which Teva agrees it is bound, including the right to terminate the sublicense pursuant to Section 10.1 of this Agreement. 

(c) In order for Teva to have any rights as a sublicensee under this Agreement, Alvotech or Teva must provide AbbVie with a copy of the
executed version of the undertaking set out in Exhibit F. 
 9.3 Sublicensing to a Sublicensee other that Teva. 

(a) Subject to written approval from AbbVie as set out in Section 9.3(c), Alvotech may sublicense the license grants in Section 5.3
to up to [***] contract manufacturers solely for the purpose of having the Alvotech Biosimilar Product made, imported, or stored for sale in the Territory beginning [***] before the License Entry Date. 

(b) Subject to written approval from AbbVie as set out in Section 9.3(c), Alvotech may sublicense the license grants in Section 5.1
to a Commercialization Partner other than Teva to import, use, distribute, have distributed, sell and offer for sale the Alvotech Biosimilar Product in the Territory. 

(c) AbbVie will respond to any request for approval pursuant to Section 9.3(a) or 9.3(b) within [***]. AbbVie will not withhold approval
for a sublicense under this Section 9 if the sublicense meets all of the following conditions: [***]. 
 (d) In order for a Sublicensee
to have any rights under this agreement, Alvotech must provide AbbVie with a copy of the executed sublicense redacted as reasonably appropriate with respect to subject matter not applicable to this Agreement. 

9.4 Reservation of Rights. All rights not expressly granted to Alvotech in this Agreement are reserved to AbbVie, and no other license
or rights under the Licensed Humira Patents or any other intellectual property of AbbVie is granted or intended to be granted under this Agreement, either expressly, by implication, estoppel, or otherwise. 

9.5 No Assignment. This Agreement and the rights herein shall not be assigned by any Party without the written consent of all Parties,
which consent shall not be unreasonably withheld, delayed or conditioned, except that each Party may upon notice to the other Party but without obtaining the consent of the other Party, assign or sublicense any or all of its rights and
obligations under this Agreement to any one or more of its Affiliates or assign to any successor in interest to such Party’s or assignee’s business relating to this Agreement in connection with a merger, reorganization, change of control,
or sale of all or substantially all of its assets relating to this Agreement. Any purported assignment or transfer in violation of the foregoing shall be null and void ab initio and of no force or effect. In the event of a permitted
assignment, this Agreement shall be binding upon and inure solely to the benefit of the Parties and their respective successors and permitted assigns. 

  
 15 

 Execution Version 

FRE 408 / Confidential 
  

 ARTICLE 10: GENERAL PROVISIONS 

10.1 Termination. 
 (a) If
Alvotech or its Sublicensees or its Sublicensees’ Affiliates breach any obligation or restriction under Section 5.2, AbbVie will provide written notice of such breach (if known to AbbVie) and Alvotech will have [***] from written notice by
AbbVie in which to cure said breach. Notwithstanding the cure period, AbbVie will be entitled to bring an action at any time before, on, or after expiration of the [***] cure period to enforce the terms of Section 5.2 of this Agreement and
to seek any relief to which it is entitled, including, but not limited to, injunctive relief, whether temporary, preliminary, or permanent, and specific performance, which relief shall be cumulative and in addition to any other rights or remedies to
which AbbVie may be entitled in law or equity. [***]. If Alvotech fails to cure within [***] from written notice by AbbVie, AbbVie may also terminate this Agreement and all licenses granted under this Agreement by AbbVie and the
Parties’ rights and obligations under Sections 3 and 5 of this Agreement shall terminate immediately upon written notice from AbbVie to Alvotech of such
termination.                 
 (b) If Alvotech or its
Sublicensees or its Sublicensees’ Affiliates breaches any of its obligations and restrictions under Sections 3, 4, 5.4, 5.7, 5.8, 5.9, 7.2, 8.1, 8.3, 9.2, 9.3 or 9.5, AbbVie will provide written notice of such breach (if known to AbbVie) and
Alvotech will have [***] from written notice by AbbVie in which to cure said breach. If Alvotech fails to cure within [***], AbbVie may terminate this Agreement and all licenses granted under this Agreement by AbbVie and the Parties’ rights and
obligations under Sections 3 and 5 of this Agreement shall terminate upon written notice from AbbVie to Alvotech of such termination. 
 (c)
In addition, if Alvotech or its Sublicensees [***] challenge the patentability, validity, or enforceability, or assert the noninfringement of any of the Licensed Humira Patents or any claims thereof; [***] in the Territory, this Agreement and all
licenses granted under this Agreement by AbbVie and the Parties’ rights and obligations under Sections 3 and 5 of this Agreement shall terminate upon written notice from AbbVie to Alvotech of such termination. [***] 

(d) [***] 
 (e) If AbbVie breaches
any of its obligations and restrictions under Sections 3, 4.3, 5.1, 5.3, 5.5 and 7.2, Alvotech will provide written notice of the breach (if known to Alvotech) and AbbVie will have [***] from receipt of written notice by Alvotech in which to cure
said breach. If AbbVie fails to cure within [***], Alvotech may terminate this Agreement and all licenses granted under this Agreement and the Parties’ rights and obligations under Sections 3 and 5 of this Agreement shall terminate upon written
notice from Alvotech to AbbVie of such termination. 

  
 16 

 Execution Version 

FRE 408 / Confidential 
  

 10.2 Governing Law; Venue. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware, without giving effect to its conflict of laws principles that would result in the application of the laws of any other jurisdiction. The Parties hereby consent to the exclusive jurisdiction of the
courts located in the State of Illinois in connection with any dispute arising out of or relating to this Agreement and expressly waive any objections or defenses based on lack of personal jurisdiction or venue. 

10.3 Severability. If a court of competent jurisdiction holds any provision of this Agreement to be illegal, unenforceable, or invalid,
in whole or in part for any reason: (a) all other provisions hereof shall remain in full force and effect and shall be liberally construed in order to carry out the intent of the Parties as near as possible, and (b) the Parties agree to
use their commercially reasonable efforts to negotiate a provision, in replacement of the provision held illegal, unenforceable, or invalid, that is consistent with applicable law and accomplishes, as nearly as possible, the original intention of
the Parties with respect thereto and without materially changing the economic value of the transactions contemplated hereby. 
 10.4
Entire Agreement. This Agreement and any exhibits, appendices, and attachments to this Agreement, constitute the final, complete, and exclusive statement of the terms of the agreement among the Parties pertaining to the subject matter of this
Agreement and supersedes all prior and contemporaneous understandings or agreements of the Parties (other than those referenced in this Agreement). No Party has been induced to enter into this Agreement by, nor is any Party relying on, any
representation or warranty outside those expressly set forth in this Agreement. 
 10.5 Amendment. No terms or conditions of this
Agreement will be varied or modified by any prior or subsequent statement, conduct or act of any Party, except that the Parties may supplement, amend, or modify this Agreement by a subsequent written agreement executed by the Parties through their
authorized representatives. 
 10.6 No Joint Venture. In making and performing this Agreement, AbbVie, on the one hand, and Alvotech,
on the other, are acting, and intend to be treated, as independent entities and nothing contained in this Agreement shall be construed or implied to create an agency, partnership, joint venture, or employer and employee relationship among AbbVie and
Alvotech. Except as otherwise provided herein, AbbVie and Alvotech may not make any representation, warranty, or commitment, whether express or implied, on behalf of or incur any charges or expenses for or in the name of each other. AbbVie and
Alvotech shall not be liable for each other’s acts unless such act is expressly authorized in writing. 
 10.7 Waiver. No waiver
of a breach, failure of any condition, or any right or remedy contained in or granted by the provisions of this Agreement will be effective unless it is in writing and signed by the Party waiving the breach, failure, right, or remedy. No waiver of
any breach, failure, right, or remedy will be deemed a waiver of any other breach, failure, right, or remedy, whether or not similar, nor will any waiver constitute a continuing waiver unless the writing so specifies. 

10.8 Interpretation. Each Party and its counsel have participated fully in the review and revision of this Agreement. Any rule of
construction to the effect that ambiguities are to be resolved against the drafting Party will not apply in interpreting this Agreement. References to any law, rule or regulation in this Agreement include all replacements, successors, amendments,
and supplements thereto. The term “including” means “including, without limitation,” and “herein”, “hereof’, and “hereunder” refer to this Agreement as a whole. 

  
 17 

 Execution Version 

FRE 408 / Confidential 
  

 10.9 Counterparts and Electronic Signature. This Agreement may be executed in any
number of counterparts, and each counterpart will be deemed an original instrument, but all counterparts together will constitute but one agreement. This Agreement may be executed by electronic signatures and such electronic signatures shall be
deemed to bind each Party as if they were original signatures. 
 10.10 Headings. The descriptive headings contained in this
Agreement are for convenience of reference only and shall not in any way affect the meaning or interpretation of this Agreement. 
 10.11
Survival. Subject to Section 10.1 above, the provisions in Sections 7, 8, 9 and 10 of this Agreement (and any other provisions of this Agreement that by their express terms survive) shall survive the expiration or termination of this
Agreement in accordance with their terms. 
 10.12 Third Party Beneficiaries. Except as expressly provided herein, nothing in this
Agreement, either express or implied, is intended to or shall confer upon any Third Party any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. 

10.13 Notices. 
 (a) All
notices, requests, demands, or other communications under this Agreement will be in writing. All notices shall be made by personal delivery, reputable overnight express courier (e.g., Federal Express/Airborne/United Parcel Service/DHL Worldwide), or
by United States Registered or Certified Mail, charges prepaid or charged to the sender’s account, in which case notice is effective on delivery. 

(b) Addresses for purpose of giving notice are as follows: 

If to AbbVie: 
 Attention:
Laura Schumacher 
 Executive Vice President, Secretary and General Counsel and 

Attention: Johanna Corbin, Vice President, Intellectual Property and Strategy 

1 N. Waukegan Road, Building AP-34 

North Chicago, IL 60064 

  
 18 

 Execution Version 

FRE 408 / Confidential 
  

 If to Alvotech: 

Attention: Tanya Zharov, Deputy CEO and 

Attention: Philip Caramanica, Chief IP Counsel & Deputy General Counsel 

Saemundargata 15-19 

102 Reykjavik, Iceland 
 10.14
Evidence. This Agreement and all of the terms herein constitute compromises and offers to compromise covered by Federal Rule of Evidence 408. Nothing in this Agreement may be used as evidence in any action or proceeding between the Parties
hereto, except in connection with any action or proceeding relating to enforcement of this Agreement. 
 [remainder of this page
intentionally left blank] 

  
 19 

 Execution Version 

FRE 408 / Confidential 
  

 IN WITNESS WHEREOF, the Parties, through their authorized officers, have executed this
Agreement as of the Effective Date. 
  

			
	AbbVie Inc.	  	Alvotech hf.
		
	By: /s/ Scott T. Reents	  	By:
	Name: Scott T. Reents	  	Name:
	Title: Treasurer	  	Title:
		
	Date: March 8, 2022	  	Date:
		
	AbbVie Biotechnology Ltd	  	
		
	By: /s/ Scott T Reents	  	
	Name: Scott T. Reents	  	
	Title: Director	  	
		
	Date: March 8, 2022	  	

 Execution Version 

FRE 408 / Confidential 
  

 IN WITNESS WHEREOF, the Parties, through their authorized officers, have executed this
Agreement as of the Effective Date. 
  

			
	AbbVie Inc.	  	Alvotech hf.
		
	By:	  	By: /s/ Robert Wessman
	Name:	  	Name: Robert Wessman
	Title:	  	Title: Chairman
		
	Date:	  	Date: March 7, 2022
		
	AbbVie Biotechnology Ltd	  	
		
	By:	  	
	Name:	  	
	Title:	  	
		
	Date:	  	

 Execution Version 

FRE 408 / Confidential 
  

 Exhibit A – BPCIA Litigation Patents 

 

													
	 6,805,686
	  	 	8,231,876	 	  	 	8,420,081	 	  	 	8,663,945	 
	 8,708,968
	  	 	8,715,664	 	  	 	8,808,700	 	  	 	8,883,156	 
	 8,889,136
	  	 	8,895,009	 	  	 	8,906,372	 	  	 	8,906,373	 
	 8,906,646
	  	 	8,911,737	 	  	 	8,911,964	 	  	 	8,916,153	 
	 8,926,975
	  	 	8,961,973	 	  	 	8,961,974	 	  	 	8,974,790	 
	 8,986,693
	  	 	8,992,926	 	  	 	8,999,337	 	  	 	9,061,005	 
	 9,062,106
	  	 	9,067,992	 	  	 	9,085,618	 	  	 	9,085,619	 
	 9,085,620
	  	 	9,090,688	 	  	 	9,090,689	 	  	 	9,090,867	 
	 9,096,666
	  	 	9,102,723	 	  	 	9,150,645	 	  	 	9,181,337	 
	 9,181,572
	  	 	9,187,559	 	  	 	9,234,032	 	  	 	9,266,949	 
	 9,273,132
	  	 	9,284,370	 	  	 	9,284,371	 	  	 	9,290,568	 
	 9,315,574
	  	 	9,328,165	 	  	 	9,334,319	 	  	 	9,339,610	 
	 9,346,879
	  	 	9,359,434	 	  	 	9,499,614	 	  	 	9,499,616	 
	 9,505,834
	  	 	9,512,216	 	  	 	9,522,953	 	  	 	9,546,212	 
	 9,550,826
	  	 	9,624,295	 	  	 	9,669,093	 	  	 	9,683,033	 
	 9,708,400
	  	 	9,957,318	 	  	 	9,913,902	 	  	 	11,083,782	 
	 11,167,030
	  	 	11,191,834	 	  				  			

 Execution Version 

FRE 408 / Confidential 
  

 Exhibit B and C to be inserted 

 Execution Version 

FRE 408 / Confidential 
  

 Exhibit B – BPCIA (l)(6) Case 

 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 1 of 34 PageID #:1 

 

 UNITED STATES DISTRICT COURT 

FOR THE NORTHERN DISTRICT OF ILLINOIS 

EASTERN DIVISION 
  

					
	 ABBVIE INC. and
ABBVIE
 BIOTECHNOLOGY LTD
  

Plaintiffs,
  

v.
  

ALVOTECH HF.
  

Defendant.
	 		  	Civil Action No. 1:21-cv-2258

 COMPLAINT 

INTRODUCTION 
 1.
AbbVie’s scientists and clinicians invested decades developing the groundbreaking drug HUMIRA®—the first fully human antibody ever approved by the U.S. Food and Drug Administration
(“FDA”)—and expanding its use into a variety of diseases and patient populations, as well as launching a new formulation that lessens pain upon injection. Over one million patients have benefited from AbbVie’s pioneering work,
which also has produced a robust portfolio of patents and trade secret manufacturing processes. 
 2. Numerous biosimilar companies—now
including Defendant Alvotech hf. (“Alvotech” or “Defendant”)—have taken note of AbbVie’s success as well, attempting to make copycat versions of HUMIRA®. 

3. The Biosimilar Price Competition and Innovation Act of 2009 (“BPCIA”) established an abbreviated process by which such biosimilar
applicants could seek FDA approval. But while the BPCIA gives would-be biosimilar makers like Alvotech a regulatory pathway for their biosimilar versions of
HUMIRA®, it does not give Alvotech license to infringe AbbVie’s patents. And it certainly did not permit Alvotech to steal AbbVie’s trade secret manufacturing processes, which
is the subject of related case AbbVie Inc. v. Alvotech hf., Civ. No. 1:21-cv-01530 (N.D. Ill. Mar. 19, 2021) (Leinenweber, J.). 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 2 of 34 PageID #:2 

 

 4. AbbVie’s HUMIRA® patent
portfolio is notable for its proven quality. Numerous biosimilar makers have previously filed a total of 20 inter partes review (“IPR”) petitions challenging 14 of AbbVie’s patents at the Patent Trial and Appeal Board
(“PTAB”) of the United States Patent and Trademark Office (“USPTO”). Despite the lower burden of proof compared to district court proceedings (a preponderance of the evidence rather than clear and convincing evidence, and at the
time a broad claim construction standard) and the high invalidation rate in IPRs, AbbVie prevailed on nine of its patents in 13 IPRs, with challenges to two more patents withdrawn. Ultimately, each of the prior biosimilar applicants recognized the
strength of the portfolio and sought licenses with AbbVie. Biosimilars to HUMIRA® will enter the U.S. market in 2023. 

5. Of particular relevance, the PTAB has already rejected four petitions challenging the validity of one of the AbbVie patents at issue in
this proceeding (namely U.S. Patent No. 9,085,619, directed to buffer-free formulations of adalimumab: the active ingredient of HUMIRA®). The PTAB similarly rejected a petition
challenging the validity of a related family member of another AbbVie patent at issue, U.S. Patent No. 8,961,973, directed to induction dosing to treat Crohn’s disease. 

6. In late 2020, Alvotech sought FDA approval to launch its own biosimilar of
HUMIRA®, and it contends that AbbVie’s patents are invalid, not infringed, and unenforceable. 

  
 2 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 3 of 34 PageID #:3 

 

 7. HUMIRA® belongs to a category of
drugs known as biologics. Biologics are complex proteins manufactured in living cells rather than by chemical synthesis. These are critically important drugs that are difficult to develop, manufacture, formulate, and administer. In bringing HUMIRA® from the laboratory to patients, AbbVie operated in uncharted territory. In 1996, AbbVie invented the antibody in HUMIRA®. But that was
only the first step. Since then, over more than two decades, AbbVie has invested hundreds of millions of dollars in continuing research and innovation. 

8. AbbVie’s investment in HUMIRA® development includes over 100 clinical trials
and has resulted in FDA approval for the treatment of thirteen different disease conditions, including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn’s disease (adult and pediatric), ulcerative colitis
(adult and pediatric), hidradenitis suppurativa (adult and pediatric), uveitis (adult and pediatric), and juvenile idiopathic arthritis. AbbVie has continued to dedicate substantial resources to an extensive clinical trial program, including
research specifically to benefit children. For example, in February of this year, AbbVie received FDA approval to treat pediatric patients living with moderately to severely active ulcerative colitis, making HUMIRA® the first and only subcutaneous biologic treatment option for pediatric patients five years and older with this condition. Alvotech seeks to copy, and profit from, the results of AbbVie’s
clinical development. 
 9. AbbVie also has continued to improve and develop the
HUMIRA® product itself. First, AbbVie invested in and created a subcutaneous, high concentration, liquid formulation of the HUMIRA®
antibody. Before AbbVie’s launch of HUMIRA®, patients had to go to the hospital to receive their medicine intravenously, or mix batches of their medicine at home (difficult for patients
with inflamed joints) and inject themselves twice a week. As a result of AbbVie’s dedication, innovation, and investment, patients were able to inject the medicine at home using pre-filled syringes or
automatic injection devices, and take fewer injections. The added convenience and precision improved patients’ lives and increased compliance, all without sacrificing HUMIRA®’s
outstanding efficacy. 

  
 3 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 4 of 34 PageID #:4 

 

 10. But AbbVie did not stop there. Through continuing investment into formulation research,
AbbVie developed a new, higher-concentration (100 mg/mL), citrate-free formulation with reduced pain upon injection. AbbVie’s inventive new formulation leverages the surprising inventions patented by AbbVie researchers, namely that the active
ingredient, adalimumab, can be formulated at high concentrations without a buffer, while maintaining solubility and stability—including during long-term storage or other processing steps. It is this latest innovative formulation that
Alvotech seeks to copy. Alvotech’s founder and Chairman—Robert Wessman—explained earlier this year how Alvotech monitored and sought to replicate AbbVie’s advances, switching gears from a 50 mg/mL concentration copy of adalimumab
to a 100 mg/mL high-concentration version as soon as Alvotech “heard that AbbVie was getting ready to launch 100mg.” Wallace, David, “Celltrion Wins Global First Approval For High-Concentration Humira Biosimilar,” Generics
Bulletin (Feb. 15, 2021), attached as Exhibit 1 (“We were actually active in developing 50mg three or four years back,” Wessman noted, but “when we heard that AbbVie was getting ready to launch 100mg we stopped that and started to
focus only on 100mg. We did not even consider 50mg any more.”). 
 11. AbbVie has also spent many years developing and improving the
complex manufacturing processes for HUMIRA® and its active ingredient, adalimumab. Again, unlike traditional drugs, HUMIRA® is a
complex biologic created in living organisms. So even minor changes to the manufacturing process can impact the drug’s stability, purity, and efficacy. AbbVie obtained patents, as well as trade secrets, covering innovations in manufacturing.

  
 4 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 5 of 34 PageID #:5 

 

 12. Alvotech seeks not only to copy and to profit from the results of AbbVie’s
innovative manufacturing work, but also has shown a willingness to take improper shortcuts in doing so. On March 19, 2021, AbbVie filed suit against Alvotech for theft of trade secrets related to the commercial manufacturing process for HUMIRA®, crucial to launching a new manufacturing facility. AbbVie Inc. v. Alvotech hf., Civ. No. 1:21-cv-01530,
Dkt. 1 at ¶¶ 3, 5, 28, 30 (N.D. Ill. Mar. 19, 2021). Manufacturing a biologic drug—particularly on a commercial scale—requires complex and finely tuned manufacturing techniques that are distinct from the manufacturing,
formulation, and indication inventions in AbbVie’s patent portfolio. AbbVie invested substantial time and expertise to develop, scale, and fine-tune its proprietary high-volume manufacturing processes, and carefully guards this trade secret
information—including sharing it with its employees only on a need-to-know basis. 

13. Instead of investing the necessary time and resources to develop its own manufacturing process for its copycat version of HUMIRA®, Alvotech surreptitiously acquired AbbVie’s confidential and proprietary trade secrets, including by hiring at least one such employee: Rongzan Ho, a Team Leader for upstream manufacturing
at AbbVie, who circumvented AbbVie’s security protocols to email himself AbbVie manufacturing trade secrets before leaving to join Alvotech in the very same role. Id. at ¶¶ 3, 40, 58, 63. Just before leaving AbbVie, for
Alvotech’s benefit and at its direction, Mr. Ho transmitted AbbVie’s confidential and proprietary trade secret information—including voluminous Excel spreadsheets full of sensitive manufacturing data—to his personal email
account. Id. at ¶¶ 54-64. These confidential materials contained detailed and closely guarded information concerning AbbVie’s upstream manufacturing process for HUMIRA® which AbbVie had developed over decades of research. Id. Alvotech then installed Mr. Ho in the very same role, supervising upstream manufacturing of the exact same product: AVT02,
Alvotech’s copy of HUMIRA®, for the purpose of using and benefitting from Mr. Ho’s intimate knowledge of AbbVie’s trade secrets. Id. at ¶¶ 54-64, 89. 

  
 5 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 6 of 34 PageID #:6 

 

 14. Alvotech has also shown it is unwilling to follow the law in connection with this case.
Under the BPCIA, 42 U.S.C. § 262(l) outlines a framework for the would-be biosimilar maker (here, Alvotech) and reference product sponsor (here, AbbVie) to resolve patent disputes.
Specifically, the BPCIA sets forth requirements for exchange of information between the parties: under the statute, Alvotech must provide not only its abbreviated Biologics License Application (aBLA), but also its manufacturing information to
AbbVie. See 42 U.S.C. § 262(l)(2)(A) (applicant shall provide “such other information that describes the process or processes used to manufacture the biological product that is the subject of such application”).
Despite multiple requests, Alvotech has failed to fulfill its obligations and disclose necessary manufacturing information for its biosimilar product. Instead of properly investigating its own records, Alvotech in many instances provided incomplete
information, hedging its disclosures about its own product and processes with statements like “upon information and belief” and “as will be confirmed through further discovery.” 

15. The BPCIA provides a mechanism for AbbVie to litigate its patents before Alvotech actually launches its biosimilar product. Through this
process, AbbVie identified 62 patents that would be infringed by Alvotech’s biosimilar product. Yet this lawsuit involves only four of those 62 patents. This is because Alvotech selected just those four patents for this first phase of
litigation, despite the fact that BPCIA specifically allows the biosimilar company to select all patents identified by the innovator, or as many as it would like to litigate. AbbVie expressly and

  
 6 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 7 of 34 PageID #:7 

 

 
clearly explained that litigating just those four patents would not resolve Alvotech’s patent issues—but Alvotech did not change course, nor did it propose including additional patents
in this litigation. As AbbVie explained, if and when Alvotech provides its 180-day Notice of Commercial Marketing, and as circumstances otherwise warrant, AbbVie will have the opportunity to assert the
remaining patents. Therefore, this is merely the first round of litigation between the parties, and (by Alvotech’s choice) there will necessarily be a second phase of litigation to adjudicate the rest of AbbVie’s substantial patent rights
relating to HUMIRA®. 
 16. AbbVie brings this suit to prevent Alvotech from
infringing the four patents identified in this Complaint. AbbVie also reserves its rights to seek preliminary injunctive relief in this action and to assert the remaining patents in a second phase, if and when Alvotech provides a Notice of
Commercial Marketing, or as circumstances otherwise warrant. 
 NATURE OF THE ACTION 

17. AbbVie Inc. and AbbVie Biotechnology Ltd (“ABL,” collectively referred to as “AbbVie” or “Plaintiffs”) for
their Complaint against Alvotech further allege as follows: 
 18. This is a civil action for patent infringement arising under the patent
laws of the United States, 35 U.S.C. §§ 1, et seq., including 35 U.S.C. § 271(e)(2)(C). 
 19. This lawsuit
results from Alvotech’s infringement of AbbVie patents that concern AbbVie’s groundbreaking drug, HUMIRA®. 

20. AbbVie Inc. is the holder of Biologic License Application (“BLA”) No. 125057 for HUMIRA®, whose active pharmaceutical ingredient is the antibody, adalimumab. 

  
 7 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 8 of 34 PageID #:8 

 

 21. In 1996, after many years of intense research, AbbVie’s predecessor first created
adalimumab. Adalimumab, a biologic, is a fully human, high-affinity, and neutralizing therapeutic antibody against human TNF-α, a protein made by the human body as part of the body’s immune response.
The mechanisms by which TNF-α affects the body are complex and not completely understood (even today). Inventing the adalimumab antibody itself, however, was only the first step in a long process.
Following the isolation and characterization of adalimumab, AbbVie and its predecessor Abbott Laboratories spent more than two decades and hundreds of millions of dollars on scientific studies and clinical trials to determine how to use HUMIRA® to treat patients for different diseases, how to formulate HUMIRA® for easier administration, how to improve and further develop the
formulation, and how to manufacture HUMIRA®. AbbVie’s scientific and clinical investments in HUMIRA® continue to this
day—leading, for example, to the February 2021 approval of HUMIRA® to treat pediatric patients living with moderately to severely active ulcerative colitis. 

22. AbbVie’s innovative work has been recognized by the medical and scientific community. For example, in 2007, HUMIRA® was awarded the Galien Prize, perhaps the most prestigious honor in the pharmaceutical and biotechnology world. 

23. More importantly, AbbVie’s work has benefited patients immensely. Children have gone from wheelchairs to playgrounds, and adults have
gone from bed to work. AbbVie is very proud of the fact that HUMIRA® has improved the lives of more than one million patients to date. 

24. Although Alvotech had the option of litigating all (or any subset) of the patents identified by AbbVie during the exchanges required under
the BPCIA, Alvotech chose instead to limit this lawsuit to only four of AbbVie’s 62 identified patents. But while Alvotech can delay justice, it cannot prevent it: pursuant to the BPCIA, AbbVie can seek additional relief, including an
injunction, on the remaining patents when Alvotech files a Notice of Commercial Marketing, which it must do at least 180 days prior to launching its biosimilar product. 

  
 8 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 9 of 34 PageID #:9 

 

 PARTIES 

25. Plaintiff AbbVie Inc. is a corporation organized and existing under the laws of Delaware with its corporate headquarters at 1 North
Waukegan Road, North Chicago, Illinois 60064. AbbVie Inc. employs thousands of people in Illinois—including named inventors of the four patents in suit—and is engaged in the development, sale, and distribution of a broad range of
pharmaceutical and biologic drugs, including HUMIRA®. HUMIRA® was developed under the leadership of AbbVie’s management in
Illinois. 
 26. Plaintiff ABL is a corporation organized and existing under the laws of Bermuda, with a place of business at Clarendon
House, 2 Church Street, Hamilton HM1l, Bermuda. Through intermediate organizations, Plaintiff AbbVie Inc. owns Plaintiff ABL. 
 27. On
information and belief, Defendant Alvotech is a company organized and existing under the laws of Iceland, with its principal place of business at Sæmundargata 15-19, 101 Reykjavík, Iceland. 

28. Alvotech is in the business of developing, manufacturing, marketing, and selling biologic drugs, including the proposed biosimilar version
of AbbVie’s HUMIRA® (adalimumab) product, AVT02. Alvotech has taken steps to enable these drugs to be distributed and sold in the State of Illinois, including in this District, and
throughout the United States. 
 JURISDICTION AND VENUE 

29. This is an action for patent infringement under the Patent Laws of the United States, Title 35, United States Code. This Court has subject
matter jurisdiction pursuant to 28 U.S.C. §§ 1331 and 1338(a). 
 30. This Court has personal jurisdiction over Alvotech for
at least the reasons set forth below. 

  
 9 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 10 of 34 PageID #:10 

 

 31. Alvotech has purposefully directed activities at residents of Illinois and this District,
and this action arises out of and relates to those activities. For example, Alvotech has taken the costly, significant step of submitting Alvotech’s abbreviated Biologics License Application (“Alvotech’s aBLA”) to the FDA seeking
approval to engage in the commercial manufacture, use, sale, and/or distribution of the Alvotech aBLA Product in Illinois, including in this District, and Alvotech will do so upon approval of its aBLA. The submission of Alvotech’s aBLA is
therefore tightly tied, both in purpose and planned effect, to the deliberate making of sales of Alvotech’s aBLA Product in Illinois, including in this District, and reliably indicates that Alvotech’s aBLA Product will be marketed in
Illinois, including in this District. Furthermore, Alvotech sent Alvotech’s aBLA to AbbVie Inc. at its corporate headquarters in North Chicago, Illinois. 

32. Alvotech prepared and submitted Alvotech’s aBLA and intends to directly benefit from the sale of the Alvotech aBLA product. Prior to
the submission of Alvotech’s aBLA (and prior to the formation of its wholly-owned U.S. subsidiary, Alvotech USA, Inc. (“Alvotech USA”), Alvotech met with the FDA regarding Alvotech’s AVT02. Alvotech prepared, created, approved,
and/or assembled documentation in support of Alvotech’s aBLA. Alvotech then directed Alvotech USA to act as its agent between the FDA and Alvotech during the regulatory process. 

33. Alvotech USA is the “wholly-owned, regulatory affairs, governmental policy and legal subsidiary” of Alvotech. See Office
Locations, Alvotech, “Our Locations,” https://www.alvotech.com/company/office-locations (last visited April 6, 2021), attached as Exhibit 2. On information and belief, Alvotech USA is a small company that is not involved with drug
development, manufacturing, or sales. On information and belief, Alvotech USA only has one office with a few thousand square feet on part of one floor of an office building, and has fewer than 15 employees—none of whom are manufacturing, sales,
or marketing employees, but rather work in legal or regulatory positions. 

  
 10 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 11 of 34 PageID #:11 

 

 34. Alvotech, not Alvotech USA, created and prepared the information in the aBLA. Indeed, at
least one clinical trial for AVT02 began before Alvotech USA even came into existence, and Alvotech communicated and/or met with the FDA before beginning that trial. Compare ClinicalTrials.gov, “Comparative Safety, Tolerability,
Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers (ALVOPAD),” https://clinicaltrials.gov/ct2/show/NCT03579823?term=AVT02&draw=2&rank=1 (last visited Mar. 10, 2021), attached as Exhibit 3 (study start
date—May 21, 2018) with Exhibit 4 (Alvotech USA incorporated on January 11, 2019). Alvotech has also stated that its aBLA “filings were based on the results of a comprehensive development program and data package comprising of
a totality of evidence demonstrating a high degree of similarity of AVT02 compared to its reference product.” See Press Release, Alvotech, “Alvotech announces that the U.S. FDA and EMA have accepted regulatory submissions for AVT02,
a proposed biosimilar to Humira® (adalimumab),” Nov. 19, 2020, https://www.alvotech.com/newsroom/alvotech-announces-that-the-u.s.-fda-and-ema-have-accepted, attached hereto as
Exhibit 5. 
 35. To support its aBLA, Alvotech submitted data generated by clinical trials to the FDA. See 42 U.S.C.
§ 262(k)(2)(A)(i)(I)(cc) (“An application . . . shall include information demonstrating that — the biologic product is a biosimilar to a reference product based upon data derived from . . . a clinical study or studies . . . that
are sufficient demonstrate safety, purity, and potency in 1 or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product.”); see also
21 C.F.R. § 601.2(a) (“To obtain a biologics license . . . the manufacturer . . . shall submit data 

  
 11 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 12 of 34 PageID #:12 

 

 
derived from . . . clinical studies which demonstrate that the manufactured product meets prescribed requirements of safety, purity, and potency . . . .”). For example, Alvotech has and is
currently sponsoring, directing, and/or authorizing at least six clinical trials of the Alvotech aBLA Product. Clinical trials for the Alvotech aBLA Product began at least as early as May 21, 2018 and Alvotech manufactured the Alvotech aBLA
Product lots that were used in the clinical trials and described in the aBLA. See Exhibit 3. 
 36. Additionally, Alvotech publicized
its Phase I and Phase III clinical trials comparing the Alvotech aBLA Product to HUMIRA®. See Press Release, Alvotech, “Alvotech announces positive
top-line results for two comparative studies for AVT02, a proposed biosimilar to HUMIRA® (adalimumab),” May 12, 2020, https://www.alvotech.com/newsroom/alvotech-announces-positive-top-line-results-for-two-comparative-studies-
 
 for-avt02-a-proposed-biosimilar-to-humira-adalimumab, attached hereto as Exhibit 6. Alvotech specifically stated
that “Alvotech is developing [the Alvotech aBLA Product] as a proposed biosimilar to HUMIRA® (adalimumab) with high concentration (100 mg/mL) dosage forms.” Id. 

37. On information and belief, Alvotech will financially benefit in a significant manner from the approval of Alvotech’s aBLA, since
Alvotech will engage in the commercial manufacture and supply of the Alvotech aBLA Product in Illinois, including this District. For example, Alvotech and Teva entered into an “exclusive strategic partnership for the commercialization in the
U.S.” of the Alvotech aBLA Product and Alvotech will share in profits from sales in the U.S. Press Release, Alvotech, “Alvotech and Teva announce strategic partnership to collaborate in the U.S. biosimilar market,” Aug. 5, 2020, https://www.alvotech.com/newsroom/alvotech-and-teva-announce-strategic-partnership-to, attached as Exhibit 7; see also Exhibit 5
(stating that the Alvotech aBLA Product is one of the biosimilar product candidates part of the Alvotech-Teva strategic partnership). Under the “partnership agreement,” Alvotech “will be responsible for the development, registration
and supply of the [AVT02], while Teva will be exclusively commercializing [AVT02] in the U.S.” Exhibit 7; see also Exhibit 5. 

  
 12 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 13 of 34 PageID #:13 

 

 38. On information and belief, if Alvotech’s aBLA is approved, the Alvotech aBLA Product
will be administered to patients in Illinois, and within this District. These activities, as well as Alvotech’s manufacturing, marketing, selling, and/or distributing of the Alvotech aBLA Product, will have a substantial effect within Illinois,
and within this District, and will constitute infringement of U.S. Patent Nos. 8,420,081, 8,926,975, 8,961,973, and 9,085,619, in the event that the Alvotech aBLA Product is approved before any of these patents expire. 

39. For the reasons described above, among others, the submission of Alvotech’s aBLA was suit-related conduct with a substantial
connection to Illinois and this District, the exercise of personal jurisdiction over Alvotech does not offend traditional notions of fair play and substantial justice, and this Court may properly exercise personal jurisdiction over Alvotech. 

D. Venue 
 40. Venue lies
in this District pursuant to 28 U.S.C. § 1391, including because, inter alia, Alvotech is a foreign entity, and thus is subject to suit in any jurisdiction in the United States including the Northern District of Illinois. 28 U.S.C.
§ 1391(c). 
 THE PARTIES’ EXCHANGES UNDER THE BPCIA 

41. On information and belief, in late August or early September 2020, Alvotech submitted abbreviated Biologics License Application
No. 761205 to the FDA pursuant to the BPCIA, specifically 42 U.S.C. § 262(k), requesting that its biosimilar adalimumab product AVT02 be licensed for commercial sale by relying on AbbVie’s demonstration that HUMIRA® is safe, pure, and potent. The BPCIA provides an abbreviated pathway for approval of a biologic product that is “biosimilar” to a “reference product.” Alvotech has
demonstrated its intention to utilize AbbVie’s data and work discovering and developing adalimumab through the use of the abbreviated BPCIA biosimilar pathway. 

  
 13 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 14 of 34 PageID #:14 

 

 42. To facilitate the protection of biologic innovators’ patent rights, Congress created
an act of infringement related to the submission of an application under subsection 262(k), see 35 U.S.C. § 271(e)(2)(C), and enumerated a set of pre-litigation exchanges under the BPCIA that are
outlined at 42 U.S.C. § 262(l). The subsection (l) procedures are intended to ensure that the maker of an innovative biologic product that is the subject of a biosimilar application will have sufficient time and opportunity to enforce
its patent rights before a biosimilar product enters the market. The BPCIA also requires that a subsection (k) applicant give at least 180 days’ notice before the first commercial marketing of a biosimilar licensed by the FDA. 42 U.S.C.
§ 262(l)(8)(A). The statute specifically contemplates injunctive relief, including preliminary injunctive relief, to prevent unlawful infringement. 

43. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before November 5,
2020. 
 44. On November 5, 2020, Alvotech contacted AbbVie and indicated that it had submitted an aBLA to the FDA and that the FDA
accepted the aBLA for review. Subsequently, in a November 19, 2020 press release, Alvotech announced that the FDA had accepted the aBLA for review. 

45. In November 2020, the parties began exchanging information in accordance with the procedures outlined in the BPCIA. On or about
November 5, 2020, Alvotech provided outside counsel for AbbVie, and AbbVie’s designated in-house attorneys, with access to Alvotech’s aBLA. 

  
 14 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 15 of 34 PageID #:15 

 

 46. On January 4, 2021, pursuant to 42 U.S.C. § 262(l)(3)(A), AbbVie provided
Alvotech with its list of patents for which it believed a claim of patent infringement could be reasonably asserted against Alvotech’s aBLA Product (“AbbVie’s 3A List”). This list identified 63 patents from among the more than
100 patents in the HUMIRA® estate. AbbVie also asked that “[i]n the event that Alvotech asserts that any of the listed patents are either not infringed or invalid pursuant to Section
(l)(3)(B)(ii)(I), Alvotech should identify and provide copies of any documentary evidence supporting those assertions to AbbVie’s outside counsel . . . so that AbbVie may fully consider it.” 

47. Despite having a sixty day statutory period to evaluate AbbVie’s 3A List, just ten days later, on January 14, 2021, Alvotech
responded by providing AbbVie with statements pursuant to 42 U.S.C. § 262(l)(3)(B) contesting Alvotech’s infringement of certain patents and the validity of those patents. Despite AbbVie’s requests, Alvotech did not provide any
additional evidence (e.g., additional manufacturing documents or product information beyond that contained in the aBLA) relating to its non-infringement contentions. This lack of information was compounded by
the fact that for several patents, Alvotech failed to provide any support for its non-infringement positions. 

48. On March 15, 2021, AbbVie provided Alvotech with its detailed statement pursuant to 42 U.S.C. § 262(l)(3)(C) (AbbVie’s
“3C Statement”). AbbVie’s nearly 2,000-page 3C Statement shows that AbbVie reasonably believes that the Alvotech aBLA Product, AVT02, would infringe the following 62 AbbVie patents (AbbVie removed one of the patents from its prior
list) and that those patent claims are valid and enforceable: 
  

							
	 	  	 U.S. Patent No.
	  	 Lead Inventor
	  	 Title

	1.	  	6,805,686	  	Fathallah	  	Autoinjector with Extendable Needle Protector Shroud
				
	2.	  	8,231,876	  	Wan	  	Purified Antibody Composition

  
 15 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 16 of 34 PageID #:16 

 

							
	 	  	 U.S. Patent No.
	  	 Lead Inventor
	  	 Title

	3.	  	8,420,081	  	Fraunhofer	  	Antibody Formulations and Methods of Making Same
				
	4.	  	8,663,945	  	Pla	  	Methods of Producing Anti-TNF-Alpha Antibodies in Mammalian Cell Culture
				
	5.	  	8,708,968	  	Julian	  	Removal of Needle Shields from Syringes and Automatic Injection Devices
				
	6.	  	8,715,664	  	Hoffman	  	Use of Human TNFα Antibodies for Treatment of Erosive Polyarthritis
				
	7.	  	8,808,700	  	Hoffman	  	Use of TNF Alpha Inhibitor for Treatment of Erosive Polyarthritis
				
	8.	  	8,883,156	  	Wan	  	Purified Antibody Composition
				
	9.	  	8,889,136	  	Hoffman	  	Multiple-Variable Dose Regimen for Treating TNFα-Related Disorders
				
	10.	  	8,895,009	  	Wan	  	Purified Antibody Composition
				
	11.	  	8,906,372	  	Wan	  	Purified Antibody Composition
				
	12.	  	8,906,373	  	Banerjee	  	Use of TNF-Alpha Inhibitor for Treatment of Psoriasis
				
	13.	  	8,906,646	  	Pla	  	Fed-Batch Method of Making Human Anti-TNF-Alpha Antibody
				
	14.	  	8,911,737	  	Fischkoff	  	Methods of Administering Anti-TNFα Antibodies
				
	15.	  	8,911,964	  	Pla	  	Fed-Batch Method of Making Human Anti-TNF-Alpha Antibody
				
	16.	  	8,916,153	  	Wan	  	Purified Antibody Composition
				
	17.	  	8,926,975	  	Wong	  	Method of Treating Ankylosing Spondylitis
				
	18.	  	8,961,973	  	Hoffman	  	Multiple-Variable Dose Regimen for Treating TNFα-Related Disorders
				
	19.	  	8,961,974	  	Hoffman	  	Multiple-Variable Dose Regimen for Treating TNFα-Related Disorders
				
	20.	  	8,974,790	  	Fischkoff	  	Methods of Administering Anti-TNFα Antibodies
				
	21.	  	8,986,693	  	Hoffman	  	Use of TNFα Inhibitor for Treatment of Psoriasis
				
	22.	  	8,992,926	  	Fischkoff	  	Methods of Administering Anti-TNFα Antibodies
				
	23.	  	8,999,337	  	Medich	  	Methods for Treating Juvenile Idiopathic Arthritis by Inhibition of TNFα
				
	24.	  	9,061,005	  	Hoffman	  	Multiple-Variable Dose Regimen for Treating Idiopathic Inflammatory Bowel Disease

  
 16 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 17 of 34 PageID #:17 

 

							
	 	  	 U.S. Patent No.
	  	 Lead Inventor
	  	 Title

	25.	  	9,062,106	  	Bengea	  	Methods for Controlling the Galactosylation Profile of Recombinantly-Expressed Proteins
				
	26.	  	9,067,992	  	Hoffman	  	Use of TNFα Inhibitor for Treatment of Psoriatic Arthritis
				
	27.	  	9,085,618	  	Ramasubramanyan	  	Low Acidic Species Compositions and Methods for Producing and Using the Same
				
	28.	  	9,085,619	  	Fraunhofer	  	Anti-TNF Antibody Formulations
				
	29.	  	9,085,620	  	Hoffman	  	Use of TNFα Inhibitor for Treatment of Psoriatic Arthritis
				
	30.	  	9,090,688	  	Bengea	  	Methods for Controlling the Galactosylation Profile of Recombinantly-Expressed Proteins
				
	31.	  	9,090,689	  	Hoffman	  	Use of TNFα Inhibitor for Treatment of Psoriasis
				
	32.	  	9,090,867	  	Pla	  	Fed-Batch Method of Making Anti-TNF-Alpha Antibody
				
	33.	  	9,096,666	  	Wan	  	Purified Antibody Composition
				
	34.	  	9,102,723	  	Wan	  	Purified Antibody Composition
				
	35.	  	9,150,645	  	Subramanian	  	Cell Culture Methods to Reduce Acidic Species
				
	36.	  	9,181,337	  	Subramanian	  	Modulated Lysine Variant Species Compositions and Methods for Producing and Using the Same
				
	37.	  	9,181,572	  	Subramanian	  	Methods to Modulate Lysine Variant Distribution
				
	38.	  	9,187,559	  	Hoffman	  	Multiple-Variable Dose Regimen for Treating Idiopathic Inflammatory Bowel Disease
				
	39.	  	9,234,032	  	Pla	  	Fed-Batch Methods for Producing Adalimumab
				
	40.	  	9,266,949	  	Ramasubramanyan	  	Low Acidic Species Compositions and Methods for Producing and Using the Same
				
	41.	  	9,273,132	  	Wan	  	Purified Antibody Composition
				
	42.	  	9,284,370	  	Medich	  	Methods for Treating Juvenile Idiopathic Arthritis
				
	43.	  	9,284,371	  	Pla	  	Methods of Producing Adalimumab
				
	44.	  	9,290,568	  	Rives	  	 Methods to Control Protein

Heterogeneity

  
 17 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 18 of 34 PageID #:18 

 

							
	 	  	 U.S. Patent No.
	  	 Lead Inventor
	  	 Title

	45.	  	9,315,574	  	Ramasubramanyan	  	Low Acidic Species Compositions and Methods for Producing and Using the Same
				
	46.	  	9,328,165	  	Wan	  	Purified Antibody Composition
				
	47.	  	9,334,319	  	Ramasubramanyan	  	Low Acidic Species Compositions
				
	48.	  	9,339,610	  	Julian	  	Removal of Needle Shield From Syringes and Automatic Injection Devices
				
	49.	  	9,346,879	  	Ramasubramanyan	  	Protein Purification Methods to Reduce Acidic Species
				
	50.	  	9,359,434	  	Subramanian	  	Cell Culture Methods to Reduce Acidic Species
				
	51.	  	9,499,614	  	Hossler	  	Methods for Modulating Protein Glycosylation Profiles of Recombinant Protein Therapeutics Using Monosaccharides and Oligosaccharides
				
	52.	  	9,499,616	  	Subramanian	  	Modulated Lysine Variant Species Compositions and Methods for Producing and Using the Same
				
	53.	  	9,505,834	  	Bengea	  	Methods for Controlling the Galactosylation Profile of Recombinantly-Expressed Proteins
				
	54.	  	9,512,216	  	Hoffman	  	Use of TNFα Inhibitor
				
	55.	  	9,522,953	  	Ramasubramanyan	  	Low Acidic Species Compositions and Methods for Producing and Using the Same
				
	56.	  	9,546,212	  	Fischkoff	  	Methods of Administering Anti-TNFα Antibodies
				
	57.	  	9,550,826	  	Labkovsky	  	Glycoengineered Binding Protein Compositions
				
	58.	  	9,624,295	  	Medich	  	Uses and Compositions for Treatment of Psoriatic Arthritis
				
	59.	  	9,669,093	  	Medich	  	Methods for Treating Juvenile Idiopathic Arthritis
				
	60.	  	9,683,033	  	Subramanian	  	Cell Culture Methods to Reduce Acidic Species
				
	61.	  	9,708,400	  	Subramanian	  	Methods to Modulate Lysine Variant Distribution
				
	62.	  	9,957,318	  	Ramasubramanyan	  	Protein Purification Methods to Reduce Acidic Species

 49. After AbbVie provided its 3C Statement, on March 23, 2021, Alvotech proposed that only four of the 62
patents, namely U.S. Pat. Nos. 8,420,081, 8,926,975, 8,961,973, and 9,085,619, be the subject of the 42 U.S.C. § 262(l)(6) suit. Alvotech had the right under the BPCIA to select all 62 patents, or any subset of those patents it wanted, but
instead proposed litigating just four in this first round of litigation. 

  
 18 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 19 of 34 PageID #:19 

 

 50. On March 29, 2021, AbbVie wrote to Alvotech, explaining that litigating only these
four patents would not resolve all issues of patent infringement with respect to the Alvotech aBLA Product and that, unless Alvotech chose to include them in the first phase of litigation, the remaining patents would still need to be addressed in a
second phase of litigation as contemplated by the BPCIA. See 42 U.S.C. § 262(l)(8). Despite this express notice, Alvotech chose to move forward with only four patents as the subject of the initial 42 U.S.C. § 262(l)(6)
litigation. 
 51. Consequently, AbbVie will have a second opportunity, if and when Alvotech provides a
180-day Notice of Commercial Marketing (or as circumstances otherwise warrant), to assert its remaining patents. So, while Alvotech’s tactics may create delay, it still must face AbbVie’s other
patents before going to market. 
 THE ALVOTECH aBLA PRODUCT 

52. Alvotech has undertaken the development of a proposed biosimilar to AbbVie’s
HUMIRA® (adalimumab) product. 
 53. Alvotech has submitted an aBLA to the FDA
seeking approval to market in the United States a biosimilar version of AbbVie’s HUMIRA® adalimumab product. 

54. On November 19, 2020, Alvotech publicly announced that the FDA had accepted its submission of an aBLA with the FDA for AVT02, a
biosimilar candidate to HUMIRA® (adalimumab). See Exhibit 5. 
 55. Alvotech stated
that “AVT02 is a monoclonal antibody (mAb) and a proposed biosimilar to HUMIRA® (adalimumab)” and that “AVT02 is highly similar to its reference product in terms of structure
and function.” See id. Alvotech further stated that “AVT02 is a proposed biosimilar to the reference product HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage
forms . . . matching the newest dosage forms of the reference product.” Id. 

  
 19 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 20 of 34 PageID #:20 

 

 56. Alvotech stated that its “filings were based on the results of a
comprehensive development program and data package comprising of a totality of evidence demonstrating a high degree of similarity of AVT02 compared to its reference product.” See id. 

57. Alvotech has completed clinical trials with AVT02, testing its use in subjects with moderate to severe chronic psoriasis and has relied on
these clinical trials to support Alvotech’s aBLA. See Exhibit 8; see also Exhibit 9. Alvotech is also sponsoring ongoing clinical trials testing the use of AVT02 in subjects with moderate to severe active rheumatoid arthritis.

 58. The FDA has not yet approved Alvotech’s proposed biosimilar product. 

59. Alvotech has committed a statutory act of patent infringement under 35 U.S.C. § 271(e)(2)(C) by submitting an application
seeking approval of a biological product with respect to patents identified by AbbVie pursuant to 42 U.S.C. § 262(l)(3)(A)(i). 

ABBVIE’S ADALIMUMAB PATENTS 

60. AbbVie identified 62 patents that it reasonably believes would be infringed by Alvotech’s biosimilar product, including its
administration, its formulation, and the processes for manufacturing it. 
 61. Because of Alvotech’s selections during the BPCIA
process, AbbVie is limited at this stage to asserting the following four patents in the present lawsuit: U.S. Patent No. 8,420,081; 8,926,975; 8,961,973; and 9,085,619 (the “AbbVie Patents”). 

62. AbbVie asserts the following four patents in this suit. 

  
 20 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 21 of 34 PageID #:21 

 

 U.S. Patent No. 8,420,081 

63. U.S. Patent No. 8,420,081 (the “’081 patent”), titled “Antibody Formulations and Methods of Making Same,”
was duly and legally issued by the USPTO on April 16, 2013. A true and correct copy of the ’081 patent is attached as Exhibit 10. 

64. ABL is the owner by assignment of the ’081 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’081 patent in the United States. ABL and AbbVie Inc. together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’081 patent. 

65. A related family member of the ’081 patent, U.S. Patent No. 9,085,619 (see Count IV), was previously subject to four separate
IPR challenges before the PTAB (IPR2017-01008, IPR2017-01009, IPR2017-00822, and IPR2017-00823) and its validity was upheld after every challenge. 

66. AbbVie included the ’081 patent in its disclosures to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(A), as described in Count
I below. 
 67. AbbVie has provided to Alvotech, pursuant to confidential exchanges under U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for each of the claims described in Count I below. 

U.S. Patent No. 8,926,975 

68. U.S. Patent No. 8,926,975 (the “’975 patent”), titled “Method of Treating Ankylosing Spondylitis,” was duly
and legally issued by the USPTO on January 6, 2015. A true and correct copy of the ’975 patent is attached as Exhibit 11. 
 69.
ABL is the owner by assignment of the ’975 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through distributors products that would infringe the ’975 patent in the United States. AbbVie Inc. and ABL
together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’975 patent. 

  
 21 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 22 of 34 PageID #:22 

 

 70. AbbVie included the ’975 patent in its disclosures to Alvotech, pursuant to 42
U.S.C. § 262(l)(3)(A), as described in Count II below. 
 71. AbbVie has provided to Alvotech, pursuant to confidential exchanges
under U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for each of the claims described in Count II below. 

U.S. Patent No. 8,961,973 

72. U.S. Patent No. 8,961,973 (the “’973 patent”), titled “Multiple-Variable Dose Regimen for Treating
TNFα-Related Disorders,” was duly and legally issued by the USPTO on February 24, 2015. A true and correct copy of the ’973 patent is attached as Exhibit 12. 

73. ABL is the owner by assignment of the ’973 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’973 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’973 patent. 

74. A related family member of the ’973 patent, U.S. Patent No. 9,187,559, was previously subject to a separate IPR challenge before
the PTAB (IPR2018-00156) and its validity was upheld. 
 75. AbbVie included the ’973 patent in its disclosures to Alvotech, pursuant
to 42 U.S.C. § 262(l)(3)(A), as described in Count III below. 
 76. AbbVie has provided to Alvotech, pursuant to confidential
exchanges under U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for each of the claims described in Count III below. 

  
 22 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 23 of 34 PageID #:23 

 

 U.S. Patent No. 9,085,619 

77. U.S. Patent No. 9,085,619 (the “’619 patent”), titled “Anti-TNF Antibody
Formulations,” was duly and legally issued by the USPTO on July 21, 2015. A true and correct copy of the ’619 patent is attached as Exhibit 13. 

78. ABL is the owner by assignment of the ’619 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’619 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’619 patent. 

79. The ’619 patent was previously subject to four separate IPR challenges before the PTAB (IPR2017-01008, IPR2017-01009, IPR2017-00822,
and IPR2017-00823) and its validity was upheld after every challenge. 
 80. AbbVie included the ’619 patent in its disclosures to
Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(A), as described in Count IV below. 
 81. AbbVie has provided to Alvotech, pursuant
to confidential exchanges under U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for each of the claims described in Count IV below. 

COUNT I 
 INFRINGEMENT
OF U.S. PATENT NO. 8,420,081 
 82. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

83. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 23 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 24 of 34 PageID #:24 

 

 84. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 85. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 86. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of
the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 87. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’081 patent is an act of infringement of one or more of the claims of the ’081 patent under 35 U.S.C. § 271(e)(2)(C), either literally or under the doctrine of equivalents. 

88. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the indications, dosage, and
methods of use for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates,
subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 25, 33, 57-61, 63-67, 84, 86-89, 91-93, and 95-99 of the ’081 patent under 35 U.S.C.
§§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to U.S.C. § 262(l)(3)(C),
claim-by-claim infringement contentions for claims 25, 33, 57-61, 63-67, 84, 86-89, 91-93, and 95-99 of the ’081 patent. For at least one claim, however, Alvotech’s failure to provide sufficient
manufacturing information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’081 patent. 

  
 24 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 25 of 34 PageID #:25 

 

 89. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to
the fact that the formulation of the Alvotech aBLA Product directly infringes at least one claim of the ’081 patent, either literally or under the doctrine of equivalents. 

90. Alvotech has knowledge of and is aware of the ’081 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C.
§ 262(l)(3)(A) and to the filing of this Complaint. 
 91. AbbVie will suffer irreparable injury for which damages are an
inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’081 patent. 
 92. AbbVie seeks an injunction pursuant
to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT II 
 INFRINGEMENT
OF U.S. PATENT NO. 8,926,975 
 93. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

94. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 95. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before November 5,
2020. 

  
 25 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 26 of 34 PageID #:26 

 

 96. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

97. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of the
Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 98. Based on confidential information disclosed to AbbVie by Alvotech
pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, offer to sell, or sale of the Alvotech aBLA Product prior to the expiration of the ’975
patent is an act of infringement of one or more of the claims of the ’975 patent under 35 U.S.C. § 271(e)(2)(C), either literally or under the doctrine of equivalents. 

99. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the indications, dosage, and
methods of use for the Alvotech aBLA Product. Based on this confidential information and on information and belief, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly
or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will actively induce infringement by others or contribute to infringement by others of at least claims 1-6 of the
’975 patent under 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-6 of the ’975 patent. 

100. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’975 patent, either literally or under the doctrine of equivalents. 
 101. On information and belief, Alvotech is aware,
has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims
1-6 of the ’975 patent, either literally or under the doctrine of equivalents. 

  
 26 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 27 of 34 PageID #:27 

 

 102. On information and belief, Alvotech will knowingly or with willful blindness induce or
contribute to another’s direct infringement of at least claims 1-6 of the ’975 patent, either literally or under the doctrine of equivalents. 

103. Alvotech has knowledge of and is aware of the ’975 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C.
§ 262(l)(3)(A) and to the filing of this Complaint. 
 104. AbbVie will suffer irreparable injury for which damages are an
inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’975 patent. 
 105. AbbVie seeks an injunction pursuant
to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT III 
 INFRINGEMENT
OF U.S. PATENT NO. 8,961,973 
 106. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein.

 107. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 108. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before November 5,
2020. 

  
 27 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 28 of 34 PageID #:28 

 

 109. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

110. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of the
Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 111. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, offer to sell, sale, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’973 patent is an act of infringement of one or more of the claims of the ’973 patent under 35 U.S.C. § 271(e)(2)(C), either literally or under the doctrine of equivalents. 

112. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the indications, dosage, and
methods of use for the Alvotech aBLA Product. Based on this confidential information and on information and belief, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly
or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will actively induce infringement by others or contribute to infringement by others of at least claims 1-30 of the
’973 patent under 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-30 of the ’973 patent. 

113. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’973 patent, either literally or under the doctrine of equivalents. 
 114. On information and belief, Alvotech is aware,
has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims
1-30 of the ’973 patent, either literally or under the doctrine of equivalents. 

  
 28 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 29 of 34 PageID #:29 

 

 115. On information and belief, Alvotech will knowingly or with willful blindness induce or
contribute to another’s direct infringement of at least claims 1-30 of the ’973 patent, either literally or under the doctrine of equivalents, by at least Alvotech’s proposed package insert for
the Alvotech aBLA Product. 
 116. Alvotech has knowledge of and is aware of the ’973 patent, including due to AbbVie’s disclosure
of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 117. AbbVie will suffer irreparable
injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’973 patent. 
 118.
AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within, and/or importation into the United States of the Alvotech aBLA Product. 

COUNT IV 
 INFRINGEMENT
OF U.S. PATENT NO. 9,085,619 
 119. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein.

 120. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 29 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 30 of 34 PageID #:30 

 

 121. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 122. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 123. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of
the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 124. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, offer to sell, sale, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’619 patent is an act of infringement of one or more of the claims of the ’619 patent under 35 U.S.C. § 271(e)(2)(C), either literally or under the doctrine of equivalents. 

125. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the indications, dosage, and
methods of use for the Alvotech aBLA Product. Based on this confidential information and on information and belief, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly
or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe or actively induce infringement by others or contribute to infringement by others of at least claims
1-5 and 16-30 of the ’619 patent under 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to
Alvotech, pursuant to U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-5 and 16-30 of the ’619 patent. 
 126. On information and belief, Alvotech is aware, has knowledge, and/or
is willfully blind to the fact that the formulation of the Alvotech aBLA Product directly infringes at least claims 1-5 and 16-30 of the ’619 patent, either
literally or under the doctrine of equivalents. 

  
 30 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 31 of 34 PageID #:31 

 

 127. Alvotech has knowledge of and is aware of the ’619 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 128. AbbVie
will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’619 patent. 

129. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 PRAYER FOR RELIEF 

WHEREFORE, Plaintiffs respectfully request that this Court enter judgment in their favor against Defendant and grant the following relief:

 a. a judgment that Alvotech has infringed, induced infringement, or contributed to infringement of one or more claims of the AbbVie
Patents under 35 U.S.C. § 271(e)(2)(C); 
 b. a judgment that Alvotech has or will infringe or has or will induce or contribute to
infringement of one or more claims of the AbbVie Patents by engaging in the manufacture, import, offer for sale, sale, or use within the United States of the Alvotech aBLA Product before the expirations of the AbbVie Patents; 

c. preliminary and/or permanent equitable relief, including but not limited to an injunction that enjoins Alvotech, its officers, partners,
agents, servants, employees, parents, subsidiaries, affiliate corporations, other related business entities, and all other persons acting in concert, participation, or in privity with them and/or their successors or assigns from infringing the
AbbVie Patents, or contributing to or inducing anyone to do the same, by acts including the manufacture, use, offer to sell, sale, or distribution within the United States, or importation into the United States, of any current or future versions of
the Alvotech aBLA Product, the use or manufacturing of which infringes the AbbVie Patents; 

  
 31 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 32 of 34 PageID #:32 

 

 d. a declaration that this is an exceptional case and an award to Plaintiffs of their
attorneys’ fees, costs, and expenses pursuant to 35 U.S.C. § 271(e)(4) and 35 U.S.C. § 285; and 
 e. such other
relief as this Court may deem just and proper. 

  
 32 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 33 of 34 PageID #:33 

 

					
	  
  

Dated: April 27, 2021
	 	                                    	  	 Respectfully submitted,
  

/s/ Sean M. Berkowitz

Sean M. Berkowitz (ARDC No. 6209701)

sean.berkowitz@lw.com
 LATHAM & WATKINS LLP

330 North Wabash Avenue, Suite 2800
 Chicago, Illinois 60611

Telephone: (312) 876-7700

Facsimile: (312) 993-9767

			
		 		  	 Michael A. Morin (ARDC No. 6229902)
 David
P. Frazier (pro hac vice forthcoming)
 michael.morin@lw.com

david.frazier@lw.com
 LATHAM & WATKINS LLP

555 Eleventh Street, N.W., Suite 1000
 Washington, D.C.
20004-1304
 Telephone: (202) 637-2200

Facsimile: (202) 637-2201

			
		 		  	 Arlene L. Chow (pro hac vice forthcoming)

Herman H. Yue (pro hac vice forthcoming)

arlene.chow@lw.com
 herman.yue@lw.com

LATHAM & WATKINS LLP
 885 Third Avenue

New York, NY 10022
 Telephone: (212) 906-1200
 Facsimile: (212) 751-4864

			
		 		  	 Michael Seringhaus (pro hac vice forthcoming)

michael.seringhaus@lw.com
 LATHAM & WATKINS LLP

140 Scott Drive
 Menlo Park, CA 94025

Telephone: (650) 328-4600

Facsimile: (650) 463-2600

			
		 		  	Gabrielle LaHatte (pro hac vice forthcoming) gabrielle.lahatte@lw.com

  
 33 

 Case: 1:21-cv-02258 Document #: 1 Filed: 04/27/21 Page 34 of 34 PageID #:34 

 

					
		 		  	 LATHAM & WATKINS LLP
 505 Montgomery
Street Suite 2000
 San Francisco, CA 94111
 Telephone: (415) 391-0600
 Facsimile: (415) 395-8095

			
		 		  	 William B. Raich (pro hac vice forthcoming)

Charles T. Collins-Chase (pro hac vice forthcoming)

william.raich@finnegan.com
 charles.collins-chase@finnegan.com

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP
 901
New York Ave., N.W.
 Washington, D.C. 20001
 Telephone: (202) 408-4000
 Facsimile: (202) 408-4400

			
		 		  	 Oulu Wang (pro hac vice forthcoming)

lulu.wang@finnegan.com
 FINNEGAN, HENDERSON, FARABOW,

GARRETT & DUNNER, LLP
 2 Seaport Lane

Boston, MA 02210
 Telephone: (617)
646-1600
 Facsimile: (617) 646-1666

			
		 		  	 Counsel for Plaintiffs AbbVie Inc.

and AbbVie Biotechnology Ltd

  
 34 

 Execution Version 

FRE 408 / Confidential 
 Exhibit C – BPCIA
(l)(8) Case 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 1 of 323 PageID #:22568 

 

 UNITED STATES DISTRICT COURT 

FOR THE NORTHERN DISTRICT OF ILLINOIS 

EASTERN DIVISION 
  

					
	 ABBVIE INC. and ABBVIE

BIOTECHNOLOGY LTD
  

Plaintiffs,
	 		  	
	 		
	 v.

 
 ALVOTECH HF.

 
 Defendant.
	 		  	 Civil Action No. 1:21-cv-02899

 
 Hon. John Z. Lee

 
 Magistrate Judge M. David Weisman

 SECOND AMENDED COMPLAINT 

INTRODUCTION 
 1. This is
the second action for patent infringement that AbbVie Inc. and AbbVie Biotechnology Ltd (“ABL,” collectively referred to as “AbbVie” or “Plaintiffs”) have brought against Alvotech hf. (“Alvotech”) under the
Biosimilar Price Competition and Innovation Act of 2009 (“BPCIA”) in connection with Alvotech’s proposed biosimilar version of AbbVie’s ground-breaking drug HUMIRA®. AbbVie
brought the first action in this District on April 27, 2021, to adjudicate Alvotech’s infringement of four AbbVie patents that Alvotech selected for the first phase of litigation prescribed by the BPCIA. See AbbVie Inc. and AbbVie
Biotechnology Ltd v. Alvotech hf., Civ. No. 1:21-cv-02258 (N.D. Ill. Apr. 27, 2021) (Lee, J.). Rather than answer or otherwise respond to that complaint, however,
Alvotech sought an end-run around AbbVie’s choice of forum by filing a declaratory judgment action on those same four patents in the Eastern District of Virginia on May 11, 2021. Alvotech USA Inc.
and Alvotech hf. v. AbbVie Inc. and AbbVie Biotechnology Ltd, Civ. No. 2:21-cv-00265 (E.D. Va. May 11, 2021) (Jackson, J.). Although that suit has now been
transferred to this district and dismissed, see Alvotech USA Inc. 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 2 of 323 PageID #:22568 

 

 
and Alvotech hf. v. AbbVie Inc. and AbbVie Biotechnology Ltd, Civ. No. 2:21-cv-00265, Dkt. 51 (E.D. Va.
May 11, 2021) (Jackson, J.) and Alvotech USA Inc. and Alvotech hf. v. AbbVie Inc. and AbbVie Biotechnology Ltd, Civ. No. 1:21-cv-05645, Dkt. 55 (N.D. Ill.
Nov. 10, 2021) (notice of voluntary dismissal), Alvotech’s filing and additional actions, discussed below, have triggered this second suit under the BPCIA to protect AbbVie’s rights and promote the orderly disposition of all the patent
infringement issues raised by Alvotech’s proposed biosimilar product. 
 2. AbbVie’s patents at issue in this suit and in the
first-filed BPCIA action already pending in this District result from decades of work by AbbVie’s scientists and clinicians developing HUMIRA®—the first fully human antibody ever
approved by the U.S. Food and Drug Administration (“FDA”)—and expanding its use into a variety of diseases and patient populations, as well as launching a new, higher-concentration, citrate-free formulation with reduced injection
volume and pain upon injection. Over one million patients have benefited from AbbVie’s pioneering work, which also has produced a robust portfolio of patents and trade secrets, including trade secret manufacturing processes. 

3. Numerous biosimilar companies—now including Alvotech—have taken note of AbbVie’s success as well, attempting to make
biosimilar versions of HUMIRA®. Ultimately, each of the prior biosimilar applicants recognized the strength of the portfolio and sought licenses from AbbVie. AbbVie settled with each, allowing
market entry years before expiration of many of its patents. As a result, biosimilar versions of HUMIRA® will enter the U.S. market in 2023. 

4. AbbVie’s HUMIRA® patent portfolio is also notable for its proven quality.
Numerous biosimilar makers have previously filed a total of 20 inter partes review (“IPR”) petitions challenging 14 of AbbVie’s patents at the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and
Trademark Office (“USPTO”). Despite the lower burden of proof 

  
 2 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 3 of 323 PageID #:22568 

 

 
compared to district court proceedings (a preponderance of the evidence rather than clear and convincing evidence and, at the time, a broad claim construction standard) and the high invalidation
rate in IPRs, AbbVie prevailed on nine of its patents in 13 IPRs, with challenges to two more patents withdrawn. Ultimately, each of the prior biosimilar applicants recognized the strength of the portfolio and sought licenses from AbbVie. 

5. Of particular relevance, the PTAB has already rejected five petitions challenging the validity of AbbVie patents at issue in this
proceeding. Specifically, the PTAB rejected a petition challenging the validity of U.S. Patent No. 8,911,737, directed to treatment of Crohn’s disease. The PTAB also rejected a petition challenging the validity of U.S. Patent
No. 9,187,559, directed to induction dosing to treat Crohn’s disease. The PTAB similarly rejected a petition challenging the validity of U.S. Patent No. 8,974,790, directed to treatment of ulcerative colitis. The PTAB also rejected
two petitions challenging the validity of U.S. Patent No. 9,512,216, directed to treatment of chronic plaque psoriasis. 
 6.
AbbVie’s investment in HUMIRA® development includes over 100 clinical trials and has resulted in FDA approval for the treatment of 13 different disease conditions, including rheumatoid
arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn’s disease (adult and pediatric), ulcerative colitis (adult and pediatric), hidradenitis suppurativa (adult and pediatric), uveitis (adult and pediatric), and juvenile
idiopathic arthritis. AbbVie has continued to dedicate substantial resources to an extensive clinical trial program, including research specifically to benefit children. For example, in February of this year, AbbVie received FDA approval to treat
pediatric patients living with moderately to severely active ulcerative colitis, making HUMIRA® the first and only subcutaneous biologic treatment option for pediatric patients five years and
older with this condition. 

  
 3 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 4 of 323 PageID #:22568 

 

 7. AbbVie also has continued to improve and develop the HUMIRA® product itself. First, AbbVie invested in and created a subcutaneous, high concentration, liquid formulation of the HUMIRA® antibody.
Before AbbVie’s launch of HUMIRA®, patients had to go to the hospital to receive their medicine intravenously, or mix batches of their medicine at home (difficult for patients with
inflamed joints) and inject themselves twice a week. As a result of AbbVie’s dedication, innovation, and investment, patients were able to inject the medicine at home using pre-filled syringes or
automatic injection devices, and take fewer injections. The added convenience and precision improved patients’ lives and increased compliance, all without sacrificing HUMIRA®’s
outstanding efficacy. 
 8. But AbbVie did not stop there. Through continuing investment into formulation research, AbbVie developed a new,
higher-concentration (100 mg/mL), citrate-free formulation with reduced pain upon injection. AbbVie’s inventive new formulation leverages the surprising inventions patented by AbbVie researchers, namely that the active ingredient, adalimumab,
can be formulated at high concentrations without a buffer, while maintaining solubility and stability— including during long-term storage or other processing steps. It is this latest innovative formulation that Alvotech seeks to copy.
Alvotech’s founder and Chairman—Robert Wessman— explained earlier this year how Alvotech monitored and sought to replicate AbbVie’s advances, switching gears from a 50 mg/mL concentration copy of adalimumab to a 100 mg/mL
high-concentration version as soon as Alvotech “heard that AbbVie was getting ready to launch 100mg.” Wallace, David, “Celltrion Wins Global First Approval For High-Concentration Humira Biosimilar,” Generics Bulletin (Feb. 15,
2021), attached as Exhibit 1 (“We were actually active in developing 50mg three or four years back,” Wessman noted, but “when we heard that AbbVie was getting ready to launch 100mg we stopped that and started to focus only on 100mg.
We did not even consider 50mg any more.”). 

  
 4 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 5 of 323 PageID #:22568 

 

 9. AbbVie has also spent many years developing and improving the complex manufacturing
processes for HUMIRA® and its active ingredient, adalimumab. Unlike traditional drugs, HUMIRA® is a complex biologic created in living
organisms. So even minor changes to the manufacturing process can impact the drug’s stability, purity, and efficacy. AbbVie obtained patents and developed trade secrets covering innovations in manufacturing. 

10. In late 2020, Alvotech filed its abbreviated Biologics License Application (“Alvotech’s aBLA”) seeking FDA approval to
launch its own biosimilar of HUMIRA®. 
 11. The BPCIA permits Alvotech to file its
aBLA, but it does so only in tandem with a specific framework for innovator companies like AbbVie to litigate their patents before a would-be biosimilar applicant launches its product. In particular, the BPCIA
contemplates two waves of litigation. The first wave follows an exchange between the parties under 42 U.S.C. § 262(l)(3) of information about the biosimilar applicant’s proposed product and the reference product sponsor’s
patents that the biosimilar product would infringe. After that exchange, the biosimilar applicant can elect how many (and which) of the reference product sponsor’s patents it would like to litigate in the first wave. 42 U.S.C.
§ 262(l)(4)-(6). The second wave of litigation, which may involve additional patents, is not triggered until the biosimilar applicant provides its notice of commercial marketing, after which the reference product sponsor may sue for
relief on its remaining patents. 42 U.S.C. § 262(l)(8)-(9). 

  
 5 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 6 of 323 PageID #:22568 

 

 12. Alvotech chose to litigate only four patents in the first wave, despite the fact that
AbbVie identified 62 patents that would be infringed by Alvotech’s biosimilar product. See AbbVie Inc. and AbbVie Biotechnology Ltd v. Alvotech hf., Civ. No.
1:21-cv-02258 (N.D. Ill. Apr. 27, 2021) (Lee, J.). Yet, Alvotech then abandoned the BPCIA’s procedures by seeking to litigate the same four patents in a declaratory
judgment action in a different federal court after AbbVie filed its first BPCIA-prescribed suit. On the same day it filed its Eastern District of Virginia complaint, Alvotech provided AbbVie with Alvotech’s notice of commercial marketing under
42 U.S.C. § 262(l)(8)(A). 
 13. Filing a separate suit on the same patents in an effort to change courts is improper. The
Eastern District of Virginia recently ended that gambit by transferring the case back to this Court, and Alvotech agreed to dismiss the case without prejudice. Alvotech USA Inc. and Alvotech hf. v. AbbVie Inc. and AbbVie Biotechnology Ltd,
Civ. No. 2:21-cv-00265, Dkt. 51 (E.D. Va. May 11, 2021) (Jackson, J.). 

14. Alvotech’s attempt to forum-shop is not the first time it has shown its unwillingness to adhere to the requirements of the BPCIA. As
part of the exchanges under 42 U.S.C. § 262(l)(3), Alvotech was required to provide not only its aBLA, but also its manufacturing information to AbbVie. See 42 U.S.C. § 262(l)(2)(A) (applicant shall provide
“such other information that describes the process or processes used to manufacture the biological product that is the subject of such application”). Despite multiple requests, Alvotech failed to fulfill its obligations and disclose
necessary manufacturing information for its biosimilar product. Instead of properly investigating its own records, Alvotech in many instances provided incomplete information, hedging its disclosures about its own product and processes with
statements like “upon information and belief” and “as will be confirmed through further discovery.” 

  
 6 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 7 of 323 PageID #:22568 

 

 15. Now, Alvotech’s decision to provide its notice of commercial marketing pursuant to
42 U.S.C. § 262(l)(8)(A) indicates that Alvotech may attempt to market its biosimilar version of HUMIRA® at-risk before resolution of
AbbVie’s related patent infringement action in this District.1 Under the BPCIA, that notice of commercial marketing also triggers this declaratory judgment action so AbbVie can enforce the 58
patents that Alvotech declined to litigate in both the related action in this District and its improper declaratory judgment action in the Eastern District of Virginia and any newly issued patents. 42 U.S.C. § 262(l)(7)-(9).
Although Alvotech’s notice indicated that it might market its biosimilar product as soon as November 2021, to date Alvotech does not have regulatory approval and has agreed to wait to launch its biosimilar product until at least the district
court’s decision on the August 2022 trial on the ten patents. See 9/2/2021 Hearing Tr. at 7:23-9:13; see also Dkt. 53 at ¶ 13. The fact that Alvotech seeks to market its biosimilar
version of HUMIRA® potentially before the expiration of AbbVie’s patents and before the conclusion of AbbVie’s related patent infringement action reinforces that there is a
substantial controversy, between parties having adverse legal interests, of sufficient immediacy and reality to warrant relief, including in the form of a preliminary injunction. 

NATURE OF THE ACTION 
 16.
Plaintiffs for their Complaint against Alvotech further allege as follows: 
 17. This civil action arises under the Patent Laws of the
United States, 35 U.S.C. §§ 1, et seq., including 35 U.S.C. § 271(a)-(c), (e)(2)(C), and (g), the BPCIA, including 42 U.S.C. § 262(l), and the Declaratory Judgment Act, 28 U.S.C.
§§ 2201-2202. 
 18. This lawsuit results from Alvotech’s infringement of AbbVie patents that concern AbbVie’s
groundbreaking drug, HUMIRA®. 
  

	1 	 AbbVie has proposed procedures to consolidate this action with AbbVie Inc. and AbbVie Biotechnology
Ltd v. Alvotech hf., Civ. No. 1:21-cv-02258 (N.D. Ill. Apr. 27, 2021) (Lee, J.) for purposes of discovery, claim construction, and the August 2022 trial on the ten
patents, although each case would retain its own judgment. Aside from the ten patents in the August 2022 trial, all of the remaining patents would be stayed. 

  
 7 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 8 of 323 PageID #:22568 

 

 19. AbbVie Inc. is the holder of Biologic License Application (“BLA”)
No. 125057 for HUMIRA®, whose active pharmaceutical ingredient is the antibody, adalimumab. 

20. In 1996, after many years of intense research, AbbVie’s predecessor first created adalimumab. Adalimumab, a biologic, is a fully
human, high-affinity, and neutralizing therapeutic antibody against human TNF-α, a protein made by the human body as part of the body’s immune response. The mechanisms by which TNF-α affects the body are complex and not completely understood (even today). Inventing the adalimumab antibody itself, however, was only the first step in a long process. Following the isolation and
characterization of adalimumab, AbbVie and its predecessors spent more than two decades and hundreds of millions of dollars on scientific studies and clinical trials to determine how to use
HUMIRA® to treat patients for different diseases, how to formulate HUMIRA® for easier administration, how to improve and further
develop the formulation, how to manufacture HUMIRA®, and how to develop devices for administration. AbbVie’s scientific and clinical investments in HUMIRA® continue to this day—leading, for example, to the February 2021 approval of HUMIRA® to treat pediatric patients living with
moderately to severely active ulcerative colitis. 
 21. AbbVie’s innovative work has been recognized by the medical and scientific
community. For example, in 2007, HUMIRA® was awarded the Galien Prize, perhaps the most prestigious honor in the pharmaceutical and biotechnology world. 

22. More importantly, AbbVie’s work has benefited patients immensely. Children have gone from wheelchairs to playgrounds, and adults have
gone from bed to work. AbbVie is very proud of the fact that HUMIRA® has improved the lives of more than one million patients to date. 

  
 8 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 9 of 323 PageID #:22568 

 

 23. Although Alvotech had the option of litigating all (or any subset) of the patents
identified by AbbVie during the exchanges required under the BPCIA, Alvotech chose instead to limit the initial lawsuit to only four of AbbVie’s 62 identified patents. Alvotech then chose to serve a notice of commercial marketing and file a
duplicative lawsuit on those same four patents in the Eastern District of Virginia. Pursuant to the BPCIA, AbbVie now brings this suit seeking additional relief, including an injunction, on the remaining patents based on Alvotech’s notice of
commercial marketing. 
 PARTIES 

24. Plaintiff AbbVie Inc. is a corporation organized and existing under the laws of Delaware with its corporate headquarters at 1 North
Waukegan Road, North Chicago, Illinois 60064. AbbVie Inc. owns patents relating to HUMIRA® and owns Biologics License Application No. 125057 for HUMIRA®. AbbVie Inc. also employs thousands of people in Illinois—including named inventors of the patents in suit—and is engaged in the development, sale, and distribution of a broad range of
pharmaceutical and biologic drugs, including HUMIRA®. Indeed, HUMIRA® was developed and is marketed under the leadership of
AbbVie’s management in Illinois. 
 25. Plaintiff ABL is a corporation organized and existing under the laws of Bermuda, with a place of
business at Harbour Fiduciary Services Limited, Thistle House, 4 Burnaby Street, Hamilton Pembroke HM11, Bermuda. Through intermediate organizations, Plaintiff AbbVie Inc. owns Plaintiff ABL. ABL has licensed its patents relating to HUMIRA® to AbbVie Inc. and also maintains extensive business relationships with AbbVie Inc., including supplying AbbVie Inc. with HUMIRA® for
marketing. 

  
 9 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 10 of 323 PageID #:22568 

 

 26. On information and belief, Defendant Alvotech is a company organized and existing under
the laws of the Republic of Iceland, with its principal place of business at Sæmundargata 15-19, 101 Reykjavík, Iceland. 

27. Alvotech is in the business of developing, manufacturing, marketing, and selling biosimilar drugs, including the proposed biosimilar
version of AbbVie’s HUMIRA® (adalimumab) product, AVT02. Alvotech has taken steps to enable AVT02 to be distributed and sold in the State of Illinois, including in this District, and
throughout the United States. 
 JURISDICTION AND VENUE 

28. This is an action for patent infringement under the Patent Laws of the United States, 35 U.S.C. §§ 1, et seq.,
including 35 U.S.C. § 271(a)-(c), (e)(2)(C), and (g), the BPCIA, including 42 U.S.C. § 262(l), and the Declaratory Judgment Act, 28 U.S.C. §§ 2201-2202. This Court has subject matter jurisdiction pursuant to 28
U.S.C. §§ 1331, 1338(a), 2201(a), and 2202. 
 29. This Court has personal jurisdiction over Alvotech for at least the reasons
set forth below. 
 30. Alvotech has purposefully directed activities at residents of Illinois and this District, and this action arises out
of and relates to those activities. For example, Alvotech has taken the costly, significant step of submitting Alvotech’s aBLA to the FDA seeking approval to engage in the commercial manufacture, use, sale, and/or distribution of the Alvotech
aBLA Product in Illinois, including in this District, and Alvotech will do so upon approval of its aBLA. The submission of Alvotech’s aBLA is therefore tightly tied, both in purpose and planned effect, to the deliberate making of sales of
Alvotech’s aBLA Product in Illinois, including in this District, and reliably indicates that Alvotech’s aBLA Product will be marketed in Illinois, including in this District. Furthermore, Alvotech sent Alvotech’s aBLA to AbbVie Inc.
at its corporate headquarters in North Chicago, Illinois. Alvotech also provided notice of commercial marketing indicating its intent to market its product nationwide, including in this District. 

  
 10 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 11 of 323 PageID #:22568 

 

 31. Alvotech prepared and submitted Alvotech’s aBLA and intends to directly benefit from
the sale of the Alvotech aBLA product. Prior to the submission of Alvotech’s aBLA (and prior to the formation of its wholly-owned U.S. subsidiary, Alvotech USA), Alvotech met with the FDA regarding Alvotech’s AVT02. Alvotech prepared,
created, approved, and/or assembled documentation in support of Alvotech’s aBLA. Alvotech then directed Alvotech USA to act as its agent between the FDA and Alvotech during the regulatory process. 

32. Alvotech USA is the “wholly-owned, regulatory affairs, governmental policy and legal subsidiary” of Alvotech. See Office
Locations, Alvotech, “Our Locations,” https://www.alvotech.com/company/office-locations (last visited April 6, 2021), attached as Exhibit 2. On information and belief, Alvotech USA is a small company that is not involved with drug
development, manufacturing, marketing, or sales. On information and belief, Alvotech USA only has one office with a few thousand square feet on part of one floor of an office building, and has fewer than 15 employees—none of whom are
manufacturing, sales, or marketing employees, but rather work in legal or regulatory positions. 
 33. Alvotech, not Alvotech USA,
created and prepared the information in the aBLA. Indeed, at least one clinical trial for AVT02 began before Alvotech USA even came into existence, and Alvotech communicated and/or met with the FDA before beginning that trial. Compare
ClinicalTrials.gov, “Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers (ALVOPAD),” https://clinicaltrials.gov/ct2/show/NCT03579823?term=AVT02&draw=2&rank=1 (last
visited Mar. 10, 2021), attached as Exhibit 3 (study start date—May 21, 2018) with Exhibit 4 (Alvotech 

  
 11 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 12 of 323 PageID #:22568 

 

 
USA incorporated on January 11, 2019). Alvotech has also stated that its aBLA “filings were based on the results of a comprehensive development program and data package comprising of a
totality of evidence demonstrating a high degree of similarity of AVT02 compared to its reference product.” See Press Release, Alvotech, “Alvotech announces that the U.S. FDA and EMA have accepted regulatory submissions for AVT02, a
proposed biosimilar to Humira® (adalimumab),” Nov. 19, 2020, https://www.alvotech.com/newsroom/alvotech-announces-that-the-u.s.-fda-and-ema-have-accepted, attached hereto as
Exhibit 5. 
 34. To support its aBLA, Alvotech submitted data generated by clinical trials to the FDA. See 42 U.S.C.
§ 262(k)(2)(A)(i)(I)(cc) (“An application . . . shall include information demonstrating that — the biologic product is a biosimilar to a reference product based upon data derived from . . . a clinical study or studies . . . that
are sufficient demonstrate safety, purity, and potency in 1 or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product.”); see
also 21 C.F.R. § 601.2(a) (“To obtain a biologics license . . . the manufacturer . . . shall submit data derived from . . . clinical studies which demonstrate that the manufactured product meets prescribed requirements of safety,
purity, and potency . . . .”). For example, Alvotech has and is currently sponsoring, directing, and/or authorizing at least six clinical trials of the Alvotech aBLA Product. Clinical trials for the Alvotech aBLA Product began at least as early
as May 21, 2018 and Alvotech manufactured the Alvotech aBLA Product lots that were used in the clinical trials and described in the aBLA. See Exhibit 3. 

  
 12 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 13 of 323 PageID #:22568 

 

 35. Additionally, Alvotech publicized its Phase I and Phase III clinical trials comparing the
Alvotech aBLA Product to HUMIRA®. See Press Release, Alvotech, “Alvotech announces positive top-line results for two comparative studies for
AVT02, a proposed biosimilar to HUMIRA® (adalimumab),” May 12, 2020, https://www.alvotech.com/newsroom/alvotech- announces-positive-top-line-results-for-two-comparative-
studies-for-avt02-a-proposed-biosimilar-to-humira-adalimumab,
 attached hereto as Exhibit 6. Alvotech specifically stated that “Alvotech is developing [the Alvotech aBLA Product] as a proposed biosimilar to
HUMIRA® (adalimumab) with high concentration (100 mg/mL) dosage forms.” Id. 

36. On information and belief, Alvotech will financially benefit in a significant manner from the approval of Alvotech’s aBLA, since
Alvotech will engage in the commercial manufacture and supply of the Alvotech aBLA Product in Illinois, including this District. For example, Alvotech and Teva Pharmaceutical Industries Ltd. (“Teva”) entered into an “exclusive
strategic partnership for the commercialization in the U.S.” of the Alvotech aBLA Product and Alvotech will share in profits from sales in the U.S. See Press Release, Alvotech, “Alvotech and Teva announce strategic partnership to
collaborate in the U.S. biosimilar market,” Aug. 5, 2020,
https://www.alvotech.com/newsroom/alvotech-and-teva-announce-strategic-partnership-to, attached as Exhibit 7; see
also Exhibit 5 (stating that the Alvotech aBLA Product is one of the biosimilar product candidates part of the Alvotech-Teva strategic partnership). Under the “partnership agreement,” Alvotech “will be responsible for the development,
registration and supply of the [AVT02], while Teva will be exclusively commercializing [AVT02] in the U.S.” Exhibit 7; see also Exhibit 5. 

37. On information and belief, if Alvotech’s aBLA is approved, the Alvotech aBLA Product will be administered to patients in Illinois, and
within this District. These activities, as well as Alvotech’s manufacturing, marketing, selling, and/or distributing of the Alvotech aBLA Product, will have a substantial effect within Illinois, and within this District, and will constitute
infringement of U.S. Patent Nos. 6,805,686, 8,231,876, 8,420,081, 8,663,945, 8,708,968, 

  
 13 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 14 of 323 PageID #:22568 

 

 
8,715,664, 8,808,700, 8,883,156, 8,889,136, 8,895,009, 8,906,372, 8,906,373, 8,906,646, 8,911,737, 8,911,964, 8,916,153, 8,926,975, 8,961,973, 8,961,974, 8,974,790, 8,986,693, 8,992,926,
8,999,337, 9,061,005, 9,062,106, 9,067,992, 9,085,618, 9,085,619, 9,085,620, 9,090,688, 9,090,689, 9,090,867, 9,096,666, 9,102,723, 9,150,645, 9,181,337, 9,181,572, 9,187,559, 9,234,032, 9,266,949, 9,273,132, 9,284,370, 9,284,371, 9,290,568,
9,315,574, 9,328,165, 9,334,319, 9,339,610, 9,346,879, 9,359,434, 9,499,614, 9,499,616, 9,505,834, 9,512,216, 9,522,953, 9,546,212, 9,550,826, 9,624,295, 9,669,093, 9,683,033, 9,708,400, 9,957,318, 11,147,782, 11,167,030, and 11,191,834 in the event
that the Alvotech aBLA Product is approved before any of these patents expire.2 
 38.
For the reasons described above, among others, the submission of Alvotech’s aBLA was suit-related conduct with a substantial connection to Illinois and this District, the exercise of personal jurisdiction over Alvotech does not offend
traditional notions of fair play and substantial justice, and this Court may properly exercise personal jurisdiction over Alvotech. 

VENUE 
 39. Venue lies in
this District pursuant to 28 U.S.C. § 1391, including because, inter alia, Alvotech is a foreign entity, and thus is subject to suit in any jurisdiction in the United States including the Northern District of Illinois. 28 U.S.C.
§ 1391(c). 
 THE PARTIES’ EXCHANGES UNDER THE BPCIA 

40. On information and belief, in late August or early September 2020, Alvotech submitted aBLA No. 761205 to the FDA pursuant to the
BPCIA, specifically 42 U.S.C. § 262(k), requesting that its biosimilar adalimumab product AVT02 be licensed for commercial sale by relying on AbbVie’s demonstration that HUMIRA®
is safe, pure, and potent. The BPCIA provides an abbreviated pathway for approval of a biologic product that is “biosimilar” to a “reference product.” Alvotech has demonstrated its intention to utilize AbbVie’s data and work
discovering and developing adalimumab through the use of the abbreviated BPCIA biosimilar pathway. 
  

	2 	 U.S. Patent Nos. 8,420,081, 8,926,975, 8,961,973, and 9,085,619 are the subject of AbbVie’s first
infringement suit against Alvotech. See AbbVie Inc. and AbbVie Biotechnology Ltd v. Alvotech hf., Civ. No. 1:21-cv-02258 (N.D. Ill. Apr. 27, 2021) (Lee, J.).

  
 14 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 15 of 323 PageID #:22568 

 

 41. To facilitate the protection of biologic innovators’ patent rights, Congress created
an act of infringement related to the submission of an application under subsection 262(k), see 35 
 U.S.C. § 271(e)(2)(C), and
enumerated a set of pre-litigation exchanges under the BPCIA that are outlined at 42 U.S.C. § 262(l). The subsection (l) procedures are intended to ensure that the maker of an
innovative biologic product that is the subject of a biosimilar application will have sufficient time and opportunity to enforce its patent rights before a biosimilar product enters the market. The BPCIA also requires that a subsection
(k) applicant give at least 180 days’ notice before the first commercial marketing of a biosimilar licensed by the FDA. 42 U.S.C. § 262(l)(8)(A). The statute specifically contemplates injunctive relief, including
preliminary injunctive relief, to prevent unlawful infringement. 
 42. Alvotech represents that the FDA accepted Alvotech’s aBLA for
the Alvotech aBLA Product for review on or before November 5, 2020. 
 43. On November 5, 2020, Alvotech contacted AbbVie and
indicated that it had submitted an aBLA to the FDA and that the FDA accepted the aBLA for review. Subsequently, in a November 19, 2020 press release, Alvotech announced that the FDA had accepted the aBLA for review. 

44. In November 2020, the parties began exchanging information in accordance with the procedures outlined in the BPCIA. On or about
November 5, 2020, Alvotech provided outside counsel for AbbVie, and AbbVie’s designated in-house attorneys in North Chicago, with access to Alvotech’s aBLA. 

  
 15 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 16 of 323 PageID #:22568 

 

 45. On January 4, 2021, pursuant to 42 U.S.C. § 262(l)(3)(A), AbbVie
provided Alvotech with its list of patents for which it believed a claim of patent infringement could be reasonably asserted against Alvotech’s aBLA Product (“AbbVie’s 3A List”). This list identified 63 patents from among the
more than 100 patents in the HUMIRA® estate. AbbVie also asked that, “[i]n the event that Alvotech asserts that any of the listed patents are either not infringed or invalid pursuant to
Section (l)(3)(B)(ii)(I), Alvotech should identify and provide copies of any documentary evidence supporting those assertions to AbbVie’s outside counsel . . . so that AbbVie may fully consider it.” 

46. Despite having a sixty-day statutory period to evaluate AbbVie’s 3A List, just ten days later,
on January 14, 2021, Alvotech responded by providing AbbVie with statements pursuant to 42 U.S.C. § 262(l)(3)(B) contesting Alvotech’s infringement of certain patents and the validity of those patents. Despite
AbbVie’s requests, Alvotech did not provide any additional evidence (e.g., additional manufacturing documents or product information beyond that contained in the aBLA) relating to its
non-infringement contentions. This lack of information was compounded by the fact that for several patents, Alvotech failed to provide any support for its
non-infringement positions. 
 47. On March 15, 2021, AbbVie provided Alvotech with its detailed
statement pursuant to 42 U.S.C. § 262(l)(3)(C) (AbbVie’s “3C Statement”). AbbVie’s nearly 2,000-page 3C Statement shows that AbbVie reasonably believes that the Alvotech
aBLA Product, AVT02, would infringe the following 62 AbbVie patents (AbbVie removed one of the patents from its prior list) and that those patent claims are valid and enforceable: 

  
 16 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 17 of 323 PageID #:22568 

 

							
	 	  	U.S. Patent No.	  	 Lead Inventor
	  	 Title

	1.	  	6,805,686	  	Fathallah	  	Autoinjector with Extendable Needle Protector Shroud
				
	2.	  	8,231,876	  	Wan	  	Purified Antibody Composition
				
	3.	  	8,420,081	  	Fraunhofer	  	Antibody Formulations and Methods of Making Same
				
	4.	  	8,663,945	  	Pla	  	Methods of Producing Anti-TNF-Alpha Antibodies in Mammalian Cell Culture
				
	5.	  	8,708,968	  	Julian	  	Removal of Needle Shields from Syringes and Automatic Injection Devices
				
	6.	  	8,715,664	  	Hoffman	  	Use of Human TNFα Antibodies for Treatment of Erosive Polyarthritis
				
	7.	  	8,808,700	  	Hoffman	  	Use of TNF Alpha Inhibitor for Treatment of Erosive Polyarthritis
				
	8.	  	8,883,156	  	Wan	  	Purified Antibody Composition
				
	9.	  	8,889,136	  	Hoffman	  	Multiple-Variable Dose Regimen for Treating TNFα-Related Disorders
				
	10.	  	8,895,009	  	Wan	  	Purified Antibody Composition
				
	11.	  	8,906,372	  	Wan	  	Purified Antibody Composition
				
	12.	  	8,906,373	  	Banerjee	  	Use of TNF-Alpha Inhibitor for Treatment of Psoriasis
				
	13.	  	8,906,646	  	Pla	  	Fed-Batch Method of Making Human Anti-TNF-Alpha Antibody
				
	14.	  	8,911,737	  	Fischkoff	  	Methods of Administering Anti-TNFα Antibodies
				
	15.	  	8,911,964	  	Pla	  	Fed-Batch Method of Making Human Anti-TNF-Alpha Antibody
				
	16.	  	8,916,153	  	Wan	  	Purified Antibody Composition
				
	17.	  	8,926,975	  	Wong	  	Method of Treating Ankylosing Spondylitis
				
	18.	  	8,961,973	  	Hoffman	  	Multiple-Variable Dose Regimen for Treating TNFα-Related Disorders
				
	19.	  	8,961,974	  	Hoffman	  	Multiple-Variable Dose Regimen for Treating TNFα-Related Disorders
				
	20.	  	8,974,790	  	Fischkoff	  	Methods of Administering Anti-TNFα Antibodies
				
	21.	  	8,986,693	  	Hoffman	  	Use of TNFα Inhibitor for Treatment of Psoriasis
				
	22.	  	8,992,926	  	Fischkoff	  	Methods of Administering Anti-TNFα Antibodies
				
	23.	  	8,999,337	  	Medich	  	Methods for Treating Juvenile Idiopathic Arthritis by Inhibition of TNFα

  
 17 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 18 of 323 PageID #:22568 

 

							
	 	  	U.S. Patent No.	  	 Lead Inventor
	  	 Title

	24.	  	9,061,005	  	Hoffman	  	Multiple-Variable Dose Regimen for Treating Idiopathic Inflammatory Bowel Disease
				
	25.	  	9,062,106	  	Bengea	  	Methods for Controlling the Galactosylation Profile of Recombinantly-Expressed Proteins
				
	26.	  	9,067,992	  	Hoffman	  	Use of TNFα Inhibitor for Treatment of Psoriatic Arthritis
				
	27.	  	9,085,618	  	Ramasubramanyan	  	Low Acidic Species Compositions and Methods for Producing and Using the Same
				
	28.	  	9,085,619	  	Fraunhofer	  	Anti-TNF Antibody Formulations
				
	29.	  	9,085,620	  	Hoffman	  	Use of TNFα Inhibitor for Treatment of Psoriatic Arthritis
				
	30.	  	9,090,688	  	Bengea	  	Methods for Controlling the Galactosylation Profile of Recombinantly-Expressed Proteins
				
	31.	  	9,090,689	  	Hoffman	  	Use of TNFα Inhibitor for Treatment of Psoriasis
				
	32.	  	9,090,867	  	Pla	  	Fed-Batch Method of Making Anti-TNF-Alpha Antibody
				
	33.	  	9,096,666	  	Wan	  	Purified Antibody Composition
				
	34.	  	9,102,723	  	Wan	  	Purified Antibody Composition
				
	35.	  	9,150,645	  	Subramanian	  	Cell Culture Methods to Reduce Acidic Species
				
	36.	  	9,181,337	  	Subramanian	  	Modulated Lysine Variant Species Compositions and Methods for Producing and Using the Same
				
	37.	  	9,181,572	  	Subramanian	  	Methods to Modulate Lysine Variant Distribution
				
	38.	  	9,187,559	  	Hoffman	  	Multiple-Variable Dose Regimen for Treating Idiopathic Inflammatory Bowel Disease
				
	39.	  	9,234,032	  	Pla	  	Fed-Batch Methods for Producing Adalimumab
				
	40.	  	9,266,949	  	Ramasubramanyan	  	Low Acidic Species Compositions and Methods for Producing and Using the Same
				
	41.	  	9,273,132	  	Wan	  	Purified Antibody Composition
				
	42.	  	9,284,370	  	Medich	  	Methods for Treating Juvenile Idiopathic Arthritis
				
	43.	  	9,284,371	  	Pla	  	Methods of Producing Adalimumab
				
	44.	  	9,290,568	  	Rives	  	Methods to Control Protein Heterogeneity

  
 18 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 19 of 323 PageID #:22568 

 

							
	 	  	U.S. Patent No.	  	 Lead Inventor
	  	 Title

	45.	  	9,315,574	  	Ramasubramanyan	  	Low Acidic Species Compositions and Methods for Producing and Using the Same
				
	46.	  	9,328,165	  	Wan	  	Purified Antibody Composition
				
	47.	  	9,334,319	  	Ramasubramanyan	  	Low Acidic Species Compositions
				
	48.	  	9,339,610	  	Julian	  	Removal of Needle Shield from Syringes and Automatic Injection Devices
				
	49.	  	9,346,879	  	Ramasubramanyan	  	Protein Purification Methods to Reduce Acidic Species
				
	50.	  	9,359,434	  	Subramanian	  	Cell Culture Methods to Reduce Acidic Species
				
	51.	  	9,499,614	  	Hossler	  	Methods for Modulating Protein Glycosylation Profiles of Recombinant Protein Therapeutics Using Monosaccharides and Oligosaccharides
				
	52.	  	9,499,616	  	Subramanian	  	Modulated Lysine Variant Species Compositions and Methods for Producing and Using the Same
				
	53.	  	9,505,834	  	Bengea	  	Methods for Controlling the Galactosylation Profile of Recombinantly-Expressed Proteins
				
	54.	  	9,512,216	  	Hoffman	  	Use of TNFα Inhibitor
				
	55.	  	9,522,953	  	Ramasubramanyan	  	Low Acidic Species Compositions and Methods for Producing and Using the Same
				
	56.	  	9,546,212	  	Fischkoff	  	Methods of Administering Anti-TNFα Antibodies
				
	57.	  	9,550,826	  	Labkovsky	  	Glycoengineered Binding Protein Compositions
				
	58.	  	9,624,295	  	Medich	  	Uses and Compositions for Treatment of Psoriatic Arthritis
				
	59.	  	9,669,093	  	Medich	  	Methods for Treating Juvenile Idiopathic Arthritis
				
	60.	  	9,683,033	  	Subramanian	  	Cell Culture Methods to Reduce Acidic Species
				
	61.	  	9,708,400	  	Subramanian	  	Methods to Modulate Lysine Variant Distribution
				
	62.	  	9,957,318	  	Ramasubramanyan	  	Protein Purification Methods to Reduce Acidic Species

  
 19 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 20 of 323 PageID #:22568 

 

 48. After AbbVie provided its 3C Statement, on March 23, 2021, Alvotech proposed that
only four of the 62 patents, namely U.S. Pat. Nos. 8,420,081, 8,926,975, 8,961,973, and 9,085,619, be the subject of the 42 U.S.C. § 262(l)(6) suit. Alvotech had the right under the BPCIA to select all 62 patents, or any subset of
those patents it wanted, but instead proposed litigating just four in this first round of litigation. 
 49. On March 29, 2021, AbbVie
wrote to Alvotech, explaining that litigating only these four patents would not resolve all issues of patent infringement with respect to the Alvotech aBLA Product and that, unless Alvotech chose to include them in the first phase of litigation, the
remaining patents would still need to be addressed in a second phase of litigation as contemplated by the BPCIA. See 42 U.S.C. § 262(l)(8). Despite this express notice, Alvotech chose to move forward with only four patents as the
subject of the initial 42 U.S.C. § 262(l)(6) litigation. 
 50. On April 27, 2021, AbbVie brought the first action in
this District to adjudicate Alvotech’s infringement of the four AbbVie patents that Alvotech selected for the first phase of litigation prescribed by the BPCIA. See AbbVie Inc. v. Alvotech hf., Civ. No. 1:21-cv-02258 (N.D. Ill. Apr. 27, 2021) (Lee, J.). Alvotech waived service of summons, and its counsel entered appearances shortly thereafter. Id. at Dkts. 9-12,
21-24. 
 51. On May 11, 2021, without answering or otherwise responding to the complaint
pending in this District, Alvotech filed an improper declaratory judgment action on those same four patents in the Eastern District of Virginia in an effort to change courts. Alvotech USA Inc. and Alvotech hf. v. AbbVie Inc. and AbbVie
Biotechnology Ltd, Civ. No. 2:21-cv-00265 (E.D. Va. May 11, 2021) (Jackson, J.). The Virigina court granted AbbVie’s request to transfer the case to this
Court, and Alvotech subsequently dismissed its declaratory judgment case without prejudice. Alvotech USA Inc. and Alvotech hf. v. AbbVie Inc. and AbbVie Biotechnology Ltd, Civ. No. 1:21-cv-05645, Dkt. 54 (N.D. Ill. May 11, 2021). 

  
 20 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 21 of 323 PageID #:22568 

 

 52. On the same day that Alvotech filed its improper declaratory judgment action, Alvotech
provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A). After Alvotech provided its notice of commercial marketing, AbbVie requested information regarding the degree of immediacy of Alvotech’s
marketing plans, but Alvotech declined to provide any such information. In view of Alvotech’s notice indicating that it intended to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
promptly upon receiving FDA approval to do so and as soon as 180 days from its date of providing the notice, AbbVie brought a second action under 42 U.S.C. § 262(l)(8) on its remaining 58 patents. Although Alvotech has agreed to
refrain from marketing until after the court issues a decision on the ten patents that will be subject of the August 2022 trial, Alvotech continues to state that it intends to market AVT02 as soon as possible. 

53. On August 10, 2021, the USPTO issued U.S. Pat. No. 11,083,792. AbbVie provided Alvotech notice of the issuance that same day
under 42 U.S.C. § 262(l)(7). 
 54. On September 2, 2021, the Court scheduled a bench trial in August 2022 on ten
AbbVie patents from the two filed actions. See 9/2/2021 Hearing Tr. at 9:16-22, 16:4-6, 21:17-18, 23:5-7. In addition, the Order indicated that AbbVie would amend its complaint in the second-filed action to add U.S. Patent Nos. 11,083,792 and the patent issuing from U.S. Patent Application No. 17/137,201
(U.S. Patent No. 11,167,030), as well as a third patent that had not yet issued and would not be part of the ten AbbVie patents to be tried in August 2022, i.e., the patent issuing from U.S. Patent Application No. 17/137,246 (U.S. Patent
No. 11,191,834). Dkt. 53 at 3. Additionally, Alvotech represented to the Court that it would not launch its proposed biosimilar product in the United States prior to the issuance of the Court’s decision on the ten patents that will be
subject of the August 2022 trial. Id. at 7:23-9:13; see also Dkt. 53 at ¶ 13. The Court plans to issue its decision by the end of October 2022 on those ten patents. Dkt. 53 at ¶ 13.

  
 21 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 22 of 323 PageID #:22568 

 

 55. On September 3, 2021, AbbVie identified the ten patents that will be subject to a
first trial: U.S. Patent Nos. 6,805,686, 8,926,975, 8,961,973, 8,999,337, 9,067,992, 9,085,619, 9,187,559, 9,512,216, 11,083,792, and the patent issuing from U.S. Patent Application No. 17/137,201 (U.S. Patent No. 11,167,030). 

56. On September 20, 2021, the Court entered a Scheduling and Discovery Order (9/20/21 Order) for the first action in this District and
the instant action that included parameters for discovery and trial related to the ten patents that will be subject to a first trial. Dkt. 53. 

57. On November 9, 2021, the USPTO issued U.S. Pat. No. 11,167,030. AbbVie provided Alvotech notice of the issuance that same day
under 42 U.S.C. § 262(l)(7). 
 58. On November 12, 2021, AbbVie filed a first amended complaint in the instant action
to add U.S. Patent Nos. 11,083,792 and 11,167,030 pursuant to the 9/20/21 Order. Dkt. 53 at 3. 
 59. On December 7, 2021, the USPTO
issued U.S. Pat. No. 11,191,834. AbbVie provided Alvotech notice of the issuance that same day under 42 U.S.C. § 262(l)(7). 

THE ALVOTECH aBLA PRODUCT 

60. Alvotech has undertaken the development of a proposed biosimilar to AbbVie’s
HUMIRA® (adalimumab) product. 
 61. Alvotech has submitted an aBLA to the FDA
seeking approval to market in the United States a biosimilar version of AbbVie’s HUMIRA® (adalimumab) product. 

  
 22 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 23 of 323 PageID #:22568 

 

 62. On November 19, 2020, Alvotech publicly announced that the FDA had accepted its
submission of an aBLA with the FDA for AVT02, a biosimilar candidate to HUMIRA® (adalimumab). See Exhibit 5. 

63. Alvotech stated that “AVT02 is a monoclonal antibody (mAb) and a proposed biosimilar to HUMIRA® (adalimumab)” and that “AVT02 is highly similar to its reference product in terms of structure and function.” See id. Alvotech further stated that “AVT02 is a proposed
biosimilar to the reference product HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms . . . matching the newest dosage forms of the reference product.” Id. 

64. Alvotech stated that its “filings were based on the results of a comprehensive development program and data package comprising of a
totality of evidence demonstrating a high degree of similarity of AVT02 compared to its reference product.” See id. 
 65.
Alvotech has completed clinical trials with AVT02, testing its use in subjects with moderate to severe chronic psoriasis and has relied on these clinical trials to support Alvotech’s aBLA. See Exhibit 8; see also Exhibit 9.
Alvotech is also sponsoring ongoing clinical trials testing the use of AVT02 in subjects with moderate to severe active rheumatoid arthritis. 

66. The FDA has not yet approved Alvotech’s proposed biosimilar product. 

67. Alvotech has committed a statutory act of patent infringement under 35 U.S.C. § 271(e)(2)(C) by submitting an application seeking
approval of a biological product with respect to patents identified by AbbVie pursuant to 42 U.S.C. § 262(l)(3)(A)(i). 

ABBVIE’S ADALIMUMAB PATENTS 

68. In the course of developing HUMIRA®, AbbVie has obtained more than 100 patents
related to HUMIRA®, including its administration, its formulation, the processes for its manufacture, and the devices for its administration. 

  
 23 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 24 of 323 PageID #:22568 

 

 69. AbbVie asserts the following 61 patents in this suit (the “AbbVie Patents”).

 U.S. Patent No. 6,805,686 

70. U.S. Patent No. 6,805,686 (the “’686 patent”), titled “Autoinjector with Extendable Needle Protector
Shroud,” was duly and legally issued by the USPTO on October 19, 2004. A true and correct copy of the ’686 patent is attached as Exhibit 10. 

71. AbbVie Inc. is the owner by assignment of the ’686 patent. ABL is exclusively licensed to import, have imported, manufacture, or have
manufactured products, and to use methods that would infringe the ’686 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the
’686 patent. 
 U.S. Patent No. 8,231,876 

72. U.S. Patent No. 8,231,876 (the “’876 patent”), titled “Purified Antibody Composition,” was duly and legally
issued by the USPTO on July 31, 2012. A true and correct copy of the ’876 patent is attached as Exhibit 11. 
 73. ABL is the owner
by assignment of the ’876 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through distributors products that would infringe the ’876 patent in the United States. ABL and AbbVie Inc. together hold the
exclusive right to initiate, control, and defend any patent infringement litigation involving the ’876 patent. 
 U.S. Patent
No. 8,663,945 
 74. U.S. Patent No. 8,663,945 (the “’945 patent”), titled “Methods of Producing Anti-TNF-Alpha Antibodies in Mammalian Cell Culture,” was duly and legally issued by the USPTO on March 4, 2014. A true and correct copy of the ’945 patent is
attached as Exhibit 12. 

  
 24 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 25 of 323 PageID #:22568 

 

 75. AbbVie Inc. is the owner by assignment of the ’945 patent. ABL is exclusively
licensed to import, have imported, manufacture, or have manufactured products, and to use methods that would infringe the ’945 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend
any patent infringement litigation involving the ’945 patent. 
 U.S. Patent No. 8,708,968 

76. U.S. Patent No. 8,708,968 (the “’968 patent”), titled “Removal of Needle Shields from Syringes and Automatic
Injection Devices,” was duly and legally issued by the USPTO on April 29, 2014. A true and correct copy of the ’968 patent is attached as Exhibit 13. 

77. ABL is a co-owner by assignment of the ’968 patent. ABL has the right to initiate patent
infringement litigation involving the ’968 patent against Alvotech and has sole and exclusive control over enforcement and defense of the ’968 patent against Alvotech. 

U.S. Patent No. 8,715,664 

78. U.S. Patent No. 8,715,664 (the “’664 patent”), titled “Use of Human TNFα Antibodies for Treatment of Erosive
Polyarthritis,” was duly and legally issued by the USPTO on May 6, 2014. A true and correct copy of the ’664 patent is attached as Exhibit 14. 

79. ABL is the owner by assignment of the ’664 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’664 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’664 patent. 

  
 25 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 26 of 323 PageID #:22568 

 

 U.S. Patent No. 8,808,700 

80. U.S. Patent No. 8,808,700 (the “’700 patent”), titled “Use of TNF Alpha Inhibitor for Treatment of Erosive
Polyarthritis,” was duly and legally issued by the USPTO on August 19, 2014. A true and correct copy of the ’700 patent is attached as Exhibit 15. 

81. ABL is the owner by assignment of the ’700 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’700 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’700 patent. 

U.S. Patent No. 8,883,156 

82. U.S. Patent No. 8,883,156 (the “’156 patent”), titled “Purified Antibody Composition,” was duly and legally
issued by the USPTO on November 11, 2014. A true and correct copy of the ’156 patent is attached as Exhibit 16. 
 83. ABL is the
owner by assignment of the ’156 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through distributors products that would infringe the ’156 patent in the United States. ABL and AbbVie Inc. together hold the
exclusive right to initiate, control, and defend any patent infringement litigation involving the ’156 patent. 
 U.S. Patent
No. 8,889,136 
 84. U.S. Patent No. 8,889,136 (the “’136 patent”), titled “Multiple-Variable Dose Regimen
for Treating TNFα-Related Disorders,” was duly and legally issued by the USPTO on November 18, 2014. A true and correct copy of the ’136 patent is attached as Exhibit 17. 

85. ABL is the owner by assignment of the ’136 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’136 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’136 patent. 

  
 26 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 27 of 323 PageID #:22568 

 

 U.S. Patent No. 8,895,009 

86. U.S. Patent No. 8,895,009 (the “’009 patent”), titled “Purified Antibody Composition,” was duly and legally
issued by the USPTO on November 25, 2014. A true and correct copy of the ’009 patent is attached as Exhibit 18. 
 87. ABL is the
owner by assignment of the ’009 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through distributors products that would infringe the ’009 patent in the United States. ABL and AbbVie Inc. together hold the
exclusive right to initiate, control, and defend any patent infringement litigation involving the ’009 patent. 
 U.S. Patent
No. 8,906,372 
 88. U.S. Patent No. 8,906,372 (the “’372 patent”), titled “Purified Antibody
Composition,” was duly and legally issued by the USPTO on December 9, 2014. A true and correct copy of the ’372 patent is attached as Exhibit 19. 

89. ABL is the owner by assignment of the ’372 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’372 patent in the United States. ABL and AbbVie Inc. together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’372 patent. 

U.S. Patent No. 8,906,373 

90. U.S. Patent No. 8,906,373 (the “’373 patent”), titled “Use of TNF-Alpha
Inhibitor for Treatment of Psoriasis,” was duly and legally issued by the USPTO on December 9, 2014. A true and correct copy of the ’373 patent is attached as Exhibit 20. 

  
 27 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 28 of 323 PageID #:22568 

 

 91. ABL is the owner by assignment of the ’373 patent. AbbVie Inc. is exclusively
licensed to offer for sale, sell, or have sold through distributors products that would infringe the ’373 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent
infringement litigation involving the ’373 patent. 
 U.S. Patent No. 8,906,646 

92. U.S. Patent No. 8,906,646 (the “’646 patent”), titled “Fed-Batch Method
of Making Human Anti-TNF-Alpha Antibody,” was duly and legally issued by the USPTO on December 9, 2014. A true and correct copy of the ’646 patent is
attached as Exhibit 21. 
 93. AbbVie Inc. is the owner by assignment of the ’646 patent. ABL is exclusively licensed to import, have
imported, manufacture, or have manufactured products, and to use methods that would infringe the ’646 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement
litigation involving the ’646 patent. 
 U.S. Patent No. 8,911,737 

94. U.S. Patent No. 8,911,737 (the “’737 patent”), titled “Methods of Administering
Anti-TNFα Antibodies,” was duly and legally issued by the USPTO on December 16, 2014. A true and correct copy of the ’737 patent is attached as Exhibit 22. 

95. ABL is the owner by assignment of the ’737 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’737 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’737 patent. 

  
 28 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 29 of 323 PageID #:22568 

 

 U.S. Patent No. 8,911,964 

96. U.S. Patent No. 8,911,964 (the “’964 patent”), titled “Fed-Batch Method of
Making Human Anti-TNF-Alpha Antibody,” was duly and legally issued by the USPTO on December 16, 2014. A true and correct copy of the ’964 patent is
attached as Exhibit 23. 
 97. AbbVie Inc. is the owner by assignment of the ’964 patent. ABL is exclusively licensed to import, have
imported, manufacture, or have manufactured products, and to use methods that would infringe the ’964 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement
litigation involving the ’964 patent. 
 U.S. Patent No. 8,916,153 

98. U.S. Patent No. 8,916,153 (the “’153 patent”), titled “Purified Antibody Composition,” was duly and legally
issued by the USPTO on December 23, 2014. A true and correct copy of the ’153 patent is attached as Exhibit 24. 
 99. ABL is the
owner by assignment of the ’153 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through distributors products that would infringe the ’153 patent in the United States. ABL and AbbVie Inc. together hold the
exclusive right to initiate, control, and defend any patent infringement litigation involving the ’153 patent. 
 U.S. Patent
No. 8,961,974 
 100. U.S. Patent No. 8,961,974 (the “’974 patent”), titled “Multiple-Variable Dose
Regimen for Treating TNFα-Related Disorders,” was duly and legally issued by the USPTO on February 24, 2015. A true and correct copy of the ’974 patent is attached as Exhibit 25. 

101. ABL is the owner by assignment of the ’974 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’974 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’974 patent. 

  
 29 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 30 of 323 PageID #:22568 

 

 U.S. Patent No. 8,974,790 

102. U.S. Patent No. 8,974,790 (the “’790 patent”), titled “Methods of Administering
Anti-TNFα Antibodies,” was duly and legally issued by the USPTO on March 10, 2015. A true and correct copy of the ’790 patent is attached as Exhibit 26. 

103. ABL is the owner by assignment of the ’790 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’790 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’790 patent. 

U.S. Patent No. 8,986,693 

104. U.S. Patent No. 8,986,693 (the “’693 patent”), titled “Use of TNFα Inhibitor for Treatment of
Psoriasis,” was duly and legally issued by the USPTO on March 24, 2015. A true and correct copy of the ’693 patent is attached as Exhibit 27. 

105. ABL is the owner by assignment of the ’693 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’693 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’693 patent. 

U.S. Patent No. 8,992,926 

106. U.S. Patent No. 8,992,926 (the “’926 patent”), titled “Methods of Administering
Anti-TNFα Antibodies,” was duly and legally issued by the USPTO on March 31, 2015. A true and correct copy of the ’926 patent is attached as Exhibit 28. 

  
 30 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 31 of 323 PageID #:22568 

 

 107. ABL is the owner by assignment of the ’926 patent. AbbVie Inc. is exclusively
licensed to offer for sale, sell, or have sold through distributors products that would infringe the ’926 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent
infringement litigation involving the ’926 patent. 
 U.S. Patent No. 8,999,337 

108. U.S. Patent No. 8,999,337 (the “’9337 patent”), titled “Methods for Treating Juvenile Idiopathic Arthritis by
Inhibition of TNFα,” was duly and legally issued by the USPTO on April 7, 2015. A true and correct copy of the ’9337 patent is attached as Exhibit 29. 

109. ABL is the owner by assignment of the ’9337 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’9337 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’9337 patent. 

U.S. Patent No. 9,061,005 

110. U.S. Patent No. 9,061,005 (the “’005 patent”), titled “Multiple-Variable Dose Regimen for Treating Idiopathic
Inflammatory Bowel Disease,” was duly and legally issued by the USPTO on June 23, 2015. A true and correct copy of the ’005 patent is attached as Exhibit 30. 

111. ABL is the owner by assignment of the ’005 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’005 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’005 patent. 

  
 31 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 32 of 323 PageID #:22568 

 

 U.S. Patent No. 9,062,106 

112. U.S. Patent No. 9,062,106 (the “’106 patent”), titled “Methods for Controlling the Galactosylation Profile of
Recombinantly-Expressed Proteins,” was duly and legally issued by the USPTO on June 23, 2015. A true and correct copy of the ’106 patent is attached as Exhibit 31. 

113. AbbVie Inc. is the owner by assignment of the ’106 patent. ABL is exclusively licensed to import, have imported, manufacture, or have
manufactured products, and to use methods that would infringe the ’106 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the
’106 patent. 
 U.S. Patent No. 9,067,992 

114. U.S. Patent No. 9,067,992 (the “’992 patent”), titled “Use of TNFα Inhibitor for Treatment of Psoriatic
Arthritis,” was duly and legally issued by the USPTO on June 30, 2015. A true and correct copy of the ’992 patent is attached as Exhibit 32. 

115. ABL is the owner by assignment of the ’992 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’992 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’992 patent. 

U.S. Patent No. 9,085,618 

116. U.S. Patent No. 9,085,618 (the “’618 patent”), titled “Low Acidic Species Compositions and Methods for Producing
and Using the Same,” was duly and legally issued by the USPTO on July 21, 2015. A true and correct copy of the ’618 is attached as Exhibit 33. 

  
 32 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 33 of 323 PageID #:22568 

 

 117. AbbVie Inc. is the owner by assignment of the ’618 patent. ABL is exclusively
licensed to import, have imported, manufacture, or have manufactured products, and to use methods that would infringe the ’618 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend
any patent infringement litigation involving the ’618 patent. 
 U.S. Patent No. 9,085,620 

118. U.S. Patent No. 9,085,620 (the “’620 patent”), titled “Use of TNFα Inhibitor for Treatment of Psoriatic
Arthritis,” was duly and legally issued by the USPTO on July 21, 2015. A true and correct copy of the ’620 patent is attached as Exhibit 34. 

119. ABL is the owner by assignment of the ’620 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’620 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’620 patent. 

U.S. Patent No. 9,090,688 

120. U.S. Patent No. 9,090,688 (the “’688 patent”), titled “Methods for Controlling the Galactosylation Profile of
Recombinantly-Expressed Proteins,” was duly and legally issued by the USPTO on July 28, 2015. A true and correct copy of the ’688 patent is attached as Exhibit 35. 

121. AbbVie Inc. is the owner by assignment of the ’688 patent. ABL is exclusively licensed to import, have imported, manufacture, or have
manufactured products, and to use methods that would infringe the ’688 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the
’688 patent. 

  
 33 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 34 of 323 PageID #:22568 

 

 U.S. Patent No. 9,090,689 

122. U.S. Patent No. 9,090,689 (the “’689 patent”), titled “Use of TNFα Inhibitor for Treatment of
Psoriasis,” was duly and legally issued by the USPTO on July 28, 2015. A true and correct copy of the ’689 patent is attached as Exhibit 36. 

123. ABL is the owner by assignment of the ’689 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’689 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’689 patent. 

U.S. Patent No. 9,090,867 

124. U.S. Patent No. 9,090,867 (the “’867 patent”), titled “Fed-Batch Method
of Making Anti-TNF-Alpha Antibody,” was duly and legally issued by the USPTO on July 28, 2015. A true and correct copy of the ’867 patent is attached as
Exhibit 37. 
 125. AbbVie Inc. is the owner by assignment of the ’867 patent. ABL is exclusively licensed to import, have imported,
manufacture, or have manufactured products, and to use methods that would infringe the ’867 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation
involving the ’867 patent. 
 U.S. Patent No. 9,096,666 

126. U.S. Patent No. 9,096,666 (the “’666 patent”), titled “Purified Antibody Composition,” was duly and legally
issued by the USPTO on August 4, 2015. A true and correct copy of the ’666 patent is attached as Exhibit 38. 

  
 34 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 35 of 323 PageID #:22568 

 

 127. ABL is the owner by assignment of the ’666 patent. AbbVie Inc. is exclusively
licensed to offer for sale, sell, or have sold through distributors products that would infringe the ’666 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent
infringement litigation involving the ’666 patent. 
 U.S. Patent No. 9,102,723 

128. U.S. Patent No. 9,102,723 (the “’723 patent”), titled “Purified Antibody Composition,” was duly and legally
issued by the USPTO on August 11, 2015. A true and correct copy of the ’723 patent is attached as Exhibit 39. 
 129. ABL is the
owner by assignment of the ’723 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through distributors products that would infringe the ’723 patent in the United States. AbbVie Inc. and ABL together hold the
exclusive right to initiate, control, and defend any patent infringement litigation involving the ’723 patent. 
 U.S. Patent
No. 9,150,645 
 130. U.S. Patent No. 9,150,645 (the “’645 patent”), titled “Cell Culture Methods to
Reduce Acidic Species,” was duly and legally issued by the USPTO on October 6, 2015. A true and correct copy of the ’645 patent is attached as Exhibit 40. 

131. AbbVie Inc. is the owner by assignment of the ’645 patent. ABL is exclusively licensed to import, have imported, manufacture, or have
manufactured products, and to use methods that would infringe the ’645 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the
’645 patent. 
 U.S. Patent No. 9,181,337 

132. U.S. Patent No. 9,181,337 (the “’1337 patent”), titled “Modulated Lysine Variant Species Compositions and
Methods for Producing and Using the Same,” was duly and legally issued by the USPTO on November 10, 2015. A true and correct copy of the ’1337 patent is attached as Exhibit 41. 

  
 35 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 36 of 323 PageID #:22568 

 

 133. AbbVie Inc. is the owner by assignment of the ’1337 patent. ABL is exclusively
licensed to import, have imported, manufacture, or have manufactured products, and to use methods that would infringe the ’1337 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend
any patent infringement litigation involving the ’1337 patent. 
 U.S. Patent No. 9,181,572 

134. U.S. Patent No. 9,181,572 (the “’572 patent”), titled “Methods to Modulate Lysine Variant Distribution,”
was duly and legally issued by the USPTO on November 10, 2015. A true and correct copy of the ’572 patent is attached as Exhibit 42. 

135. AbbVie Inc. is the owner by assignment of the ’572 patent. ABL is exclusively licensed to import, have imported, manufacture, or have
manufactured products, and to use methods that would infringe the ’572 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the
’572 patent. 
 U.S. Patent No. 9,187,559 

136. U.S. Patent No. 9,187,559 (the “’559 patent”), titled “Multiple-Variable Dose Regimen for Treating Idiopathic
Inflammatory Bowel Disease,” was duly and legally issued by the USPTO on November 17, 2015. A true and correct copy of the ’559 patent is attached as Exhibit 43. 

137. ABL is the owner by assignment of the ’559 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’559 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’559 patent. 

  
 36 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 37 of 323 PageID #:22568 

 

 U.S. Patent No. 9,234,032 

138. U.S. Patent No. 9,234,032 (the “’032 patent”), titled “Fed-Batch Methods
for Producing Adalimumab,” was duly and legally issued by the USPTO on January 12, 2016. A true and correct copy of the ’032 patent is attached as Exhibit 44. 

139. AbbVie Inc. is the owner by assignment of the ’032 patent. ABL is exclusively licensed to import, have imported, manufacture, or have
manufactured products, and to use methods that would infringe the ’032 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the
’032 patent. 
 U.S. Patent No. 9,266,949 

140. U.S. Patent No. 9,266,949 (the “’949 patent”), titled “Low Acidic Species Compositions and Methods for Producing
and Using the Same,” was duly and legally issued by the USPTO on February 23, 2016. A true and correct copy of the ’949 patent is attached as Exhibit 45. 

141. AbbVie Inc. is the owner by assignment of the ’949 patent. ABL is exclusively licensed to import, have imported, manufacture, or have
manufactured products, and to use methods that would infringe the ’949 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the
’949 patent. 

  
 37 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 38 of 323 PageID #:22568 

 

 U.S. Patent No. 9,273,132 

142. U.S. Patent No. 9,273,132 (the “’132 patent”), titled “Purified Antibody Composition,” was duly and legally
issued by the USPTO on March 1, 2016. A true and correct copy of the ’132 patent is attached as Exhibit 46. 
 143. ABL is the
owner by assignment of the ’132 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through distributors products that would infringe the ’132 patent in the United States. AbbVie Inc. and ABL together hold the
exclusive right to initiate, control, and defend any patent infringement litigation involving the ’132 patent. 
 U.S. Patent
No. 9,284,370 
 144. U.S. Patent No. 9,284,370 (the “’370 patent”), titled “Methods for Treating Juvenile
Idiopathic Arthritis,” was duly and legally issued by the USPTO on March 15, 2016. A true and correct copy of the ’370 patent is attached as Exhibit 47. 

145. ABL is the owner by assignment of the ’370 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’370 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’370 patent. 

U.S. Patent No. 9,284,371 

146. U.S. Patent No. 9,284,371 (the “’371 patent”), titled “Methods of Producing Adalimumab,” was duly and
legally issued by the USPTO on March 15, 2016. A true and correct copy of the ’371 patent is attached as Exhibit 48. 
 147. AbbVie
Inc. is the owner by assignment of the ’371 patent. ABL is exclusively licensed to import, have imported, manufacture, or have manufactured products, and to use methods that would infringe the ’371 patent in the United States. AbbVie Inc.
and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’371 patent. 

  
 38 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 39 of 323 PageID #:22568 

 

 U.S. Patent No. 9,290,568 

148. U.S. Patent No. 9,290,568 (the “’568 patent”), titled “Methods to Control Protein Heterogeneity,” was duly
and legally issued by the USPTO on March 22, 2016. A true and correct copy of the ’568 patent is attached as Exhibit 49. 
 149.
AbbVie Inc. is the owner by assignment of the ’568 patent. ABL is exclusively licensed to import, have imported, manufacture, or have manufactured products, and to use methods that would infringe the ’568 patent in the United States.
AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’568 patent. 

U.S. Patent No. 9,315,574 

150. U.S. Patent No. 9,315,574 (the “’574 patent”), titled “Low Acidic Species Compositions and Methods for Producing
and Using the Same,” was duly and legally issued by the USPTO on April 19, 2016. A true and correct copy of the ’574 patent is attached as Exhibit 50. 

151. AbbVie Inc. is the owner by assignment of the ’574 patent. ABL is exclusively licensed to import, have imported, manufacture, or have
manufactured products, and to use methods that would infringe the ’574 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the
’574 patent. 

  
 39 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 40 of 323 PageID #:22568 

 

 U.S. Patent No. 9,328,165 

152. U.S. Patent No. 9,328,165 (the “’165 patent”), titled “Purified Antibody Composition,” was duly and legally
issued by the USPTO on May 3, 2016. A true and correct copy of the ’165 patent is attached as Exhibit 51. 
 153. ABL is the owner
by assignment of the ’165 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through distributors products that would infringe the ’165 patent in the United States. AbbVie Inc. and ABL together hold the
exclusive right to initiate, control, and defend any patent infringement litigation involving the ’165 patent. 
 U.S. Patent
No. 9,334,319 
 154. U.S. Patent No. 9,334,319 (the “’319 patent”), titled “Low Acidic Species
Compositions,” was duly and legally issued by the USPTO on May 10, 2016. A true and correct copy of the ’319 patent is attached as Exhibit 52. 

155. AbbVie Inc. is the owner by assignment of the ’319 patent. ABL is exclusively licensed to import, have imported, manufacture, or have
manufactured products, and to use methods that would infringe the ’319 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the
’319 patent. 
 U.S. Patent No. 9,339,610 

156. U.S. Patent No. 9,339,610 (the “’610 patent”), titled “Removal of Needle Shield from Syringes and Automatic
Injection Devices,” was duly and legally issued by the USPTO on May 17, 2016. A true and correct copy of the ’610 patent is attached as Exhibit 53. 

  
 40 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 41 of 323 PageID #:22568 

 

 157. ABL is a co-owner by assignment of the ’610
patent. ABL has the right to initiate patent infringement litigation involving the ’610 patent against Alvotech and has sole and exclusive control over enforcement and defense of the ’610 patent against Alvotech. 

U.S. Patent No. 9,346,879 

158. U.S. Patent No. 9,346,879 (the “’879 patent”), titled “Protein Purification Methods to Reduce Acidic
Species,” was duly and legally issued by the USPTO on May 24, 2016. A true and correct copy of the ’879 patent is attached as Exhibit 54. 

159. AbbVie Inc. is the owner by assignment of the ’879 patent. ABL is exclusively licensed to import, have imported, manufacture, or have
manufactured products, and to use methods that would infringe the ’879 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the
’879 patent. 
 U.S. Patent No. 9,359,434 

160. U.S. Patent No. 9,359,434 (the “’434 patent”), titled “Cell Culture Methods to Reduce Acidic Species,” was
duly and legally issued by the USPTO on June 7, 2016. A true and correct copy of the ’434 patent is attached as Exhibit 55. 
 161.
AbbVie Inc. is the owner by assignment of the ’434 patent. ABL is exclusively licensed to import, have imported, manufacture, or have manufactured products, and to use methods that would infringe the ’434 patent in the United States.
AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’434 patent. 

  
 41 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 42 of 323 PageID #:22568 

 

 U.S. Patent No. 9,499,614 

162. U.S. Patent No. 9,499,614 (the “’614 patent”), titled “Methods for Modulating Protein Glycosylation Profiles of
Recombinant Protein Therapeutics Using Monosaccharides and Oligosaccharides,” was duly and legally issued by the USPTO on November 22, 2016. A true and correct copy of the ’614 patent is attached as Exhibit 56. 

163. AbbVie Inc. is the owner by assignment of the ’614 patent. ABL is exclusively licensed to import, have imported, manufacture, or have
manufactured products, and to use methods that would infringe the ’614 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the
’614 patent. 
 U.S. Patent No. 9,499,616 

164. U.S. Patent No. 9,499,616 (the “’616 patent”), titled “Modulated Lysine Variant Species Compositions and Methods
for Producing and Using the Same,” was duly and legally issued by the USPTO on November 22, 2016. A true and correct copy of the ’616 patent is attached as Exhibit 57. 

165. AbbVie Inc. is the owner by assignment of the ’616 patent. ABL is exclusively licensed to import, have imported, manufacture, or have
manufactured products, and to use methods that would infringe the ’616 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the
’616 patent. 
 U.S. Patent No. 9,505,834 

166. U.S. Patent No. 9,505,834 (the “’834 patent”), titled “Methods for Controlling the Galactosylation Profile of
Recombinantly-Expressed Proteins,” was duly and legally issued by the USPTO on November 29, 2016. A true and correct copy of the ’834 patent is attached as Exhibit 58. 

  
 42 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 43 of 323 PageID #:22568 

 

 167. AbbVie Inc. is the owner by assignment of the ’834 patent. ABL is exclusively
licensed to import, have imported, manufacture, or have manufactured products, and to use methods that would infringe the ’834 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend
any patent infringement litigation involving the ’834 patent. 
 U.S. Patent No. 9,512,216 

168. U.S. Patent No. 9,512,216 (the “’216 patent”), titled “Use of TNFα Inhibitor,” was duly and legally
issued by the USPTO on December 6, 2016. A true and correct copy of the ’216 patent is attached as Exhibit 59. 
 169. ABL is the
owner by assignment of the ’216 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through distributors products that would infringe the ’216 patent in the United States. AbbVie Inc. and ABL together hold the
exclusive right to initiate, control, and defend any patent infringement litigation involving the ’216 patent. 
 U.S. Patent
No. 9,522,953 
 170. U.S. Patent No. 9,522,953 (the “’953 patent”), titled “Low Acidic Species
Compositions and Methods for Producing and Using the Same,” was duly and legally issued by the USPTO on December 20, 2016. A true and correct copy of the ’953 patent is attached as Exhibit 60. 

171. AbbVie Inc. is the owner by assignment of the ’953 patent. ABL is exclusively licensed to import, have imported, manufacture, or have
manufactured products, and to use methods that would infringe the ’953 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the
’953 patent. 

  
 43 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 44 of 323 PageID #:22568 

 

 U.S. Patent No. 9,546,212 

172. U.S. Patent No. 9,546,212 (the “’212 patent”), titled “Methods of Administering
Anti-TNFα Antibodies,” was duly and legally issued by the USPTO on January 17, 2017. A true and correct copy of the ’212 patent is attached as Exhibit 61. 

173. ABL is the owner by assignment of the ’212 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’212 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’212 patent. 

U.S. Patent No. 9,550,826 

174. U.S. Patent No. 9,550,826 (the “’826”), titled “Glycoengineered Binding Protein Compositions,” was duly and
legally issued by the USPTO on January 24, 2017. A true and correct copy of the ’826 patent is attached as Exhibit 62. 
 175.
AbbVie Inc. is the owner by assignment of the ’826 patent. ABL is exclusively licensed to import, have imported, manufacture, or have manufactured products, and to use methods that would infringe the ’826 patent in the United States.
AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’826 patent. 

U.S. Patent No. 9,624,295 

176. U.S. Patent No. 9,624,295 (the “’295 patent”), titled “Uses and Compositions for Treatment of Psoriatic
Arthritis,” was duly and legally issued by the USPTO on April 18, 2017. A true and correct copy of the ’295 patent is attached as Exhibit 63. 

  
 44 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 45 of 323 PageID #:22568 

 

 177. ABL is the owner by assignment of the ’295 patent. AbbVie Inc. is exclusively
licensed to offer for sale, sell, or have sold through distributors products that would infringe the ’295 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent
infringement litigation involving the ’295 patent. 
 U.S. Patent No. 9,669,093 

178. U.S. Patent No. 9,669,093 (the “’093 patent”), titled “Methods for Treating Juvenile Idiopathic Arthritis,”
was duly and legally issued by the USPTO on June 6, 2017. A true and correct copy of the ’093 patent is attached as Exhibit 64. 

179. ABL is the owner by assignment of the ’093 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’093 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’093 patent. 

U.S. Patent No. 9,683,033 

180. U.S. Patent No. 9,683,033 (the “’033 patent”), titled “Cell Culture Methods to Reduce Acidic Species,” was
duly and legally issued by the USPTO on June 20, 2017. A true and correct copy of the ’033 patent is attached as Exhibit 65. 

181. AbbVie Inc. is the owner by assignment of the ’033 patent. ABL is exclusively licensed to import, have imported, manufacture, or have
manufactured products, and to use methods that would infringe the ’033 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the
’033 patent. 

  
 45 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 46 of 323 PageID #:22568 

 

 U.S. Patent No. 9,708,400 

182. U.S. Patent No. 9,708,400 (the “’400 patent”), titled “Methods to Modulate Lysine Variant Distribution,”
was duly and legally issued by the USPTO on July 18, 2017. A true and correct copy of the ’400 patent is attached as Exhibit 66. 

183. AbbVie Inc. is the owner by assignment of the ’400 patent. ABL is exclusively licensed to import, have imported, manufacture, or have
manufactured products, and to use methods that would infringe the ’400 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the
’400 patent. 
 U.S. Patent No. 9,957,318 

184. U.S. Patent No. 9,957,318 (the “’318 patent”), titled “Protein Purification Methods to Reduce Acidic
Species,” was duly and legally issued by the USPTO on May 1, 2018. A true and correct copy of the ’318 patent is attached as Exhibit 67. 

185. AbbVie Inc. is the owner by assignment of the ’318 patent. ABL is exclusively licensed to import, have imported, manufacture, or have
manufactured products, and to use methods that would infringe the ’318 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the
’318 patent. 
 U.S. Patent No. 11,083,792 

186. U.S. Patent No. 11,083,792 (the “’792 patent”), titled “Purified Antibody Composition,” was duly and
legally issued by the USPTO on August 10, 2021. A true and correct copy of the ’792 patent is attached as Exhibit 68. 

  
 46 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 47 of 323 PageID #:22568 

 

 187. ABL is the owner by assignment of the ’792 patent. AbbVie Inc. is exclusively
licensed to offer for sale, sell, or have sold through distributors products that would infringe the ’792 patent in the United States. ABL and AbbVie Inc. together hold the exclusive right to initiate, control, and defend any patent
infringement litigation involving the ’792 patent. 
 U.S. Patent No. 11,167,030 

188. U.S. Patent No. 11,167,030 (the “’030 patent”), titled “Protein Formulations and Methods of Making Same,”
was duly and legally issued by the USPTO on November 9, 2021. A true and correct copy of the ’030 patent is attached as Exhibit 69. 

189. ABL is the owner by assignment of the ’030 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’030 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’030 patent. 

U.S. Patent No. 11,191,834 

190. U.S. Patent No. 11,191,834 (the “’1834 patent”), titled “Protein Formulations and Methods of Making Same,”
was duly and legally issued by the USPTO on December 7, 2021. A true and correct copy of the ’1834 patent is attached as Exhibit 71. 

191. ABL is the owner by assignment of the ’1834 patent. AbbVie Inc. is exclusively licensed to offer for sale, sell, or have sold through
distributors products that would infringe the ’1834 patent in the United States. AbbVie Inc. and ABL together hold the exclusive right to initiate, control, and defend any patent infringement litigation involving the ’1834 patent. 

192. AbbVie included in its disclosures to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(A) and 42 U.S.C.
§ 262(l)(7), each of the patents described in Counts I-CXXII below. 

  
 47 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 48 of 323 PageID #:22568 

 

 193. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for each of the claims described in Counts I-CXXII below. 

COUNT I. 
 INFRINGEMENT
OF U.S. PATENT NO. 6,805,686 
 194. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein.

 195. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 196. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before November 5,
2020. 
 197. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

198. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 199. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of
the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 200. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’686 patent is an act of infringement of one or more claims of the ’686 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 48 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 49 of 323 PageID #:22568 

 

 201. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1, 3, 4, 11, 12, 19-21, and 24 of the ’686 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents.
AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1, 3, 4, 11, 12, 19-21, and 24 of the ’686 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that
could further support AbbVie’s allegation of infringement of the ’686 patent. 
 202. On information and belief, Alvotech has an
affirmative intent to actively induce or contribute to infringement by others of one or more claims of the ’686 patent, either literally or under the doctrine of equivalents. 

203. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product (including the delivery device) directly infringes at least one claim of the ’686 patent, either literally or under the doctrine of equivalents. 

204. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of
at least claims 1, 3, 4, 11, 12, 19-21, and 24 of the ’686 patent, either literally or under the doctrine of equivalents. 

  
 49 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 50 of 323 PageID #:22568 

 

 205. Alvotech has knowledge of and is aware of the ’686 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 206. AbbVie
will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’686 patent. 

207. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT II. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 6,805,686 

208. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

209. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

210. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 211. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before November 5,
2020. 
 212. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

213. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 50 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 51 of 323 PageID #:22568 

 

 214. On information and belief, Alvotech intends to engage in the commercial manufacture,
use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so and 180 days after its notice of commercial marketing.3 

215. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’686 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’686 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 
 216. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating
to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the
Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least
claims 1, 3, 4, 11, 12, 19-21, and 24 of the ’686 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech,
pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1, 3, 4, 11, 12, 19-21,
and 24 of the ’686 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s
allegation of infringement of the ’686 patent. 
  

	3 	 With respect to this paragraph and those therafter concerning Alvotech’s intention to launch, Alvotech has
agreed not to launch until after the Court’s decision on the ten patents that are the subject of the August 2022 trial. 

  
 51 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 52 of 323 PageID #:22568 

 

 217. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’686 patent, either literally or under the doctrine of equivalents. 

218. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product (including the delivery device) directly infringes at least one claim of the ’686 patent, either literally or under the doctrine of equivalents. 

219. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of
at least claims 1, 3, 4, 11, 12, 19-21, and 24 of the ’686 patent, either literally or under the doctrine of equivalents. 

220. Alvotech has knowledge of and is aware of the ’686 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C.
§ 262(l)(3)(A) and to the filing of this Complaint. 
 221. AbbVie will suffer irreparable injury for which damages are an
inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’686 patent. 
 222. AbbVie seeks a declaratory judgment
that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’686 patent. 

  
 52 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 53 of 323 PageID #:22568 

 

 223. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use,
sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT III. 

INFRINGEMENT OF U.S. PATENT NO. 8,231,876 

224. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

225. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 226. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before November 5,
2020. 
 227. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

228. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 229. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of
the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 230. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’876 patent is an act of infringement of one or more claims of the ’876 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 53 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 54 of 323 PageID #:22568 

 

 231. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 3-8, 10-12 of the ’876 patent under at least 35 U.S.C. § 271(a)-(c), either literally or under the doctrine of
equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 3-8 and 10-12 of the ’876 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented
AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’876 patent. 
 232. On
information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’876 patent, either literally or under the doctrine
of equivalents. 
 233. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s
direct infringement of at least claims 3-8 and 10-12 of the ’876 patent, either literally or under the doctrine of equivalents. 

234. Alvotech has knowledge of and is aware of the ’876 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C.
§ 262(l)(3)(A) and to the filing of this Complaint. 

  
 54 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 55 of 323 PageID #:22568 

 

 235. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless
Alvotech is enjoined from infringing the claims of the ’876 patent. 
 236. AbbVie seeks an injunction pursuant to at least 35 U.S.C.
§ 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT IV. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,231,876 
 237. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 238. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 239. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 240. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before November 5,
2020. 
 241. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

242. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 243. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of
the Alvotech aBLA Product promptly upon receiving FDA approval to do so and 180 days after its notice of commercial marketing. 

  
 55 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 56 of 323 PageID #:22568 

 

 244. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’876
patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’876 patent, literally or under the
doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination
of infringement is necessary and appropriate to resolve this controversy. 
 245. Alvotech has provided information to AbbVie pursuant to 42
U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to
the infringement by others of at least claims 3-8 and 10-12 of the ’876 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the
doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 3-8 and 10-12 of the ’876 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented
AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’876 patent. 

  
 56 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 57 of 323 PageID #:22568 

 

 246. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’876 patent, either literally or under the doctrine of equivalents. 

247. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of
at least claims 3-8 and 10-12 of the ’876 patent, either literally or under the doctrine of equivalents. 

248. Alvotech has knowledge of and is aware of the ’876 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C.
§ 262(l)(3)(A) and to the filing of this Complaint. 
 249. AbbVie will suffer irreparable injury for which damages are an
inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’876 patent. 
 250. AbbVie seeks a declaratory judgment
that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’876 patent. 

251. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT V. 

INFRINGEMENT OF U.S. PATENT NO. 8,663,945 

252. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

253. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 57 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 58 of 323 PageID #:22568 

 

 254. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 255. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 256. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 257. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 258. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’945 patent is an act of infringement of one or more claims of the ’945 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

259. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1-3, 5, 6, 9, 10, 12-14,
16, 17, 20, 21, 23-25, 27, 28, 31, 32, 34, 36, and 38 of the ’945 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to
Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-

  
 58 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 59 of 323 PageID #:22568 

 

 
claim infringement contentions for claims 1-3, 5, 6, 9, 10, 12-14, 16, 17, 20, 21,
23-25, 27, 28, 31, 32, 34, 36, and 38 of the ’945 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from
learning relevant facts that could further support AbbVie’s allegation of infringement of the ’945 patent. 
 260. On information
and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’945 patent, either literally or under the doctrine of
equivalents. 
 261. Alvotech has knowledge of and is aware of the ’945 patent, including due to AbbVie’s disclosure of patents
pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 262. AbbVie will suffer irreparable injury for
which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’945 patent. 
 263. AbbVie seeks
an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT VI. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,663,945 
 264. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 265. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 266. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 59 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 60 of 323 PageID #:22568 

 

 267. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 268. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 269. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 270. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

271. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’945 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’945 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 
 272. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating
to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the
Alvotech aBLA Product (either 

  
 60 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 61 of 323 PageID #:22568 

 

 
directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1-3, 5, 6, 9, 10, 12-14, 16, 17, 20, 21, 23-25, 27, 28, 31, 32, 34, 36, and 38 of the ’945 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of
equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-3, 5, 6, 9, 10, 12-14, 16, 17, 20, 21, 23-25, 27, 28, 31, 32, 34, 36, and 38 of the ’945 patent. For at least one claim,
however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’945 patent. 

273. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’945 patent, either literally or under the doctrine of equivalents. 
 274.
Alvotech has knowledge of and is aware of the ’945 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

275. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of
the ’945 patent. 
 276. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or
importation of the Alvotech aBLA Product will infringe the ’945 patent. 
 277. AbbVie seeks an injunction preventing Alvotech from the
commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

  
 61 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 62 of 323 PageID #:22568 

 

 COUNT VII. 

INFRINGEMENT OF U.S. PATENT NO. 8,708,968 

278. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

279. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 280. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before November 5,
2020. 
 281. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

282. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 283. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of
the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 284. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’968 patent is an act of infringement of one or more claims of the ’968 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 62 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 63 of 323 PageID #:22568 

 

 285. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 22, 24, 25, and 28-30 of the ’968 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has
provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 22, 24, 25, and 28-30 of the ’968 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could
further support AbbVie’s allegation of infringement of the ’968 patent. 
 286. On information and belief, Alvotech has an
affirmative intent to actively induce or contribute to infringement by others of one or more claims of the ’968 patent, either literally or under the doctrine of equivalents. 

287. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product (including the delivery device) directly infringes at least one claim of the ’968 patent, either literally or under the doctrine of equivalents. 

288. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of
at least claims 22, 24, 25, and 28-30 of the ’968 patent, either literally or under the doctrine of equivalents. 

289. Alvotech has knowledge of and is aware of the ’968 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C.
§ 262(l)(3)(A) and to the filing of this Complaint. 

  
 63 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 64 of 323 PageID #:22568 

 

 290. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless
Alvotech is enjoined from infringing the claims of the ’968 patent. 
 291. AbbVie seeks an injunction pursuant to at least 35 U.S.C.
§ 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT VIII. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,708,968 
 292. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 293. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 294. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 295. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before November 5,
2020. 
 296. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

297. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 298. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 64 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 65 of 323 PageID #:22568 

 

 299. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’968
patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’968 patent, literally or under the
doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination
of infringement is necessary and appropriate to resolve this controversy. 
 300. Alvotech has provided information to AbbVie pursuant to 42
U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to
the infringement by others of at least claims 22, 24, 25, and 28-30 of the ’968 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie
has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 22, 24, 25, and 28-30 of the ’968 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could
further support AbbVie’s allegation of infringement of the ’968 patent. 

  
 65 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 66 of 323 PageID #:22568 

 

 301. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’968 patent, either literally or under the doctrine of equivalents. 

302. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product (including the delivery device) directly infringes at least one claim of the ’968 patent, either literally or under the doctrine of equivalents. 

303. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 22, 24, 25, and 28-30 of the ’968 patent, either literally or under the doctrine of equivalents. 

304. Alvotech has knowledge of and is aware of the ’968 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 305. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’968 patent. 
 306. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’968 patent. 

307. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT IX. 

INFRINGEMENT OF U.S. PATENT NO. 8,715,664 

308. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

  
 66 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 67 of 323 PageID #:22568 

 

 309. On information and belief, in late August or early September 2020, Alvotech submitted an
aBLA to the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc.
is the holder of BLA No. 125057. 
 310. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product
for review on or before November 5, 2020. 
 311. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

312. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 313. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 314. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’664 patent is an act of infringement of one or more claims of the ’664 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

315. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 11 and 17 of the
’664 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C),
claim-by-claim infringement contentions for claims 11 and 17 of the ’664 patent. 

  
 67 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 68 of 323 PageID #:22568 

 

 316. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’664 patent, either literally or under the doctrine of equivalents. 

317. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or
use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 11 and 17 of the ’664 patent, either literally or under the doctrine of equivalents. 

318. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 11 and 17 of the ’664 patent, either literally or under the doctrine of equivalents. 
 319. Alvotech has knowledge
of and is aware of the ’664 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

320. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’664 patent. 
 321. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from
the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

  
 68 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 69 of 323 PageID #:22568 

 

 COUNT X. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,715,664 

322. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

323. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

324. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 325. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 326. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

327. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 328. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 329. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’664 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will

  
 69 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 70 of 323 PageID #:22568 

 

 
infringe one or more of the claims of ’664 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to
Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 

330. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 11 and 17 of the
’664 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C),
claim-by-claim infringement contentions for claims 11 and 17 of the ’664 patent. 

331. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’664 patent, either literally or under the doctrine of equivalents. 
 332. On information and belief, Alvotech is aware,
has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 11 and 17 of the ’664
patent, either literally or under the doctrine of equivalents. 

  
 70 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 71 of 323 PageID #:22568 

 

 333. On information and belief, Alvotech will knowingly or with willful blindness induce or
contribute to another’s direct infringement of at least claims 11 and 17 of the ’664 patent, either literally or under the doctrine of equivalents. 

334. Alvotech has knowledge of and is aware of the ’664 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 335. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’664 patent. 
 336. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’664 patent. 

337. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT XI. 

INFRINGEMENT OF U.S. PATENT NO. 8,808,700 

338. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 339. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 340. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

  
 71 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 72 of 323 PageID #:22568 

 

 341. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant
to 42 U.S.C. § 262(l)(8)(A). 
 342. On information and belief, Alvotech intends to engage in the commercial manufacture,
use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 343. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’700 patent is an act of infringement of one or more claims of the ’700 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 344. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-30 of the ’700 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-30 of the ’700 patent. 

345. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’700 patent, either literally or under the doctrine of equivalents. 

  
 72 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 73 of 323 PageID #:22568 

 

 346. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-30 of the ’700 patent,
either literally or under the doctrine of equivalents. 
 347. On information and belief, Alvotech will knowingly or with willful blindness
induce or contribute to another’s direct infringement of at least claims 1-30 of the ’700 patent, either literally or under the doctrine of equivalents. 

348. Alvotech has knowledge of and is aware of the ’700 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 349. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’700 patent. 
 350. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XII. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,808,700 
 351. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 352. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 353. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 73 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 74 of 323 PageID #:22568 

 

 354. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 355. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 356. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 357. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

358. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’700 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’700 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 

  
 74 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 75 of 323 PageID #:22568 

 

 359. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-30 of the ’700 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to
Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-30 of the
’700 patent. 
 360. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by
others of one or more claims of the ’700 patent, either literally or under the doctrine of equivalents. 
 361. On information and
belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-30 of the ’700 patent, either literally or under the doctrine of equivalents. 
 362. On
information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1-30 of the ’700 patent, either literally or under
the doctrine of equivalents. 
 363. Alvotech has knowledge of and is aware of the ’700 patent, including due to AbbVie’s
disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 364. AbbVie will suffer
irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’700 patent. 

365. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech
aBLA Product will infringe the ’700 patent. 

  
 75 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 76 of 323 PageID #:22568 

 

 366. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use,
sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XIII. 

INFRINGEMENT OF U.S. PATENT NO. 8,883,156 

367. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 368. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 369. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

370. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 371. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 372. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’156 patent is an act of infringement of one or more claims of the ’156 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 76 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 77 of 323 PageID #:22568 

 

 373. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-7 and 10-19 of the ’156 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the
doctrine of equivalents. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of
infringement of the ’156 patent. 
 374. On information and belief, Alvotech has an affirmative intent to actively induce or contribute
to infringement by others of one or more claims of the ’156 patent, either literally or under the doctrine of equivalents. 
 375. On
information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’156 patent, either literally or under the doctrine
of equivalents. 
 376. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s
direct infringement of at least claims 1-7 and 10-19 of the ’156 patent, either literally or under the doctrine of equivalents. 

377. Alvotech has knowledge of and is aware of the ’156 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

  
 77 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 78 of 323 PageID #:22568 

 

 378. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless
Alvotech is enjoined from infringing the claims of the ’156 patent. 
 379. AbbVie seeks an injunction pursuant to at least 35 U.S.C.
§ 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XIV. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,883,156 
 380. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 381. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 382. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 383. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 384. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

385. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 386. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 78 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 79 of 323 PageID #:22568 

 

 387. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’156
patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of the ’156 patent, literally or under the
doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination
of infringement is necessary and appropriate to resolve this controversy. 
 388. Alvotech has provided information to AbbVie pursuant to 42
U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to
the infringement by others of at least claims 1-7 and 10-19 of the ’156 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under
the doctrine of equivalents. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation
of infringement of the ’156 patent. 
 389. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’156 patent, either literally or under the doctrine of equivalents. 

  
 79 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 80 of 323 PageID #:22568 

 

 390. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’156 patent, either literally or under the doctrine of equivalents. 

391. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 1-7 and 10-19 of the ’156 patent, either literally or under the doctrine of equivalents. 

392. Alvotech has knowledge of and is aware of the ’156 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 393. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’156 patent. 
 394. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’156 patent. 

395. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT XV. 

INFRINGEMENT OF U.S. PATENT NO. 8,889,136 

396. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

397. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 80 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 81 of 323 PageID #:22568 

 

 398. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 399. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 400. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 401. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 402. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’136 patent is an act of infringement of one or more claims of the ’136 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

403. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-18 of the ’136 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-18 of the ’136 patent. 

  
 81 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 82 of 323 PageID #:22568 

 

 404. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’136 patent, either literally or under the doctrine of equivalents. 

405. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or
use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-18 of the ’136 patent, either literally or under the doctrine of
equivalents. 
 406. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s
direct infringement of at least claims 1-18 of the ’136 patent, either literally or under the doctrine of equivalents. 

407. Alvotech has knowledge of and is aware of the ’136 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 408. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’136 patent. 
 409. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XVI. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,889,136 
 410. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 

  
 82 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 83 of 323 PageID #:22568 

 

 411. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C.
§§ 2201 and 2202. 
 412. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to
the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the
holder of BLA No. 125057. 
 413. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for
review on or before November 5, 2020. 
 414. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

415. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 416. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 417. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’136 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’136 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 

  
 83 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 84 of 323 PageID #:22568 

 

 418. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-18 of the ’136 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to
Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-18 of the
’136 patent. 
 419. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by
others of one or more claims of the ’136 patent, either literally or under the doctrine of equivalents. 
 420. On information and
belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-18 of the ’136 patent, either literally or under the doctrine of equivalents. 
 421. On
information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1-18 of the ’136 patent, either literally or under
the doctrine of equivalents. 

  
 84 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 85 of 323 PageID #:22568 

 

 422. Alvotech has knowledge of and is aware of the ’136 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 423.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’136 patent. 

424. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech
aBLA Product will infringe the ’136 patent. 
 425. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XVII. 

INFRINGEMENT OF U.S. PATENT NO. 8,895,009 

426. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

427. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 428. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 429. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

430. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 85 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 86 of 323 PageID #:22568 

 

 431. On information and belief, Alvotech intends to engage in the commercial manufacture,
use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 432. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’009 patent is an act of infringement of one or more claims of the ’009 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 433. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-7 and 9-13 of the ’009 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. For at least one claim,
however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’009 patent. 

434. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’009 patent, either literally or under the doctrine of equivalents. 

  
 86 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 87 of 323 PageID #:22568 

 

 435. On information and belief, Alvotech will knowingly or with willful blindness induce or
contribute to another’s direct infringement of at least claims 1-7 and 9-13 of the ’009 patent, either literally or under the doctrine of equivalents. 

436. Alvotech has knowledge of and is aware of the ’009 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 437. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’009 patent. 
 438. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XVIII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,895,009 

439. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

440. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

441. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 442. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 

  
 87 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 88 of 323 PageID #:22568 

 

 443. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

444. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 445. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 446. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’009 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’009 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 
 447.
Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential
information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will
infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-7 and 9-13 of the ’009 patent under at least 35
U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning
relevant facts that could further support AbbVie’s allegation of infringement of the ’009 patent. 

  
 88 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 89 of 323 PageID #:22568 

 

 448. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’009 patent, either literally or under the doctrine of equivalents. 

449. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 1-7 and 9-13 of the ’009 patent, either literally or under the doctrine of equivalents. 

450. Alvotech has knowledge of and is aware of the ’009 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 451. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’009 patent. 
 452. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’009 patent. 

453. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT XIX. 

INFRINGEMENT OF U.S. PATENT NO. 8,906,372 

454. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 89 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 90 of 323 PageID #:22568 

 

 455. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 456. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 457. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 458. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 459. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’372 patent is an act of infringement of one or more claims of the ’372 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

460. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-7 and 9-19 of the ’372 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. For at least one claim,
however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’372 patent. 

  
 90 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 91 of 323 PageID #:22568 

 

 461. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’372 patent, either literally or under the doctrine of equivalents. 

462. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’372 patent, either literally or under the doctrine of equivalents. 
 463.
On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1-7 and 9-19
of the ’372 patent, either literally or under the doctrine of equivalents. 
 464. Alvotech has knowledge of and is aware of the
’372 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

465. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’372 patent. 
 466. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from
the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XX. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,906,372 
 467. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 

  
 91 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 92 of 323 PageID #:22568 

 

 468. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C.
§§ 2201 and 2202. 
 469. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to
the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the
holder of BLA No. 125057. 
 470. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for
review on or before November 5, 2020. 
 471. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

472. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 473. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 474. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’372 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of the ’372 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42
U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 

  
 92 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 93 of 323 PageID #:22568 

 

 475. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-7 and 9-19 of the ’372 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the
doctrine of equivalents. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of
infringement of the ’372 patent. 
 476. On information and belief, Alvotech has an affirmative intent to actively induce or contribute
to infringement by others of one or more claims of the ’372 patent, either literally or under the doctrine of equivalents. 
 477. On
information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’372 patent, either literally or under the doctrine
of equivalents. 
 478. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s
direct infringement of at least claims 1-7 and 9-19 of the ’372 patent, either literally or under the doctrine of equivalents. 

  
 93 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 94 of 323 PageID #:22568 

 

 479. Alvotech has knowledge of and is aware of the ’372 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 480.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’372 patent. 

481. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech
aBLA Product will infringe the ’372 patent. 
 482. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XXI. 

INFRINGEMENT OF U.S. PATENT NO. 8,906,373 

483. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

484. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 485. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 486. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

487. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 94 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 95 of 323 PageID #:22568 

 

 488. On information and belief, Alvotech intends to engage in the commercial manufacture,
use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 489. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’373 patent is an act of infringement of one or more claims of the ’373 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 490. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 4, 5, and 8
of the ’373 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 4, 5, and 8 of the ’373 patent. 

491. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’373 patent, either literally or under the doctrine of equivalents. 
 492. On information and belief, Alvotech is aware,
has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 4, 5, and 8 of the ’373
patent, either literally or under the doctrine of equivalents. 

  
 95 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 96 of 323 PageID #:22568 

 

 493. On information and belief, Alvotech will knowingly or with willful blindness induce or
contribute to another’s direct infringement of at least claims 4, 5, and 8 of the ’373 patent, either literally or under the doctrine of equivalents. 

494. Alvotech has knowledge of and is aware of the ’373 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 495. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’373 patent. 
 496. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XXII. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,906,373 
 497. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 498. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 499. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 96 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 97 of 323 PageID #:22568 

 

 500. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 501. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 502. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 503. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

504. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’373 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’373 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 
 505. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating
to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the
Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least
claims 4, 5, and 8 of the ’373 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 4, 5, and 8 of the ’373 patent. 

  
 97 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 98 of 323 PageID #:22568 

 

 506. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’373 patent, either literally or under the doctrine of equivalents. 

507. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or
use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 4, 5, and 8 of the ’373 patent, either literally or under the doctrine of equivalents. 

508. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 4, 5, and 8 of the ’373 patent, either literally or under the doctrine of equivalents. 
 509. Alvotech has
knowledge of and is aware of the ’373 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

510. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’373 patent. 
 511. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or
importation of the Alvotech aBLA Product will infringe the ’373 patent. 

  
 98 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 99 of 323 PageID #:22568 

 

 512. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use,
sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XXIII. 

INFRINGEMENT OF U.S. PATENT NO. 8,906,646 

513. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

514. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 515. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 516. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

517. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 518. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 519. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’646 patent is an act of infringement of one or more claims of the ’646 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 99 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 100 of 323 PageID #:22568 

 

 520. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 25-28 of
the ’646 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 25-28 of the ’646 patent. 

521. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’646 patent, either literally or under the doctrine of equivalents. 
 522.
Alvotech has knowledge of and is aware of the ’646 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

523. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’646 patent. 
 524. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from
the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

  
 100 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 101 of 323 PageID #:22568 

 

 COUNT XXIV. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,906,646 

525. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

526. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

527. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 528. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 529. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

530. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 531. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 532. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’646 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’646 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 

  
 101 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 102 of 323 PageID #:22568 

 

 533. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 25-28 of
the ’646 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 25-28 of the ’646 patent. 

534. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’646 patent, either literally or under the doctrine of equivalents. 
 535.
Alvotech has knowledge of and is aware of the ’646 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

536. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’646 patent. 
 537. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or
importation of the Alvotech aBLA Product will infringe the ’646 patent. 

  
 102 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 103 of 323 PageID #:22568 

 

 538. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use,
sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XXV. 

INFRINGEMENT OF U.S. PATENT NO. 8,911,737 

539. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

540. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 541. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 542. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

543. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 544. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 545. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’737 patent is an act of infringement of one or more claims of the ’737 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 103 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 104 of 323 PageID #:22568 

 

 546. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-6 of the ’737 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to
Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-6 of the
’737 patent. 
 547. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by
others of one or more claims of the ’737 patent, either literally or under the doctrine of equivalents. 
 548. On information and
belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-6 of the ’737 patent, either literally or under the doctrine of equivalents. 
 549. On information
and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1-6 of the ’737 patent, either literally or under the doctrine
of equivalents. 

  
 104 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 105 of 323 PageID #:22568 

 

 550. Alvotech has knowledge of and is aware of the ’737 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 551.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’737 patent. 

552. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XXVI. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,911,737 

553. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

554. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

555. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 556. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 557. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

558. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 105 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 106 of 323 PageID #:22568 

 

 559. On information and belief as of May 28, 2021, Alvotech intends to engage in the
commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

560. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’737 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’737 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 
 561. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating
to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the
Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least
claims 1-6 of the ’737 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-6 of the ’737 patent. 

  
 106 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 107 of 323 PageID #:22568 

 

 562. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’737 patent, either literally or under the doctrine of equivalents. 

563. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or
use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-6 of the ’737 patent, either literally or under the doctrine of equivalents.

 564. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct
infringement of at least claims 1-6 of the ’737 patent, either literally or under the doctrine of equivalents. 

565. Alvotech has knowledge of and is aware of the ’737 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 566. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’737 patent. 
 567. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’737 patent. 

568. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT XXVII. 

INFRINGEMENT OF U.S. PATENT NO. 8,911,964 

569. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

  
 107 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 108 of 323 PageID #:22568 

 

 570. On information and belief, in late August or early September 2020, Alvotech submitted an
aBLA to the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc.
is the holder of BLA No. 125057. 
 571. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product
for review on or before November 5, 2020. 
 572. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

573. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 574. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 575. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’964 patent is an act of infringement of one or more claims of the ’964 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

576. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the 

  
 108 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 109 of 323 PageID #:22568 

 

 
FDA, will infringe at least claims 23, 24, 26, 27, and 29 of the ’964 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has
provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 23, 24, 26, 27, and 29 of the ’964
patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of
the ’964 patent. 
 577. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the
manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’964 patent, either literally or under the doctrine of equivalents. 

578. Alvotech has knowledge of and is aware of the ’964 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 579. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’964 patent. 
 580. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XXVIII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,911,964 

581. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

582. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

  
 109 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 110 of 323 PageID #:22568 

 

 583. On information and belief, in late August or early September 2020, Alvotech submitted an
aBLA to the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc.
is the holder of BLA No. 125057. 
 584. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product
for review on or before November 5, 2020. 
 585. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

586. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 587. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 588. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’964 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’964 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 

  
 110 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 111 of 323 PageID #:22568 

 

 589. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 23, 24, 26, 27, and 29 of the ’964 patent
under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 23, 24, 26, 27, and 29 of the ’964 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by
the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’964 patent. 

590. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’964 patent, either literally or under the doctrine of equivalents. 
 591.
Alvotech has knowledge of and is aware of the ’964 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

592. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’964 patent. 
 593. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or
importation of the Alvotech aBLA Product will infringe the ’964 patent. 

  
 111 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 112 of 323 PageID #:22568 

 

 594. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use,
sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XXIX. 

INFRINGEMENT OF U.S. PATENT NO. 8,916,153 

595. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

596. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 597. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 598. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

599. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 600. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 601. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’153 patent is an act of infringement of one or more claims of the ’153 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 112 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 113 of 323 PageID #:22568 

 

 602. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-8 and 11-14 of the ’153 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the
doctrine of equivalents. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of
infringement of the ’153 patent. 
 603. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the
fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’153 patent, either literally or under the doctrine of equivalents. 

604. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 1-8 and 11-14 of the ’153 patent, either literally or under the doctrine of equivalents. 

605. Alvotech has knowledge of and is aware of the ’153 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

  
 113 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 114 of 323 PageID #:22568 

 

 606. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless
Alvotech is enjoined from infringing the claims of the ’153 patent. 
 607. AbbVie seeks an injunction pursuant to at least 35 U.S.C.
§ 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XXX. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,916,153 
 608. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 609. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 610. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 611. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 612. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

613. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 614. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 114 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 115 of 323 PageID #:22568 

 

 615. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’153
patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’153 patent, literally or under the
doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of
infringement is necessary and appropriate to resolve this controversy. 
 616. Alvotech has provided information to AbbVie pursuant to 42
U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to
the infringement by others of at least claims 1-8 and 11-14 of the ’153 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the
doctrine of equivalents. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of
infringement of the ’153 patent. 
 617. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the
fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’153 patent, either literally or under the doctrine of equivalents. 

  
 115 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 116 of 323 PageID #:22568 

 

 618. On information and belief, Alvotech will knowingly or with willful blindness induce or
contribute to another’s direct infringement of at least claims 1-8 and 11-14 of the ’153 patent, either literally or under the doctrine of equivalents. 

619. Alvotech has knowledge of and is aware of the ’153 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 620. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’153 patent. 
 621. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’153 patent. 

622. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT XXXI. 

INFRINGEMENT OF U.S. PATENT NO. 8,961,974 

623. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

624. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 625. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 

  
 116 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 117 of 323 PageID #:22568 

 

 626. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

627. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 628. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 629. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’974 patent is an act of infringement of one or more claims of the ’974 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

630. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-28 of the ’974 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-28 of the ’974 patent. 

631. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’974 patent, either literally or under the doctrine of equivalents. 

  
 117 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 118 of 323 PageID #:22568 

 

 632. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-28 of the ’974 patent,
either literally or under the doctrine of equivalents. 
 633. On information and belief, Alvotech will knowingly or with willful blindness
induce or contribute to another’s direct infringement of at least claims 1-28 of the ’974 patent, either literally or under the doctrine of equivalents. 

634. Alvotech has knowledge of and is aware of the ’974 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 635. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’974 patent. 
 636. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XXXII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,961,974 

637. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

638. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

639. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 118 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 119 of 323 PageID #:22568 

 

 640. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 641. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 642. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 643. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

644. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’974 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’974 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 

  
 119 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 120 of 323 PageID #:22568 

 

 645. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-28 of the ’974 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to
Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-28 of the
’974 patent. 
 646. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by
others of one or more claims of the ’974 patent, either literally or under the doctrine of equivalents. 
 647. On information and
belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-28 of the ’974 patent, either literally or under the doctrine of equivalents. 
 648. On
information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1-28 of the ’974 patent, either literally or under
the doctrine of equivalents. 
 649. Alvotech has knowledge of and is aware of the ’974 patent, including due to AbbVie’s
disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 650. AbbVie will suffer
irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’974 patent. 

651. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech
aBLA Product will infringe the ’974 patent. 

  
 120 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 121 of 323 PageID #:22568 

 

 652. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use,
sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XXXIII. 

INFRINGEMENT OF U.S. PATENT NO. 8,974,790 

653. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

654. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 655. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 656. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

657. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 658. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 659. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’790 patent is an act of infringement of one or more claims of the ’790 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 121 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 122 of 323 PageID #:22568 

 

 660. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-6 of the ’790 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to
Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-6 of the
’790 patent. 
 661. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by
others of one or more claims of the ’790 patent, either literally or under the doctrine of equivalents. 
 662. On information and
belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-6 of the ’790 patent, either literally or under the doctrine of equivalents. 
 663. On information
and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1-6 of the ’790 patent, either literally or under the doctrine
of equivalents. 

  
 122 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 123 of 323 PageID #:22568 

 

 664. Alvotech has knowledge of and is aware of the ’790 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 665.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’790 patent. 

666. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XXXIV. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,974,790 

667. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

668. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

669. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 670. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 671. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

672. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 123 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 124 of 323 PageID #:22568 

 

 673. On information and belief as of May 28, 2021, Alvotech intends to engage in the
commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

674. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’790 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’790 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 
 675. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating
to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the
Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least
claims 1-6 of the ’790 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-6 of the ’790 patent. 

  
 124 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 125 of 323 PageID #:22568 

 

 676. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’790 patent, either literally or under the doctrine of equivalents. 

677. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or
use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-6 of the ’790 patent, either literally or under the doctrine of equivalents
at least one claim of the ’790 patent, either literally or under the doctrine of equivalents. 
 678. On information and belief,
Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1-6 of the ’790 patent, either literally or under the doctrine of
equivalents. 
 679. Alvotech has knowledge of and is aware of the ’790 patent, including due to AbbVie’s disclosure of patents
pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 680. AbbVie will suffer irreparable injury for
which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’790 patent. 
 681. AbbVie seeks
a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’790 patent. 

682. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 

  
 125 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 126 of 323 PageID #:22568 

 

 COUNT XXXV. 

INFRINGEMENT OF U.S. PATENT NO. 8,986,693 

683. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

684. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 685. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 686. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

687. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 688. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 689. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’693 patent is an act of infringement of one or more claims of the ’693 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 126 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 127 of 323 PageID #:22568 

 

 690. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-8 of the ’693 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to
Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-8 of the
’693 patent. 
 691. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by
others of one or more claims of the ’693 patent, either literally or under the doctrine of equivalents. 
 692. On information and
belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-8 of the ’693 patent, either literally or under the doctrine of equivalents. 
 693. On information
and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1-8 of the ’693 patent, either literally or under the doctrine
of equivalents. 
 694. Alvotech has knowledge of and is aware of the ’693 patent, including due to AbbVie’s disclosure of patents
pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 695. AbbVie will suffer irreparable injury for
which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’693 patent. 

  
 127 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 128 of 323 PageID #:22568 

 

 696. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B)
preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XXXVI. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,986,693 

697. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

698. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

699. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 700. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 701. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

702. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 703. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 128 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 129 of 323 PageID #:22568 

 

 704. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’693
patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’693 patent, literally or under the
doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination
of infringement is necessary and appropriate to resolve this controversy. 
 705. Alvotech has provided information to AbbVie pursuant to 42
U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to
the infringement by others of at least claims 1-8 of the ’693 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided
to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-8 of the
’693 patent. 
 706. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by
others of one or more claims of the ’693 patent, either literally or under the doctrine of equivalents. 
 707. On information and
belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-8 of the ’693 patent, either literally or under the doctrine of equivalents. 

  
 129 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 130 of 323 PageID #:22568 

 

 708. On information and belief, Alvotech will knowingly or with willful blindness induce or
contribute to another’s direct infringement of at least claims 1-8 of the ’693 patent, either literally or under the doctrine of equivalents. 

709. Alvotech has knowledge of and is aware of the ’693 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 710. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’693 patent. 
 711. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’693 patent. 

712. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT XXXVII. 

INFRINGEMENT OF U.S. PATENT NO. 8,992,926 

713. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

714. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 715. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 

  
 130 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 131 of 323 PageID #:22568 

 

 716. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

717. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 718. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 719. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’926 patent is an act of infringement of one or more claims of the ’926 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

720. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-4 of the ’926 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-4 of the ’926 patent. 

721. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’926 patent, either literally or under the doctrine of equivalents. 

  
 131 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 132 of 323 PageID #:22568 

 

 722. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-4 of the ’926 patent,
either literally or under the doctrine of equivalents. 
 723. On information and belief, Alvotech will knowingly or with willful blindness
induce or contribute to another’s direct infringement of at least claims 1-4 of the ’926 patent, either literally or under the doctrine of equivalents. 

724. Alvotech has knowledge of and is aware of the ’926 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 725. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’926 patent. 
 726. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XXXVIII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,992,926 

727. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

728. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

729. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 132 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 133 of 323 PageID #:22568 

 

 730. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 731. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 732. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 733. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

734. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’926 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’926 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 

  
 133 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 134 of 323 PageID #:22568 

 

 735. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-4 of the ’926 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to
Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-4 of the
’926 patent. 
 736. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by
others of one or more claims of the ’926 patent, either literally or under the doctrine of equivalents. 
 737. On information and
belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-4 of the ’926 patent, either literally or under the doctrine of equivalents. 
 738. On information
and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1-4 of the ’926 patent, either literally or under the doctrine
of equivalents. 
 739. Alvotech has knowledge of and is aware of the ’926 patent, including due to AbbVie’s disclosure of patents
pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 740. AbbVie will suffer irreparable injury for
which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’926 patent. 
 741. AbbVie seeks
a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’926 patent. 

  
 134 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 135 of 323 PageID #:22568 

 

 742. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use,
sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XXXIX. 

INFRINGEMENT OF U.S. PATENT NO. 8,999,337 

743. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

744. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 745. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 746. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

747. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 748. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 749. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’9337 patent is an act of infringement of one or more claims of the ’9337 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 135 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 136 of 323 PageID #:22568 

 

 750. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-8, 10, and 14-19 of the ’9337 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or
under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for
claims 1-8, 10, and 14-19 of the ’9337 patent. 
 751.
On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more claims of the ’9337 patent, either literally or under the doctrine of equivalents. 

752. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or
use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-8, 10, and 14-19 of the ’9337
patent, either literally or under the doctrine of equivalents. 
 753. On information and belief, Alvotech will knowingly or with willful
blindness induce or contribute to another’s direct infringement of at least claims 1-8, 10, and 14-19 of the ’9337 patent, either literally or under the
doctrine of equivalents. 

  
 136 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 137 of 323 PageID #:22568 

 

 754. Alvotech has knowledge of and is aware of the ’9337 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 755.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’9337 patent. 

756. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XL. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,999,337 

757. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

758. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

759. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 760. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 761. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

762. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 137 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 138 of 323 PageID #:22568 

 

 763. On information and belief as of May 28, 2021, Alvotech intends to engage in the
commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

764. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’9337 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’9337 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 
 765. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating
to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the
Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least
claims 1-8, 10, and 14-19 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to
Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-8, 10, and 14-19 of the ’9337 patent. 

  
 138 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 139 of 323 PageID #:22568 

 

 766. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’9337 patent, either literally or under the doctrine of equivalents. 

767. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or
use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-8, 10, and 14-19 of the ’9337
patent, either literally or under the doctrine of equivalents. 
 768. On information and belief, Alvotech will knowingly or with willful
blindness induce or contribute to another’s direct infringement of at least claims 1-8, 10, and 14-19 of the ’9337 patent, either literally or under the
doctrine of equivalents. 
 769. Alvotech has knowledge of and is aware of the ’9337 patent, including due to AbbVie’s disclosure
of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 770. AbbVie will suffer irreparable
injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’9337 patent. 
 771.
AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’9337 patent. 

772. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT XLI. 

INFRINGEMENT OF U.S. PATENT NO. 9,061,005 

773. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

  
 139 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 140 of 323 PageID #:22568 

 

 774. On information and belief, in late August or early September 2020, Alvotech submitted an
aBLA to the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc.
is the holder of BLA No. 125057. 
 775. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product
for review on or before November 5, 2020. 
 776. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

777. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 778. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 779. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’005 patent is an act of infringement of one or more claims of the ’005 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

780. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the 

  
 140 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 141 of 323 PageID #:22568 

 

 
FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-28 of the ’005 patent
under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-28 of the ’005 patent. 

781. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’005 patent, either literally or under the doctrine of equivalents. 
 782. On information and belief, Alvotech is aware,
has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims
1-28 of the ’005 patent, either literally or under the doctrine of equivalents. 
 783. On
information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1-28 of the ’005 patent, either literally or under
the doctrine of equivalents. 
 784. Alvotech has knowledge of and is aware of the ’005 patent, including due to AbbVie’s
disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 785. AbbVie will suffer
irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’005 patent. 

786. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

  
 141 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 142 of 323 PageID #:22568 

 

 COUNT XLII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,061,005 

787. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

788. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

789. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 790. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 791. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

792. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 793. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 794. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’005 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’005 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 

  
 142 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 143 of 323 PageID #:22568 

 

 795. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-28 of the ’005 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to
Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-28 of the
’005 patent. 
 796. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by
others of one or more claims of the ’005 patent, either literally or under the doctrine of equivalents. 
 797. On information and
belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-28 of the ’005 patent, either literally or under the doctrine of equivalents. 
 798. On
information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1-28 of the ’005 patent, either literally or under
the doctrine of equivalents. 

  
 143 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 144 of 323 PageID #:22568 

 

 799. Alvotech has knowledge of and is aware of the ’005 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 800.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’005 patent. 

801. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech
aBLA Product will infringe the ’005 patent. 
 802. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XLIII. 

INFRINGEMENT OF U.S. PATENT NO. 9,062,106 

803. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

804. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 805. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 806. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

807. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 144 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 145 of 323 PageID #:22568 

 

 808. On information and belief, Alvotech intends to engage in the commercial manufacture,
use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 809. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’106 patent is an act of infringement of one or more claims of the ’106 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 810. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1-12, 14-44, and 46-65 of the ’106 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-12,
14-44, and 46-65 of the ’106 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has
prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’106 patent. 

811. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’106 patent, either literally or under the doctrine of equivalents. 

  
 145 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 146 of 323 PageID #:22568 

 

 812. Alvotech has knowledge of and is aware of the ’106 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 813.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’106 patent. 

814. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XLIV. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,062,106 

815. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

816. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

817. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 818. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 819. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

820. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 146 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 147 of 323 PageID #:22568 

 

 821. On information and belief as of May 28, 2021, Alvotech intends to engage in the
commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

822. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’106 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’106 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 
 823. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating
to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the
Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1-12,
14-44, and 46-65 of the ’106 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to
Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-12, 14-44, and 46-65 of the ’106 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented
AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’106 patent. 

  
 147 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 148 of 323 PageID #:22568 

 

 824. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’106 patent, either literally or under the doctrine of equivalents. 

825. Alvotech has knowledge of and is aware of the ’106 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 826. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’106 patent. 
 827. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’106 patent. 

828. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT XLV. 

INFRINGEMENT OF U.S. PATENT NO. 9,067,992 

829. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

830. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 831. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 

  
 148 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 149 of 323 PageID #:22568 

 

 832. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

833. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 834. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 835. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’992 patent is an act of infringement of one or more claims of the ’992 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

836. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 2, 3, 7, and 8 of
the ’992 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 2, 3, 7, and 8 of the ’992 patent. 

  
 149 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 150 of 323 PageID #:22568 

 

 837. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’992 patent, either literally or under the doctrine of equivalents. 

838. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or
use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 2, 3, 7, and 8 of the ’992 patent, either literally or under the doctrine of equivalents. 

839. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 2, 3, 7, and 8 of the ’992 patent, either literally or under the doctrine of equivalents. 
 840. Alvotech has
knowledge of and is aware of the ’992 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

841. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’992 patent. 
 842. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from
the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XLVI. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,067,992 
 843. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 844. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

  
 150 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 151 of 323 PageID #:22568 

 

 845. On information and belief, in late August or early September 2020, Alvotech submitted an
aBLA to the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc.
is the holder of BLA No. 125057. 
 846. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product
for review on or before November 5, 2020. 
 847. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

848. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 849. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 850. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’992 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’992 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 

  
 151 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 152 of 323 PageID #:22568 

 

 851. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 2, 3, 7, and 8 of the ’992 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 2, 3, 7, and 8 of the ’992 patent. 

852. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’992 patent, either literally or under the doctrine of equivalents. 
 853. On information and belief, Alvotech is aware,
has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 2, 3, 7, and 8 of the ’992
patent, either literally or under the doctrine of equivalents. 
 854. On information and belief, Alvotech will knowingly or with willful
blindness induce or contribute to another’s direct infringement of at least claims 2, 3, 7, and 8 of the ’992 patent, either literally or under the doctrine of equivalents. 

855. Alvotech has knowledge of and is aware of the ’992 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

  
 152 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 153 of 323 PageID #:22568 

 

 856. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless
Alvotech is enjoined from infringing the claims of the ’992 patent. 
 857. AbbVie seeks a declaratory judgment that future commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’992 patent. 
 858. AbbVie
seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XLVII. 

INFRINGEMENT OF U.S. PATENT NO. 9,085,618 

859. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

860. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 861. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 862. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

863. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 864. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 153 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 154 of 323 PageID #:22568 

 

 865. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’618
patent is an act of infringement of one or more claims of the ’618 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

866. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 7, 8, and 22 of the
’618 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 7, 8, and 22 of the ’618 patent. 
 867. On
information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’618 patent, either literally or under the doctrine
of equivalents. 
 868. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s
direct infringement of at least claims 7, 8, and 22 of the ’618 patent, either literally or under the doctrine of equivalents. 

  
 154 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 155 of 323 PageID #:22568 

 

 869. Alvotech has knowledge of and is aware of the ’618 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 870.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’618 patent. 

871. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XLVIII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,085,618 

872. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

873. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

874. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 875. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 876. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

877. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 155 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 156 of 323 PageID #:22568 

 

 878. On information and belief as of May 28, 2021, Alvotech intends to engage in the
commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

879. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’618 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’618 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 
 880. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating
to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the
Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least
claims 7, 8, and 22 of the ’618 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 7, 8, and 22 of the ’618 patent. 

  
 156 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 157 of 323 PageID #:22568 

 

 881. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’618 patent, either literally or under the doctrine of equivalents. 

882. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 7, 8, and 22 of the ’618 patent, either literally or under the doctrine of equivalents. 
 883. Alvotech has
knowledge of and is aware of the ’618 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

884. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’618 patent. 
 885. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or
importation of the Alvotech aBLA Product will infringe the ’618 patent. 
 886. AbbVie seeks an injunction preventing Alvotech from the
commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT
XLIX. 
 INFRINGEMENT OF U.S. PATENT NO. 9,085,620 

887. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

888. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 157 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 158 of 323 PageID #:22568 

 

 889. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 890. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 891. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 892. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 893. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’620 patent is an act of infringement of one or more claims of the ’620 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

894. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1, 4, 7, 10, 13,
16, 19, 22, 25, 27, and 29 of the ’620 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1, 4, 7, 10, 13, 16, 19, 22, 25, 27, and 29 of the ’620 patent. 

  
 158 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 159 of 323 PageID #:22568 

 

 895. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’620 patent, either literally or under the doctrine of equivalents. 

896. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or
use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1, 4, 7, 10, 13, 16, 19, 22, 25, 27, and 29 of the ’620 patent, either literally or under the doctrine of equivalents.

 897. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct
infringement of at least claims 1, 4, 7, 10, 13, 16, 19, 22, 25, 27, and 29 of the ’620 patent, either literally or under the doctrine of equivalents. 

898. Alvotech has knowledge of and is aware of the ’620 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 899. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’620 patent. 
 900. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT L. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,085,620 
 901. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 

  
 159 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 160 of 323 PageID #:22568 

 

 902. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C.
§§ 2201 and 2202. 
 903. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to
the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the
holder of BLA No. 125057. 
 904. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for
review on or before November 5, 2020. 
 905. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

906. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 907. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 908. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’620 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’620 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 

  
 160 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 161 of 323 PageID #:22568 

 

 909. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1, 4, 7, 10, 13, 16, 19, 22, 25, 27, and 29 of the ’620 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to
Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1, 4, 7, 10, 13, 16, 19, 22, 25, 27, and 29 of the
’620 patent. 
 910. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by
others of one or more claims of the ’620 patent, either literally or under the doctrine of equivalents. 
 911. On information and
belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1, 4,
7, 10, 13, 16, 19, 22, 25, 27, and 29 of the ’620 patent, either literally or under the doctrine of equivalents. 
 912. On information
and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1, 4, 7, 10, 13, 16, 19, 22, 25, 27, and 29 of the ’620 patent, either literally or under the doctrine
of equivalents. 

  
 161 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 162 of 323 PageID #:22568 

 

 913. Alvotech has knowledge of and is aware of the ’620 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 914.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’620 patent. 

915. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech
aBLA Product will infringe the ’620 patent. 
 916. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT LI. 

INFRINGEMENT OF U.S. PATENT NO. 9,090,688 

917. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

918. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 919. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 920. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

921. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 162 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 163 of 323 PageID #:22568 

 

 922. On information and belief, Alvotech intends to engage in the commercial manufacture,
use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 923. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’688 patent is an act of infringement of one or more claims of the ’688 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 924. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1-26 and 28-48 of
the ’688 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-26 and 28-48 of the ’688 patent. For at least one claim, however,
Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’688 patent. 

925. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’688 patent, either literally or under the doctrine of equivalents. 

  
 163 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 164 of 323 PageID #:22568 

 

 926. Alvotech has knowledge of and is aware of the ’688 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 927.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’688 patent. 

928. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT LII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,090,688 

929. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

930. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

931. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 932. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 933. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

934. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 164 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 165 of 323 PageID #:22568 

 

 935. On information and belief as of May 28, 2021, Alvotech intends to engage in the
commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

936. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’688 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’688 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 
 937. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating
to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the
Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1-26 and
28-48 of the ’688 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-26 and
28-48 of the ’688 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could
further support AbbVie’s allegation of infringement of the ’688 patent. 

  
 165 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 166 of 323 PageID #:22568 

 

 938. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’688 patent, either literally or under the doctrine of equivalents. 

939. Alvotech has knowledge of and is aware of the ’688 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 940. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’688 patent. 
 941. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’688 patent. 

942. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT LIII. 

INFRINGEMENT OF U.S. PATENT NO. 9,090,689 

943. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

944. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 945. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 

  
 166 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 167 of 323 PageID #:22568 

 

 946. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

947. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 948. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 949. Based on confidential information disclosed to AbbVie by
Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’689 patent is an act of infringement of one or more claims of the ’689 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

950. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1, 4, 7, 10, 13,
16, and 19 of the ’689 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1, 4, 7, 10, 13, 16, and 19 of the ’689 patent. 

  
 167 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 168 of 323 PageID #:22568 

 

 951. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’689 patent, either literally or under the doctrine of equivalents. 

952. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or
use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1, 4, 7, 10, 13, 16, and 19 of the ’689 patent, either literally or under the doctrine of equivalents. 

953. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 1, 4, 7, 10, 13, 16, and 19 of the ’689 patent, either literally or under the doctrine of equivalents. 
 954.
Alvotech has knowledge of and is aware of the ’689 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

955. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’689 patent. 
 956. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from
the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LIV. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,090,689 
 957. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 958. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

  
 168 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 169 of 323 PageID #:22568 

 

 959. On information and belief, in late August or early September 2020, Alvotech submitted an
aBLA to the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc.
is the holder of BLA No. 125057. 
 960. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product
for review on or before November 5, 2020. 
 961. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

962. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 963. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 964. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’689 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’689 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 

  
 169 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 170 of 323 PageID #:22568 

 

 965. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1, 4, 7, 10, 13, 16, and 19 of the ’689 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to
42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1, 4, 7, 10, 13, 16, and 19 of the ’689 patent. 

966. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’689 patent, either literally or under the doctrine of equivalents. 
 967. On information and belief, Alvotech is aware,
has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1, 4, 7, 10, 13, 16, and 19 of
the ’689 patent, either literally or under the doctrine of equivalents. 
 968. On information and belief, Alvotech will knowingly or
with willful blindness induce or contribute to another’s direct infringement of at least claims 1, 4, 7, 10, 13, 16, and 19 of the ’689 patent, either literally or under the doctrine of equivalents. 

969. Alvotech has knowledge of and is aware of the ’689 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

  
 170 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 171 of 323 PageID #:22568 

 

 970. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless
Alvotech is enjoined from infringing the claims of the ’689 patent. 
 971. AbbVie seeks a declaratory judgment that future commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’689 patent. 
 972. AbbVie
seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LV. 
 INFRINGEMENT
OF U.S. PATENT NO. 9,090,867 
 973. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein.

 974. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 975. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 976. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

977. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 978. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 171 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 172 of 323 PageID #:22568 

 

 979. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’867
patent is an act of infringement of one or more claims of the ’867 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

980. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1-12, 16-26, and 30 of the
’867 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-12, 16-26, and 30 of the ’867 patent. For at least one claim, however,
Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’867 patent. 

981. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’867 patent, either literally or under the doctrine of equivalents. 
 982.
Alvotech has knowledge of and is aware of the ’867 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

  
 172 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 173 of 323 PageID #:22568 

 

 983. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless
Alvotech is enjoined from infringing the claims of the ’867 patent. 
 984. AbbVie seeks an injunction pursuant to at least 35 U.S.C.
§ 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LVI. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,090,867 
 985. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 986. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 987. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 988. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 989. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

990. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 991. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 173 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 174 of 323 PageID #:22568 

 

 992. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’867
patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’867 patent, literally or under the
doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination
of infringement is necessary and appropriate to resolve this controversy. 
 993. Alvotech has provided information to AbbVie pursuant to 42
U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims
1-12, 16-26, and 30 of the ’867 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to
Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-12, 16-26, and 30 of the ’867 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that
could further support AbbVie’s allegation of infringement of the ’867 patent. 
 994. On information and belief, Alvotech is
aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’867 patent, either literally or under the doctrine of equivalents. 

  
 174 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 175 of 323 PageID #:22568 

 

 995. Alvotech has knowledge of and is aware of the ’867 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 996.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’867 patent. 

997. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech
aBLA Product will infringe the ’867 patent. 
 998. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT LVII. 

INFRINGEMENT OF U.S. PATENT NO. 9,096,666 

999. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1000. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1001. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1002. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1003. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 175 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 176 of 323 PageID #:22568 

 

 1004. On information and belief, Alvotech intends to engage in the commercial manufacture,
use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1005. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’666 patent is an act of infringement of one or more claims of the ’666 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 1006. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-7, 9-13, 15-19, 21-25, and 27-30 of the ’666
patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-7, 9-13, 15-19, 21-25, and 27-30 of the ’666 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented
AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’666 patent. 

  
 176 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 177 of 323 PageID #:22568 

 

 1007. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’666 patent, either literally or under the doctrine of equivalents. 

1008. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 1-7, 9-13, 15-19, 21-25, and
27-30 of the ’666 patent, either literally or under the doctrine of equivalents. 
 1009.
Alvotech has knowledge of and is aware of the ’666 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

1010. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’666 patent. 
 1011. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech
from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LVIII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,096,666 

1012. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1013. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1014. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 177 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 178 of 323 PageID #:22568 

 

 1015. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1016. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1017. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1018. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

1019. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’666 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’666 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 

  
 178 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 179 of 323 PageID #:22568 

 

 1020. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-7, 9-13, 15-19, 21-25, and 27-30 of the ’666 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-7,
9-13, 15-19, 21-25, and 27-30 of the ’666 patent. For at least one claim, however,
Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’666 patent. 

1021. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’666 patent, either literally or under the doctrine of equivalents. 
 1022.
On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1-7, 9-13, 15-19, 21-25, and 27-30 of the ’666 patent, either literally or under the doctrine of equivalents. 

1023. Alvotech has knowledge of and is aware of the ’666 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1024. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’666 patent. 
 1025. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’666 patent. 

  
 179 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 180 of 323 PageID #:22568 

 

 1026. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use,
sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT LIX. 

INFRINGEMENT OF U.S. PATENT NO. 9,102,723 

1027. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1028. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1029. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1030. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1031. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1032. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1033. Based on confidential information disclosed to AbbVie
by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’723 patent is an act of infringement of one or more claims of the ’723 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 180 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 181 of 323 PageID #:22568 

 

 1034. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1, 9, 11-14, 16-17, and 19-28 of the ’723 patent under at least 35 U.S.C.
§ 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C),
claim-by-claim infringement contentions for claims 1, 9, 11-14, 16-17, and 19-28 of the ’723 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could
further support AbbVie’s allegation of infringement of the ’723 patent. 
 1035. On information and belief, Alvotech is aware, has
knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’723 patent, either literally or under the doctrine of equivalents. 

1036. Alvotech has knowledge of and is aware of the ’723 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1037. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’723 patent. 

  
 181 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 182 of 323 PageID #:22568 

 

 1038. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B)
preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LX. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,102,723 
 1039. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 1040. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 1041. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1042. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1043. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1044. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1045. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 182 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 183 of 323 PageID #:22568 

 

 1046. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’723
patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’723 patent, literally or under the
doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination
of infringement is necessary and appropriate to resolve this controversy. 
 1047. Alvotech has provided information to AbbVie pursuant to
42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use,
sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or
contribute to the infringement by others of at least claims 1, 9, 11-14, 16-17, and 19-28 of the ’723 patent under at least
35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C),
claim-by-claim infringement contentions for claims 1, 9, 11-14, 16-17, and 19-28 of the ’723 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could
further support AbbVie’s allegation of infringement of the ’723 patent. 
 1048. On information and belief, Alvotech is aware, has
knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’723 patent, either literally or under the doctrine of equivalents. 

  
 183 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 184 of 323 PageID #:22568 

 

 1049. Alvotech has knowledge of and is aware of the ’723 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1050.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’723 patent. 

1051. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech
aBLA Product will infringe the ’723 patent. 
 1052. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT LXI. 

INFRINGEMENT OF U.S. PATENT NO. 9,150,645 

1053. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1054. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1055. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1056. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1057. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 184 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 185 of 323 PageID #:22568 

 

 1058. On information and belief, Alvotech intends to engage in the commercial manufacture,
use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1059. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’645 patent is an act of infringement of one or more claims of the ’645 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 1060. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-34, 36-44, 46-55 of the ’645 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of
equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-34, 36-44, 46-55 of the ’645 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information,
as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’645 patent. 

1061. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’645 patent, either literally or under the doctrine of equivalents. 

  
 185 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 186 of 323 PageID #:22568 

 

 1062. Alvotech has knowledge of and is aware of the ’645 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1063.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’645 patent. 

1064. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT LXII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,150,645 

1065. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1066. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1067. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1068. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1069. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1070. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 186 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 187 of 323 PageID #:22568 

 

 1071. On information and belief as of May 28, 2021, Alvotech intends to engage in the
commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

1072. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’645 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’645 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 
 1073. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A)
relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of
the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least
claims 1-34, 36-44, 46-55 of the ’645 patent under at least 35 U.S.C. § 271(g), either literally or under the
doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-34, 36-44, 46-55 of the ’645 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information,
as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’645 patent. 

  
 187 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 188 of 323 PageID #:22568 

 

 1074. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’645 patent, either literally or under the doctrine of equivalents. 

1075. Alvotech has knowledge of and is aware of the ’645 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1076. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’645 patent. 
 1077. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’645 patent. 

1078. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT LXIII. 

INFRINGEMENT OF U.S. PATENT NO. 9,181,337 

1079. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1080. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 188 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 189 of 323 PageID #:22568 

 

 1081. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1082. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1083. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1084. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1085. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’1337 patent is an act of infringement of one or more claims of the ’1337 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 1086. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-5, 7-10, 12-13, 15-29 of the ’1337 patent under at least 35 U.S.C.
§§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C),
claim-by-claim infringement contentions for claims 1-5, 7-10, 12-13, 15-29 of the ’1337 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented
AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’1337 patent. 

  
 189 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 190 of 323 PageID #:22568 

 

 1087. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’1337 patent, either literally or under the doctrine of equivalents. 

1088. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 1-5, 7-10, 12-13, 15-29 of the ’1337 patent, either literally or
under the doctrine of equivalents. 
 1089. Alvotech has knowledge of and is aware of the ’1337 patent, including due to AbbVie’s
disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1090. AbbVie will suffer
irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’1337 patent. 

1091. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT LXIV. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,181,337 

1092. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1093. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

  
 190 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 191 of 323 PageID #:22568 

 

 1094. On information and belief, in late August or early September 2020, Alvotech submitted
an aBLA to the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie
Inc. is the holder of BLA No. 125057. 
 1095. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1096. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1097. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1098. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

1099. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’1337 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of the ’1337 patent, literally or under the doctrine of equivalent equivalents. This
declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and
appropriate to resolve this controversy. 

  
 191 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 192 of 323 PageID #:22568 

 

 1100. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-5, 7-10, 12-13, 15-29 of the ’1337
patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-5, 7-10, 12-13, 15-29 of the ’1337 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could
further support AbbVie’s allegation of infringement of the ’1337 patent. 
 1101. On information and belief, Alvotech is aware,
has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’1337 patent, either literally or under the doctrine of equivalents. 

1102. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 1-5, 7-10, 12-13, 15-29 of the ’1337 patent, either literally or
under the doctrine of equivalents. 
 1103. Alvotech has knowledge of and is aware of the ’1337 patent, including due to AbbVie’s
disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

  
 192 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 193 of 323 PageID #:22568 

 

 1104. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless
Alvotech is enjoined from infringing the claims of the ’1337 patent. 
 1105. AbbVie seeks a declaratory judgment that future
commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’1337 patent. 

1106. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT LXV. 

INFRINGEMENT OF U.S. PATENT NO. 9,181,572 

1107. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1108. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1109. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1110. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1111. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1112. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 193 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 194 of 323 PageID #:22568 

 

 1113. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’572
patent is an act of infringement of one or more claims of the ’572 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

1114. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-10, 12-27 and 29-30 of the ’572 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of
equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-10, 12-27 and 29-30 of the ’572 patent. For at least one claim, however, Alvotech’s failure to provide sufficient
information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’572 patent. 

1115. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’572 patent, either literally or under the doctrine of equivalents. 
 1116.
Alvotech has knowledge of and is aware of the ’572 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

  
 194 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 195 of 323 PageID #:22568 

 

 1117. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless
Alvotech is enjoined from infringing the claims of the ’572 patent. 
 1118. AbbVie seeks an injunction pursuant to at least 35 U.S.C.
§ 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LXVI. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,181,572 
 1119. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 1120. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 1121. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1122. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1123. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1124. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1125. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 195 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 196 of 323 PageID #:22568 

 

 1126. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’572
patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’572 patent, literally or under the
doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination
of infringement is necessary and appropriate to resolve this controversy. 
 1127. Alvotech has provided information to AbbVie pursuant to
42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use,
sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or
contribute to the infringement by others of at least claims 1-10, 12-27 and 29-30 of the ’572 patent under at least 35
U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C),
claim-by-claim infringement contentions for claims 1-10, 12-27 and 29-30 of the ’572 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could
further support AbbVie’s allegation of infringement of the ’572 patent. 

  
 196 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 197 of 323 PageID #:22568 

 

 1128. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’572 patent, either literally or under the doctrine of equivalents. 

1129. Alvotech has knowledge of and is aware of the ’572 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1130. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’572 patent. 
 1131. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’572 patent. 

1132. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT LXVII. 

INFRINGEMENT OF U.S. PATENT NO. 9,187,559 

1133. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1134. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1135. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 

  
 197 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 198 of 323 PageID #:22568 

 

 1136. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1137. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1138. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1139. Based on confidential information disclosed to AbbVie
by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’559 patent is an act of infringement of one or more claims of the ’559 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

1140. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-30 of the ’559 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-30 of the ’559 patent. 

1141. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’559 patent, either literally or under the doctrine of equivalents. 

  
 198 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 199 of 323 PageID #:22568 

 

 1142. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-30 of the ’559 patent,
either literally or under the doctrine of equivalents. 
 1143. On information and belief, Alvotech will knowingly or with willful blindness
induce or contribute to another’s direct infringement of at least claims 1-30 of the ’559 patent, either literally or under the doctrine of equivalents. 

1144. Alvotech has knowledge of and is aware of the ’559 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1145. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’559 patent. 
 1146. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LXVIII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,187,559 

1147. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1148. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1149. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 199 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 200 of 323 PageID #:22568 

 

 1150. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1151. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1152. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1153. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

1154. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’559 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’559 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 

  
 200 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 201 of 323 PageID #:22568 

 

 1155. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-30 of the ’559 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to
Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-30 of the
’559 patent. 
 1156. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by
others of one or more claims of the ’559 patent, either literally or under the doctrine of equivalents. 
 1157. On information and
belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-30 of the ’559 patent, either literally or under the doctrine of equivalents. 
 1158. On
information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1-30 of the ’559 patent, either literally or under
the doctrine of equivalents. 
 1159. Alvotech has knowledge of and is aware of the ’559 patent, including due to AbbVie’s
disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1160. AbbVie will suffer
irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’559 patent. 

1161. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech
aBLA Product will infringe the ’559 patent. 

  
 201 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 202 of 323 PageID #:22568 

 

 1162. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use,
sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT LXIX. 

INFRINGEMENT OF U.S. PATENT NO. 9,234,032 

1163. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1164. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1165. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1166. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1167. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1168. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1169. Based on confidential information disclosed to AbbVie
by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’032 patent is an act of infringement of one or more claims of the ’032 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 202 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 203 of 323 PageID #:22568 

 

 1170. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1-3, 5,
11, 13, 15-18, and 20-23 of the ’032 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided
to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-3, 5,
11, 13, 15-18, and 20-23 of the ’032 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA,
has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’032 patent. 

1171. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’032 patent, either literally or under the doctrine of equivalents. 
 1172.
Alvotech has knowledge of and is aware of the ’032 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

1173. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’032 patent. 

  
 203 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 204 of 323 PageID #:22568 

 

 1174. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B)
preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LXX. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,234,032 
 1175. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 1176. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 1177. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1178. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1179. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1180. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1181. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 204 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 205 of 323 PageID #:22568 

 

 1182. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’032
patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’032 patent, literally or under the
doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination
of infringement is necessary and appropriate to resolve this controversy. 
 1183. Alvotech has provided information to AbbVie pursuant to
42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use,
sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims
1-3, 5, 11, 13, 15-18, and 20-23 of the ’032 patent under at least 35 U.S.C. § 271(g), either literally or under
the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-3, 5, 11, 13, 15-18, and 20-23 of the ’032 patent. For at least one claim, however, Alvotech’s failure to provide
sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’032 patent. 

1184. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’032 patent, either literally or under the doctrine of equivalents. 

  
 205 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 206 of 323 PageID #:22568 

 

 1185. Alvotech has knowledge of and is aware of the ’032 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1186.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’032 patent. 

1187. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech
aBLA Product will infringe the ’032 patent. 
 1188. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT LXXI. 

INFRINGEMENT OF U.S. PATENT NO. 9,266,949 

1189. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1190. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1191. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1192. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1193. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 206 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 207 of 323 PageID #:22568 

 

 1194. On information and belief, Alvotech intends to engage in the commercial manufacture,
use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1195. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’949 patent is an act of infringement of one or more claims of the ’949 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 1196. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-30 of the ’949 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-30 of the ’949 patent. 

1197. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’949 patent, either literally or under the doctrine of equivalents. 
 1198.
Alvotech has knowledge of and is aware of the ’949 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

  
 207 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 208 of 323 PageID #:22568 

 

 1199. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless
Alvotech is enjoined from infringing the claims of the ’949 patent. 
 1200. AbbVie seeks an injunction pursuant to at least 35 U.S.C.
§ 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LXXII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,266,949 

1201. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1202. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1203. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1204. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1205. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1206. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1207. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 208 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 209 of 323 PageID #:22568 

 

 1208. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’949
patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’949 patent, literally or under the
doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination
of infringement is necessary and appropriate to resolve this controversy. 
 1209. Alvotech has provided information to AbbVie pursuant to
42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use,
sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or
contribute to the infringement by others of at least claims 1-30 of the ’949 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided
to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-30 of
the ’949 patent. 
 1210. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the
manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’949 patent, either literally or under the doctrine of equivalents. 

  
 209 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 210 of 323 PageID #:22568 

 

 1211. Alvotech has knowledge of and is aware of the ’949 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1212.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’949 patent. 

1213. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech
aBLA Product will infringe the ’949 patent. 
 1214. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT LXXIII. 

INFRINGEMENT OF U.S. PATENT NO. 9,273,132 

1215. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1216. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1217. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1218. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1219. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 210 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 211 of 323 PageID #:22568 

 

 1220. On information and belief, Alvotech intends to engage in the commercial manufacture,
use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1221. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’132 patent is an act of infringement of one or more claims of the ’132 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 1222. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-7, 10-13, and 16-25 of the ’132 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the
doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-7, 10-13, and 16-25 of the ’132 patent. For at least one claim, however, Alvotech’s failure to provide sufficient
information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’132 patent. 

1223. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’132 patent, either literally or under the doctrine of equivalents. 

  
 211 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 212 of 323 PageID #:22568 

 

 1224. On information and belief, Alvotech will knowingly or with willful blindness induce or
contribute to another’s direct infringement of at least claims 1-7, 10-13, and 16-25 of the ’132 patent, either
literally or under the doctrine of equivalents. 
 1225. Alvotech has knowledge of and is aware of the ’132 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1226.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’132 patent. 

1227. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT LXXIV. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,273,132 

1228. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1229. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1230. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1231. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 

  
 212 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 213 of 323 PageID #:22568 

 

 1232. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1233. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1234. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1235. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’132 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’132 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 
 1236.
Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential
information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will
infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-7, 10-13, and
16-25 of the ’132 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-7,
10-13, and 16-25 of the ’132 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has
prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’132 patent. 

  
 213 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 214 of 323 PageID #:22568 

 

 1237. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’132 patent, either literally or under the doctrine of equivalents. 

1238. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 1-7, 10-13, and 16-25 of the ’132 patent, either literally or under the doctrine of equivalents. 

1239. Alvotech has knowledge of and is aware of the ’132 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1240. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’132 patent. 
 1241. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’132 patent. 

1242. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT LXXV. 

INFRINGEMENT OF U.S. PATENT NO. 9,284,370 

1243. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

  
 214 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 215 of 323 PageID #:22568 

 

 1244. On information and belief, in late August or early September 2020, Alvotech submitted
an aBLA to the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie
Inc. is the holder of BLA No. 125057. 
 1245. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1246. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1247. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1248. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1249. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’370 patent is an act of infringement of one or more claims of the ’370 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 1250. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the 

  
 215 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 216 of 323 PageID #:22568 

 

 
FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-5, 7, 9-12, 14, 16-21, 23, 25-26, 28-32, 34, and 36-37 of the
’370 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C),
claim-by-claim infringement contentions for claims 1-5, 7, 9-12, 14, 16-21, 23, 25-26, 28-32, 34, and 36-37 of the ’370 patent. 

1251. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’370 patent, either literally or under the doctrine of equivalents. 
 1252. On information and belief, Alvotech is
aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-5, 7, 9-12, 14, 16-21, 23, 25-26, 28-32, 34, and 36-37 of the ’370 patent, either literally or under the doctrine of equivalents. 
 1253. On
information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1-5, 7, 9-12, 14,
16-21, 23, 25-26, 28-32, 34, and 36-37 of the ’370 patent, either literally or under
the doctrine of equivalents. 
 1254. Alvotech has knowledge of and is aware of the ’370 patent, including due to AbbVie’s
disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1255. AbbVie will suffer
irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’370 patent. 

  
 216 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 217 of 323 PageID #:22568 

 

 1256. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B)
preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LXXVI. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,284,370 

1257. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1258. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1259. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1260. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1261. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1262. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1263. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 217 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 218 of 323 PageID #:22568 

 

 1264. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’370
patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’370 patent, literally or under the
doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination
of infringement is necessary and appropriate to resolve this controversy. 
 1265. Alvotech has provided information to AbbVie pursuant to
42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use,
sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or
contribute to the infringement by others of at least claims 1-5, 7, 9-12, 14, 16-21, 23,
25-26, 28-32, 34, and 36-37 of the ’370 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally
or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for
claims 1-5, 7, 9-12, 14, 16-21, 23, 25-26, 28-32,
34, and 36-37 of the ’370 patent. 
 1266. On information and belief, Alvotech has an
affirmative intent to actively induce or contribute to infringement by others of one or more claims of the ’370 patent, either literally or under the doctrine of equivalents. 

  
 218 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 219 of 323 PageID #:22568 

 

 1267. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-5, 7, 9-12, 14, 16-21, 23, 25-26, 28-32, 34, and 36-37 of the
’370 patent, either literally or under the doctrine of equivalents. 
 1268. On information and belief, Alvotech will knowingly or with
willful blindness induce or contribute to another’s direct infringement of at least claims 1-5, 7, 9-12, 14, 16-21, 23, 25-26, 28-32, 34, and 36-37 of the ’370 patent, either literally or under the doctrine of equivalents. 

1269. Alvotech has knowledge of and is aware of the ’370 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1270. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’370 patent. 
 1271. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’370 patent. 

1272. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT LXXVII. 

INFRINGEMENT OF U.S. PATENT NO. 9,284,371 

1273. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1274. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 219 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 220 of 323 PageID #:22568 

 

 1275. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1276. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1277. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1278. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1279. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’371 patent is an act of infringement of one or more claims of the ’371 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 1280. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1, 2, 5, 8-16, 21, 22, 26, 27, and 29 of the ’371
patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1, 2, 5, 8-16, 21, 22, 26, 27, and 29 of the ’371 patent. For at least one claim, however, Alvotech’s
failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’371 patent. 

  
 220 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 221 of 323 PageID #:22568 

 

 1281. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’371 patent, either literally or under the doctrine of equivalents. 

1282. Alvotech has knowledge of and is aware of the ’371 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1283. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’371 patent. 
 1284. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LXXVIII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,284,371 

1285. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1286. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1287. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 221 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 222 of 323 PageID #:22568 

 

 1288. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1289. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1290. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1291. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

1292. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’371 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’371 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 

  
 222 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 223 of 323 PageID #:22568 

 

 1293. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1, 2, 5,
8-16, 21, 22, 26, 27, and 29 of the ’371 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1, 2, 5, 8-16, 21, 22, 26, 27, and 29 of the
’371 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of
infringement of the ’371 patent. 
 1294. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the
fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’371 patent, either literally or under the doctrine of equivalents. 

1295. Alvotech has knowledge of and is aware of the ’371 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1296. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’371 patent. 
 1297. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’371 patent. 

1298. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 

  
 223 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 224 of 323 PageID #:22568 

 

 COUNT LXXIX. 

INFRINGEMENT OF U.S. PATENT NO. 9,290,568 

1299. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1300. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1301. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1302. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1303. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1304. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1305. Based on confidential information disclosed to AbbVie
by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’568 patent is an act of infringement of one or more claims of the ’568 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 224 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 225 of 323 PageID #:22568 

 

 1306. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1-8 and 21-28 of the ’568 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-8 and
21-28 of the ’568 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could
further support AbbVie’s allegation of infringement of the ’568 patent. 
 1307. On information and belief, Alvotech is aware, has
knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’568 patent, either literally or under the doctrine of equivalents. 

1308. Alvotech has knowledge of and is aware of the ’568 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1309. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’568 patent. 
 1310. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LXXX. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,290,568 
 1311. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 

  
 225 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 226 of 323 PageID #:22568 

 

 1312. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C.
§§ 2201 and 2202. 
 1313. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to
the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the
holder of BLA No. 125057. 
 1314. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for
review on or before November 5, 2020. 
 1315. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1316. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1317. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1318. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’568 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’568 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 

  
 226 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 227 of 323 PageID #:22568 

 

 1319. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1-8 and 21-28 of the ’568 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-8 and
21-28 of the ’568 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could
further support AbbVie’s allegation of infringement of the ’568 patent. 
 1320. On information and belief, Alvotech is aware, has
knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’568 patent, either literally or under the doctrine of equivalents. 

1321. Alvotech has knowledge of and is aware of the ’568 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1322. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’568 patent. 
 1323. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’568 patent. 

  
 227 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 228 of 323 PageID #:22568 

 

 1324. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use,
sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT LXXXI. 

INFRINGEMENT OF U.S. PATENT NO. 9,315,574 

1325. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1326. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1327. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1328. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1329. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1330. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1331. Based on confidential information disclosed to AbbVie
by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’574 patent is an act of infringement of one or more claims of the ’574 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 228 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 229 of 323 PageID #:22568 

 

 1332. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-3, 5, and 19-25 of the ’574 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine
of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-3, 5, and 19-25 of the ’574 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented
AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’574 patent. 
 1333. On
information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’574 patent, either literally or under the doctrine
of equivalents. 
 1334. Alvotech has knowledge of and is aware of the ’574 patent, including due to AbbVie’s disclosure of
patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1335. AbbVie will suffer irreparable
injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’574 patent. 

  
 229 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 230 of 323 PageID #:22568 

 

 1336. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B)
preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LXXXII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,315,574 

1337. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1338. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1339. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1340. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1341. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1342. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1343. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 230 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 231 of 323 PageID #:22568 

 

 1344. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’574
patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’574 patent, literally or under the
doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination
of infringement is necessary and appropriate to resolve this controversy. 
 1345. Alvotech has provided information to AbbVie pursuant to
42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use,
sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or
contribute to the infringement by others of at least claims 1-3, 5, and 19-25 of the ’574 patent under at least 35 U.S.C. § 271(g), either literally or
under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for
claims 1-3, 5, and 19-25 of the ’574 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA,
has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’574 patent. 

1346. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’574 patent, either literally or under the doctrine of equivalents. 

  
 231 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 232 of 323 PageID #:22568 

 

 1347. Alvotech has knowledge of and is aware of the ’574 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1348.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’574 patent. 

1349. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech
aBLA Product will infringe the ’574 patent. 
 1350. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT LXXXIII. 

INFRINGEMENT OF U.S. PATENT NO. 9,328,165 

1351. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1352. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1353. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1354. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1355. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 232 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 233 of 323 PageID #:22568 

 

 1356. On information and belief, Alvotech intends to engage in the commercial manufacture,
use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1357. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’165 patent is an act of infringement of one or more claims of the ’165 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 1358. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1, 2, 9,
15, and 21 of the ’165 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1, 2, 9, 15, and 21 of the ’165 patent. For at least one claim, however, Alvotech’s failure to provide sufficient
information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’165 patent. 

1359. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’165 patent, either literally or under the doctrine of equivalents. 

  
 233 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 234 of 323 PageID #:22568 

 

 1360. On information and belief, Alvotech will knowingly or with willful blindness induce or
contribute to another’s direct infringement of at least claims 1, 2, 9, 15, and 21 of the ’165 patent, either literally or under the doctrine of equivalents. 

1361. Alvotech has knowledge of and is aware of the ’165 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1362. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’165 patent. 
 1363. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LXXXIV. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,328,165 

1364. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1365. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1366. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1367. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 

  
 234 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 235 of 323 PageID #:22568 

 

 1368. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1369. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1370. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1371. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’165 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’165 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 
 1372.
Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential
information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will
infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1, 2, 9, 15, and 21 of the ’165 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the
doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1, 2,
9, 15, and 21 of the ’165 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s
allegation of infringement of the ’165 patent. 

  
 235 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 236 of 323 PageID #:22568 

 

 1373. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’165 patent, either literally or under the doctrine of equivalents. 

1374. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 1, 2, 9, 15, and 21 of the ’165 patent, either literally or under the doctrine of equivalents. 
 1375. Alvotech has
knowledge of and is aware of the ’165 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

1376. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’165 patent. 
 1377. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or
importation of the Alvotech aBLA Product will infringe the ’165 patent. 
 1378. AbbVie seeks an injunction preventing Alvotech from
the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LXXXV. 

INFRINGEMENT OF U.S. PATENT NO. 9,334,319 

1379. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

  
 236 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 237 of 323 PageID #:22568 

 

 1380. On information and belief, in late August or early September 2020, Alvotech submitted
an aBLA to the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie
Inc. is the holder of BLA No. 125057. 
 1381. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1382. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1383. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1384. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1385. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’319 patent is an act of infringement of one or more claims of the ’319 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 1386. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the 

  
 237 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 238 of 323 PageID #:22568 

 

 
FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 3-14, 17, 19, 26-37, 40, and 42 of the ’319 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 3-14, 17, 19,
26-37, 40, and 42 of the ’319 patent. 
 1387. On information and belief, Alvotech is aware,
has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’319 patent, either literally or under the doctrine of equivalents. 

1388. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 3-14, 17, 19, 26-37, 40, and 42 of the ’319 patent, either literally or under the doctrine of equivalents. 

1389. Alvotech has knowledge of and is aware of the ’319 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1390. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’319 patent. 
 1391. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LXXXVI. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,334,319 

1392. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

  
 238 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 239 of 323 PageID #:22568 

 

 1393. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C.
§§ 2201 and 2202. 
 1394. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to
the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the
holder of BLA No. 125057. 
 1395. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for
review on or before November 5, 2020. 
 1396. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1397. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1398. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1399. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’319 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’319 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 

  
 239 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 240 of 323 PageID #:22568 

 

 1400. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 3-14, 17, 19, 26-37, 40, and 42 of the ’319 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally
or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for
claims 3-14, 17, 19, 26-37, 40, and 42 of the ’319 patent. 

1401. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’319 patent, either literally or under the doctrine of equivalents. 
 1402.
On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 3-14, 17, 19,
26-37, 40, and 42 of the ’319 patent, either literally or under the doctrine of equivalents. 

1403. Alvotech has knowledge of and is aware of the ’319 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1404. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’319 patent. 

  
 240 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 241 of 323 PageID #:22568 

 

 1405. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’319 patent. 
 1406. AbbVie seeks an injunction
preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LXXXVII. 

INFRINGEMENT OF U.S. PATENT NO. 9,339,610 

1407. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1408. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1409. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1410. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1411. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1412. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 241 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 242 of 323 PageID #:22568 

 

 1413. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’610
patent is an act of infringement of one or more claims of the ’610 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

1414. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1, 5-13, 15, 18, 19, 21, and 22 of the ’610 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42
U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1, 5-13, 15, 18, 19, 21, and 22 of the
’610 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of
infringement of the ’610 patent. 
 1415. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’610 patent, either literally or under the doctrine of equivalents. 

1416. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product (including the delivery device) directly infringes at least one claim of the ’610 patent, either literally or under the doctrine of equivalents. 

  
 242 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 243 of 323 PageID #:22568 

 

 1417. On information and belief, Alvotech will knowingly or with willful blindness induce or
contribute to another’s direct infringement of at least claims 1, 5-13, 15, 18, 19, 21, and 22 of the ’610 patent, either literally or under the doctrine of equivalents. 

1418. Alvotech has knowledge of and is aware of the ’610 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1419. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’610 patent. 
 1420. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT LXXXVIII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,339,610 

1421. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1422. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1423. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1424. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 

  
 243 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 244 of 323 PageID #:22568 

 

 1425. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1426. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1427. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1428. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’610 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’610 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 
 1429.
Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential
information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will
infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1, 5-13, 15, 18, 19, 21, and 22 of the ’610 patent under at least 35 U.S.C.
§§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C),
claim-by-claim infringement contentions for claims 1, 5-13, 15, 18, 19, 21, and 22 of the ’610 patent. For at least one
claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’610 patent. 

  
 244 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 245 of 323 PageID #:22568 

 

 1430. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’610 patent, either literally or under the doctrine of equivalents. 

1431. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product (including the delivery device) directly infringes at least one claim of the ’610 patent, either literally or under the doctrine of equivalents. 

1432. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 1, 5-13, 15, 18, 19, 21, and 22 of the ’610 patent, either literally or under the doctrine of equivalents. 

1433. Alvotech has knowledge of and is aware of the ’610 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1434. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’610 patent. 
 1435. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’610 patent. 

  
 245 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 246 of 323 PageID #:22568 

 

 1436. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use,
sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT LXXXIX 

INFRINGEMENT OF U.S. PATENT NO. 9,346,879 

1437. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1438. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1439. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1440. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1441. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1442. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1443. Based on confidential information disclosed to AbbVie
by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’879 patent is an act of infringement of one or more claims of the ’879 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 246 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 247 of 323 PageID #:22568 

 

 1444. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-3, 5, 14-15, and 19-22 of the ’879 patent under at least 35 U.S.C.
§ 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C),
claim-by-claim infringement contentions for claims 1-3, 5, 14-15, and 19-22 of the ’879 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could
further support AbbVie’s allegation of infringement of the ’879 patent. 
 1445. On information and belief, Alvotech is aware, has
knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’879 patent, either literally or under the doctrine of equivalents. 

1446. Alvotech has knowledge of and is aware of the ’879 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1447. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’879 patent. 

  
 247 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 248 of 323 PageID #:22568 

 

 1448. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B)
preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XC. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,346,879 
 1449. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 1450. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 1451. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1452. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1453. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1454. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1455. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 248 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 249 of 323 PageID #:22568 

 

 1456. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’879
patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’879 patent, literally or under the
doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination
of infringement is necessary and appropriate to resolve this controversy. 
 1457. Alvotech has provided information to AbbVie pursuant to
42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use,
sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or
contribute to the infringement by others of at least claims 1-3, 5, 14-15, and 19-22 of the ’879 patent under at least 35
U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C),
claim-by-claim infringement contentions for claims 1-3, 5, 14-15, and 19-22 of the ’879 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could
further support AbbVie’s allegation of infringement of the ’879 patent. 
 1458. On information and belief, Alvotech is aware, has
knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’879 patent, either literally or under the doctrine of equivalents. 

  
 249 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 250 of 323 PageID #:22568 

 

 1459. Alvotech has knowledge of and is aware of the ’879 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1460.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’879 patent. 

1461. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech
aBLA Product will infringe the ’879 patent. 
 1462. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XCI. 

INFRINGEMENT OF U.S. PATENT NO. 9,359,434 

1463. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1464. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1465. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1466. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1467. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 250 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 251 of 323 PageID #:22568 

 

 1468. On information and belief, Alvotech intends to engage in the commercial manufacture,
use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1469. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’434 patent is an act of infringement of one or more claims of the ’434 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 1470. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-30 of the ’434 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-30 of the ’434 patent. For at least
one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’434 patent.

 1471. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the
Alvotech aBLA Product directly infringes at least one claim of the ’434 patent, either literally or under the doctrine of equivalents. 

  
 251 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 252 of 323 PageID #:22568 

 

 1472. Alvotech has knowledge of and is aware of the ’434 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1473.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’434 patent. 

1474. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XCII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,359,434 

1475. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1476. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1477. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1478. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1479. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1480. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 252 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 253 of 323 PageID #:22568 

 

 1481. On information and belief as of May 28, 2021, Alvotech intends to engage in the
commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

1482. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’434 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’434 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 
 1483. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A)
relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of
the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least
claims 1-30 of the ’434 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-30 of the ’434 patent. For at least
one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’434 patent.

  
 253 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 254 of 323 PageID #:22568 

 

 1484. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’434 patent, either literally or under the doctrine of equivalents. 

1485. Alvotech has knowledge of and is aware of the ’434 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1486. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’434 patent. 
 1487. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’434 patent. 

1488. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT XCIII. 

INFRINGEMENT OF U.S. PATENT NO. 9,499,614 

1489. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1490. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 254 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 255 of 323 PageID #:22568 

 

 1491. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1492. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1493. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1494. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1495. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’614 patent is an act of infringement of one or more claims of the ’614 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 1496. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1-4 and 10-22 of
the ’614 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-4 and 10-22 of the ’614 patent. For at least one claim, however,
Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’614 patent. 

  
 255 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 256 of 323 PageID #:22568 

 

 1497. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’614 patent, either literally or under the doctrine of equivalents. 

1498. Alvotech has knowledge of and is aware of the ’614 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1499. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’614 patent. 
 1500. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XCIV. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,499,614 
 1501. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 1502. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 1503. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 256 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 257 of 323 PageID #:22568 

 

 1504. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1505. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1506. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1507. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

1508. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’614 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’614 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 
 1509. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A)
relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of
the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1-4 and
10-22 of the ’614 patent under at least 35 U.S.C. 

  
 257 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 258 of 323 PageID #:22568 

 

 
§ 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C),
claim-by-claim infringement contentions for claims 1-4 and 10-22 of the ’614 patent.
For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the
’614 patent. 
 1510. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the
manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’614 patent, either literally or under the doctrine of equivalents. 

1511. Alvotech has knowledge of and is aware of the ’614 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1512. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’614 patent. 
 1513. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’614 patent. 

1514. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT XCV. 

INFRINGEMENT OF U.S. PATENT NO. 9,499,616 

1515. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1516. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 258 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 259 of 323 PageID #:22568 

 

 1517. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1518. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1519. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1520. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1521. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’616 patent is an act of infringement of one or more claims of the ’616 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 1522. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-16, 18-27, and 29-30 of the ’616 patent under at least 35 U.S.C. § 271(g),

  
 259 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 260 of 323 PageID #:22568 

 

 
either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-16, 18-27, and 29-30 of the
’616 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of
infringement of the ’616 patent. 
 1523. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the
fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’616 patent, either literally or under the doctrine of equivalents. 

1524. Alvotech has knowledge of and is aware of the ’616 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1525. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’616 patent. 
 1526. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XCVI. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,499,616 
 1527. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 1528. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

  
 260 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 261 of 323 PageID #:22568 

 

 1529. On information and belief, in late August or early September 2020, Alvotech submitted
an aBLA to the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie
Inc. is the holder of BLA No. 125057. 
 1530. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1531. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1532. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1533. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

1534. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’616 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’616 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 

  
 261 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 262 of 323 PageID #:22568 

 

 1535. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-16, 18-27, and 29-30 of the ’616 patent under at least 35 U.S.C.
§ 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C),
claim-by-claim infringement contentions for claims 1-16, 18-27, and 29-30 of the ’616 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could
further support AbbVie’s allegation of infringement of the ’616 patent. 
 1536. On information and belief, Alvotech is aware, has
knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’616 patent, either literally or under the doctrine of equivalents. 

1537. Alvotech has knowledge of and is aware of the ’616 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1538. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’616 patent. 
 1539. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’616 patent. 

1540. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 

  
 262 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 263 of 323 PageID #:22568 

 

 COUNT XCVII. 

INFRINGEMENT OF U.S. PATENT NO. 9,505,834 

1541. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1542. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1543. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1544. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1545. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1546. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1547. Based on confidential information disclosed to AbbVie
by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’834 patent is an act of infringement of one or more claims of the ’834 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 263 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 264 of 323 PageID #:22568 

 

 1548. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1-30 of
the ’834 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-30 of the ’834 patent. For at least one claim, however, Alvotech’s failure to provide sufficient
information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’834 patent. 

1549. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’834 patent, either literally or under the doctrine of equivalents. 
 1550.
Alvotech has knowledge of and is aware of the ’834 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

1551. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’834 patent. 
 1552. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech
from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT XCVIII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,505,834 

1553. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

  
 264 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 265 of 323 PageID #:22568 

 

 1554. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C.
§§ 2201 and 2202. 
 1555. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to
the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the
holder of BLA No. 125057. 
 1556. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for
review on or before November 5, 2020. 
 1557. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1558. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1559. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1560. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’834 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’834 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 

  
 265 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 266 of 323 PageID #:22568 

 

 1561. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1-30 of
the ’834 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-30 of the ’834 patent. For at least one claim, however, Alvotech’s failure to provide sufficient
information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’834 patent. 

1562. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’834 patent, either literally or under the doctrine of equivalents. 
 1563.
Alvotech has knowledge of and is aware of the ’834 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

1564. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’834 patent. 
 1565. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or
importation of the Alvotech aBLA Product will infringe the ’834 patent. 

  
 266 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 267 of 323 PageID #:22568 

 

 1566. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use,
sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT XCIX. 

INFRINGEMENT OF U.S. PATENT NO. 9,512,216 

1567. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1568. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1569. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1570. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1571. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1572. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1573. Based on confidential information disclosed to AbbVie
by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’216 patent is an act of infringement of one or more claims of the ’216 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 267 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 268 of 323 PageID #:22568 

 

 1574. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-3, 6, 9-11, and 14 of the ’216 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or
under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for
claims 1-3, 6, 9-11, and 14 of the ’216 patent. 

1575. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’216 patent, either literally or under the doctrine of equivalents. 
 1576. On information and belief, Alvotech is
aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-3, 6, 9-11, and 14 of the ’216 patent, either literally or under the doctrine of equivalents. 

1577. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 1-3, 6, 9-11, and 14 of the ’216 patent, either literally or under the doctrine of equivalents. 

  
 268 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 269 of 323 PageID #:22568 

 

 1578. Alvotech has knowledge of and is aware of the ’216 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1579.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’216 patent. 

1580. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT C. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,512,216 

1581. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1582. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1583. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1584. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1585. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1586. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 269 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 270 of 323 PageID #:22568 

 

 1587. On information and belief as of May 28, 2021, Alvotech intends to engage in the
commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

1588. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’216 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’216 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 
 1589. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A)
relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of
the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least
claims 1-3, 6, 9-11, and 14 of the ’216 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents.
AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims
1-3, 6, 9-11, and 14 of the ’216 patent. 

  
 270 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 271 of 323 PageID #:22568 

 

 1590. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’216 patent, either literally or under the doctrine of equivalents. 

1591. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or
use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-3, 6, 9-11, and 14 of the ’216
patent, either literally or under the doctrine of equivalents. 
 1592. On information and belief, Alvotech will knowingly or with willful
blindness induce or contribute to another’s direct infringement of at least claims 1-3, 6, 9-11, and 14 of the ’216 patent, either literally or under the
doctrine of equivalents. 
 1593. Alvotech has knowledge of and is aware of the ’216 patent, including due to AbbVie’s disclosure
of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1594. AbbVie will suffer
irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’216 patent. 

1595. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech
aBLA Product will infringe the ’216 patent. 
 1596. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT CI. 

INFRINGEMENT OF U.S. PATENT NO. 9,522,953 

1597. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

  
 271 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 272 of 323 PageID #:22568 

 

 1598. On information and belief, in late August or early September 2020, Alvotech submitted
an aBLA to the FDA seeking approval for the commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie
Inc. is the holder of BLA No. 125057. 
 1599. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1600. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1601. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1602. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1603. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’953 patent is an act of infringement of one or more claims of the ’953 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 1604. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the 

  
 272 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 273 of 323 PageID #:22568 

 

 
FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 6, 8, 26, and 28-30 of the
’953 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 6, 8, 26, and 28-30 of the ’953 patent. 

1605. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’953 patent, either literally or under the doctrine of equivalents. 
 1606. On information and belief, Alvotech is
aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’953 patent, either literally or under the doctrine of equivalents. 

1607. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 6, 8, 26, and 28-30 of the ’953 patent, either literally or under the doctrine of equivalents. 

1608. Alvotech has knowledge of and is aware of the ’953 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1609. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’953 patent. 
 1610. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

  
 273 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 274 of 323 PageID #:22568 

 

 COUNT CII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,522,953 

1611. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1612. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1613. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1614. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1615. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1616. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1617. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1618. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’953 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’953 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 

  
 274 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 275 of 323 PageID #:22568 

 

 1619. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 6, 8, 26, and 28-30 of the ’953 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has
provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 6, 8, 26, and 28-30 of the ’953 patent. 
 1620. On information and belief, Alvotech has an affirmative intent to
actively induce or contribute to infringement by others of one or more claims of the ’953 patent, either literally or under the doctrine of equivalents. 

1621. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’953 patent, either literally or under the doctrine of equivalents. 
 1622.
On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 6, 8, 26, and 28-30 of the ’953 patent, either
literally or under the doctrine of equivalents. 

  
 275 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 276 of 323 PageID #:22568 

 

 1623. Alvotech has knowledge of and is aware of the ’953 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1624.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’953 patent. 

1625. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech
aBLA Product will infringe the ’953 patent. 
 1626. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT CIII. 

INFRINGEMENT OF U.S. PATENT NO. 9,546,212 

1627. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1628. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1629. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1630. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1631. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

  
 276 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 277 of 323 PageID #:22568 

 

 1632. On information and belief, Alvotech intends to engage in the commercial manufacture,
use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1633. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’212 patent is an act of infringement of one or more claims of the ’212 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 1634. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-24 of the ’212 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-24 of the ’212 patent. 

1635. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’212 patent, either literally or under the doctrine of equivalents. 

  
 277 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 278 of 323 PageID #:22568 

 

 1636. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-24 of the ’212 patent,
either literally or under the doctrine of equivalents. 
 1637. On information and belief, Alvotech will knowingly or with willful blindness
induce or contribute to another’s direct infringement of at least claims 1-24 of the ’212 patent, either literally or under the doctrine of equivalents. 

1638. Alvotech has knowledge of and is aware of the ’212 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1639. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’212 patent. 
 1640. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT CIV. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,546,212 
 1641. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 1642. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 1643. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 278 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 279 of 323 PageID #:22568 

 

 1644. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1645. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1646. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1647. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

1648. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’212 patent and Alvotech’s notice of commercial
marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’212 patent, literally or under the doctrine of equivalent equivalents. This declaratory
judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to
resolve this controversy. 
 1649. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A)
relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of
the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least
claims 1-24 of the ’212 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-24 of the ’212 patent. 

  
 279 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 280 of 323 PageID #:22568 

 

 1650. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’212 patent, either literally or under the doctrine of equivalents. 

1651. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or
use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-24 of the ’212 patent, either literally or under the doctrine of
equivalents. 
 1652. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s
direct infringement of at least claims 1-24 of the ’212 patent, either literally or under the doctrine of equivalents. 

1653. Alvotech has knowledge of and is aware of the ’212 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1654. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’212 patent. 
 1655. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’212 patent. 

1656. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 

  
 280 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 281 of 323 PageID #:22568 

 

 COUNT CV. 

INFRINGEMENT OF U.S. PATENT NO. 9,550,826 

1657. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1658. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1659. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1660. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1661. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1662. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1663. Based on confidential information disclosed to AbbVie
by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’826 patent is an act of infringement of one or more claims of the ’826 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 281 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 282 of 323 PageID #:22568 

 

 1664. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1-9, 11,
14, 16-19, 21, 24, and 26-30 of the ’826 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie
has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims
1-9, 11, 14, 16-19, 21, 24, and 26-30 of the ’826 patent. 

1665. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’826 patent, either literally or under the doctrine of equivalents. 
 1666.
On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1-9, 11, 14,
16-19, 21, 24, and 26-30 of the ’826 patent, either literally or under the doctrine of equivalents. 

1667. Alvotech has knowledge of and is aware of the ’826 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1668. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’826 patent. 
 1669. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

  
 282 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 283 of 323 PageID #:22568 

 

 COUNT CVI. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,550,826 

1670. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1671. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1672. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1673. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1674. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1675. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1676. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1677. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’826 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’826 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 

  
 283 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 284 of 323 PageID #:22568 

 

 1678. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe at least claims 1-9, 11,
14, 16-19, 21, 24, and 26-30 of the ’826 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie
has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims
1-9, 11, 14, 16-19, 21, 24, and 26-30 of the ’826 patent. 

1679. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’826 patent, either literally or under the doctrine of equivalents. 
 1680.
On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 1-9, 11, 14,
16-19, 21, 24, and 26-30 of the ’826 patent, either literally or under the doctrine of equivalents. 

1681. Alvotech has knowledge of and is aware of the ’826 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

  
 284 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 285 of 323 PageID #:22568 

 

 1682. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless
Alvotech is enjoined from infringing the claims of the ’826 patent. 
 1683. AbbVie seeks a declaratory judgment that future commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’826 patent. 
 1684. AbbVie
seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT CVII. 

INFRINGEMENT OF U.S. PATENT NO. 9,624,295 

1685. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1686. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1687. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1688. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1689. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1690. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 285 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 286 of 323 PageID #:22568 

 

 1691. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’295
patent is an act of infringement of one or more claims of the ’295 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

1692. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-6 of the ’295 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-6 of the ’295 patent. 

1693. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’295 patent, either literally or under the doctrine of equivalents. 
 1694. On information and belief, Alvotech is
aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-6 of the ’295 patent, either literally or under the doctrine of equivalents. 

  
 286 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 287 of 323 PageID #:22568 

 

 1695. On information and belief, Alvotech will knowingly or with willful blindness induce or
contribute to another’s direct infringement of at least claims 1-6 of the ’295 patent, either literally or under the doctrine of equivalents. 

1696. Alvotech has knowledge of and is aware of the ’295 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1697. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’295 patent. 
 1698. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT CVIII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,624,295 

1699. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1700. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1701. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1702. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 

  
 287 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 288 of 323 PageID #:22568 

 

 1703. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1704. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1705. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1706. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’295 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’295 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 
 1707.
Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential
information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will
infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-6 of the ’295 patent under at least 35 U.S.C. §§ 271(b) and (c), either
literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement
contentions for claims 1-6 of the ’295 patent. 

  
 288 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 289 of 323 PageID #:22568 

 

 1708. On information and belief, Alvotech has an affirmative intent to actively induce or
contribute to infringement by others of one or more claims of the ’295 patent, either literally or under the doctrine of equivalents. 

1709. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or
use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-6 of the ’295 patent, either literally or under the doctrine of equivalents.

 1710. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct
infringement of at least claims 1-6 of the ’295 patent, either literally or under the doctrine of equivalents. 

1711. Alvotech has knowledge of and is aware of the ’295 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1712. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’295 patent. 
 1713. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’295 patent. 

1714. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 

  
 289 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 290 of 323 PageID #:22568 

 

 COUNT CIX. 

INFRINGEMENT OF U.S. PATENT NO. 9,669,093 

1715. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1716. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1717. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1718. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1719. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1720. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1721. Based on confidential information disclosed to AbbVie
by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’093 patent is an act of infringement of one or more claims of the ’093 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 290 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 291 of 323 PageID #:22568 

 

 1722. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-5, 7, 9-12, 14, 16-21, 23, 25-27, 29, and 31
of the ’093 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-5, 7, 9-12, 14, 16-21, 23, 25-27, 29, and 31 of the ’093 patent. 
 1723. On
information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more claims of the ’093 patent, either literally or under the doctrine of equivalents. 

1724. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that patients will administer and/or
use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-5, 7, 9-12, 14, 16-21, 23, 25-27, 29, and 31 of the ’093 patent, either literally or under the doctrine of equivalents. 

1725. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 1-5, 7, 9-12, 14, 16-21, 23, 25-27, 29, and 31 of the ’093
patent, either literally or under the doctrine of equivalents. 
 1726. Alvotech has knowledge of and is aware of the ’093 patent,
including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

1727. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’093 patent. 

  
 291 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 292 of 323 PageID #:22568 

 

 1728. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B)
preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT CX. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,669,093 
 1729. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 1730. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 1731. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1732. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1733. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1734. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1735. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 292 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 293 of 323 PageID #:22568 

 

 1736. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’093
patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’093 patent, literally or under the
doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination
of infringement is necessary and appropriate to resolve this controversy. 
 1737. Alvotech has provided information to AbbVie pursuant to
42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use,
sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or
contribute to the infringement by others of at least claims 1-5, 7, 9-12, 14, 16-21, 23,
25-27, 29, and 31 of the ’093 patent under at least 35 U.S.C. §§ 271(b) and (c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42
U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-5, 7,
9-12, 14, 16-21, 23, 25-27, 29, and 31 of the ’093 patent. 

1738. On information and belief, Alvotech has an affirmative intent to actively induce or contribute to infringement by others of one or more
claims of the ’093 patent, either literally or under the doctrine of equivalents. 
  

  
 293 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 294 of 323 PageID #:22568 

 

 1739. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that patients will administer and/or use and medical practitioners will prescribe and/or administer the Alvotech aBLA Product to directly infringe at least claims 1-5, 7, 9-12, 14, 16-21, 23, 25-27, 29, and 31 of the ’093 patent, either literally or under the doctrine of equivalents. 

1740. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 1-5, 7, 9-12, 14, 16-21, 23, 25-27, 29, and 31 of the ’093
patent, either literally or under the doctrine of equivalents. 
 1741. Alvotech has knowledge of and is aware of the ’093 patent,
including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

1742. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’093 patent. 
 1743. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or
importation of the Alvotech aBLA Product will infringe the ’093 patent. 
 1744. AbbVie seeks an injunction preventing Alvotech from
the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT CXI. 
 INFRINGEMENT
OF U.S. PATENT NO. 9,683,033 
 1745. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein.

 1746. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 294 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 295 of 323 PageID #:22568 

 

 1747. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1748. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1749. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1750. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1751. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’033 patent is an act of infringement of one or more claims of the ’033 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 1752. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 5 and 22 of
the ’033 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C),
claim-by-claim infringement contentions for claims 5 and 22 of the ’033 patent. 

  
 295 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 296 of 323 PageID #:22568 

 

 1753. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’033 patent, either literally or under the doctrine of equivalents. 

1754. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 5 and 22 of the ’033 patent, either literally or under the doctrine of equivalents. 
 1755. Alvotech has knowledge
of and is aware of the ’033 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

1756. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’033 patent. 
 1757. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech
from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT CXII. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,683,033 
 1758. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 1759. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 1760. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. 

  
 296 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 297 of 323 PageID #:22568 

 

 
The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057. 

1761. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before November 5,
2020. 
 1762. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1763. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1764. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1765. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’033 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’033 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 

  
 297 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 298 of 323 PageID #:22568 

 

 1766. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 5 and 22 of the ’033 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C.
§ 262(l)(3)(C), claim-by-claim infringement contentions for claims 5 and 22 of the ’033 patent. 

1767. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’033 patent, either literally or under the doctrine of equivalents. 
 1768.
On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 5 and 22 of the ’033 patent, either literally or under the doctrine of equivalents. 

1769. Alvotech has knowledge of and is aware of the ’033 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1770. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’033 patent. 
 1771. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’033 patent. 

1772. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 

  
 298 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 299 of 323 PageID #:22568 

 

 COUNT CXIII. 

INFRINGEMENT OF U.S. PATENT NO. 9,708,400 

1773. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1774. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1775. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1776. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1777. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1778. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1779. Based on confidential information disclosed to AbbVie
by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’400 patent is an act of infringement of one or more claims of the ’400 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 299 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 300 of 323 PageID #:22568 

 

 1780. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-5, 7-13, 15-18, and 20-30 of the ’400
patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-5, 7-13, 15-18, and 20-30 of the ’400 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has prevented AbbVie from learning relevant facts that could
further support AbbVie’s allegation of infringement of the ’400 patent. 
 1781. On information and belief, Alvotech is aware, has
knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’400 patent, either literally or under the doctrine of equivalents. 

1782. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 1-5, 7-13, 15-18, and 20-30 of the ’400 patent, either literally
or under the doctrine of equivalents. 
 1783. Alvotech has knowledge of and is aware of the ’400 patent, including due to
AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1784.
AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’400 patent. 

  
 300 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 301 of 323 PageID #:22568 

 

 1785. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B)
preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT CXIV. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,708,400 
 1786. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 1787. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 1788. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1789. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1790. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1791. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1792. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 301 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 302 of 323 PageID #:22568 

 

 1793. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’400
patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’400 patent, literally or under the
doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination
of infringement is necessary and appropriate to resolve this controversy. 
 1794. Alvotech has provided information to AbbVie pursuant to
42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use,
sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or
contribute to the infringement by others of at least claims 1-5, 7-13, 15-18, and 20-30
of the ’400 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 1-5, 7-13,
15-18, and 20-30 of the ’400 patent. For at least one claim, however, Alvotech’s failure to provide sufficient information, as required by the BPCIA, has
prevented AbbVie from learning relevant facts that could further support AbbVie’s allegation of infringement of the ’400 patent. 

1795. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the manufacture of the Alvotech
aBLA Product directly infringes at least one claim of the ’400 patent, either literally or under the doctrine of equivalents. 

  
 302 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 303 of 323 PageID #:22568 

 

 1796. On information and belief, Alvotech will knowingly or with willful blindness induce or
contribute to another’s direct infringement of at least claims 1-5, 7-13, 15-18, and
20-30 of the ’400 patent, either literally or under the doctrine of equivalents. 
 1797.
Alvotech has knowledge of and is aware of the ’400 patent, including due to AbbVie’s disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 

1798. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’400 patent. 
 1799. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or
importation of the Alvotech aBLA Product will infringe the ’400 patent. 
 1800. AbbVie seeks an injunction preventing Alvotech from
the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT CXV. 
 INFRINGEMENT
OF U.S. PATENT NO. 9,957,318 
 1801. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein.

 1802. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1803. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 

  
 303 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 304 of 323 PageID #:22568 

 

 1804. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1805. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1806. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1807. Based on confidential information disclosed to AbbVie
by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’318 patent is an act of infringement of one or more claims of the ’318 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

1808. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture,
indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product
(either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 5-9 and 23-27 of the ’318 patent under at least 35 U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech,
pursuant to 42 U.S.C. § 262(l)(3)(C), claim-by-claim infringement contentions for claims 9,957,318 of the ’318 patent. 

  
 304 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 305 of 323 PageID #:22568 

 

 1809. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’318 patent, either literally or under the doctrine of equivalents. 

1810. Alvotech has knowledge of and is aware of the ’318 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1811. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’318 patent. 
 1812. AbbVie seeks an injunction
pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT CXVI. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 9,957,318 
 1813. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 1814. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 1815. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1816. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 

  
 305 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 306 of 323 PageID #:22568 

 

 1817. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1818. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1819. On information and belief as of May 28, 2021, Alvotech intends to engage in the commercial manufacture, use, sale, offer for
sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1820. Based on confidential
information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the
Alvotech aBLA Product prior to the expiration of the ’318 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more
of the claims of ’318 patent, literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C.
§ 262(l)(9)(A). A judicial determination of infringement is necessary and appropriate to resolve this controversy. 
 1821.
Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential
information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will
infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 5-9 and 23-27 of the ’318 patent under at least 35
U.S.C. § 271(g), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech, pursuant to 42 U.S.C. § 262(l)(3)(C),
claim-by-claim infringement contentions for claims 5-9 and 23-27 of the ’318 patent.

  
 306 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 307 of 323 PageID #:22568 

 

 1822. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’318 patent, either literally or under the doctrine of equivalents. 

1823. Alvotech has knowledge of and is aware of the ’318 patent, including due to AbbVie’s disclosure of patents pursuant to 42
U.S.C. § 262(l)(3)(A) and to the filing of this Complaint. 
 1824. AbbVie will suffer irreparable injury for which damages
are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’318 patent. 
 1825. AbbVie seeks a declaratory
judgment that future commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’318 patent. 

1826. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into
the United States of the Alvotech aBLA Product. 
 COUNT CXVII. 

INFRINGEMENT OF U.S. PATENT NO. 11,083,792 

1827. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1828. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 307 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 308 of 323 PageID #:22568 

 

 1829. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1830. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1831. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1832. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1833. Based on
confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or
importation of the Alvotech aBLA Product prior to the expiration of the ’792 patent is an act of infringement of one or more claims of the ’792 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of
equivalents. 
 1834. Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the
manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA
Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 1-4, 7, and 13-17 of the ’792 patent under at least 35 U.S.C. § 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to
Alvotech claim-by-claim infringement contentions for claims 1-4, 7, and 13-17 of the
’792 patent. 

  
 308 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 309 of 323 PageID #:22568 

 

 1835. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’792 patent, either literally or under the doctrine of equivalents. 

1836. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 1-4, 7, and 13-17 of the ’792 patent, either literally or under the doctrine of equivalents. 

1837. Alvotech has knowledge of and is aware of the ’792 patent, including due to AbbVie’s August 10, 2021 letter providing a
supplemental patent list pursuant to 42 U.S.C. § 262(l)(7); AbbVie’s service of Plaintiffs’ Initial Infringement Contentions on September 10, 2021; and the filing of this Complaint. 

1838. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’792 patent. 
 1839. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech
from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT CXVIII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 11,083,792 

1840. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1841. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1842. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

  
 309 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 310 of 323 PageID #:22568 

 

 1843. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA
Product for review on or before November 5, 2020. 
 1844. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA.

 1845. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C.
§ 262(l)(8)(A). 
 1846. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so and the Court’s decision on the ten patents that will be subject to a first trial in August 2022. The Court plans to issue its
decision by the end of October 2022. Dkt. 53 at ¶ 13. 
 1847. Based on confidential information disclosed to AbbVie by Alvotech
pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration
of the ’792 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’792 patent, literally or
under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial
determination of infringement is necessary and appropriate to resolve this controversy. 

  
 310 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 311 of 323 PageID #:22568 

 

 1848. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 1-4, 7, and 13-17 of the ’792 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the
doctrine of equivalents. AbbVie has provided to Alvotech claim-by-claim infringement contentions for claims 1-4, 7, and 13-17 of the ’792 patent. 
 1849. On information and belief, Alvotech is aware, has knowledge,
and/or is willfully blind to the fact that the manufacture of the Alvotech aBLA Product directly infringes at least one claim of the ’792 patent, either literally or under the doctrine of equivalents. 

1850. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 1-4, 7, and 13-17 of the ’792 patent, either literally or under the doctrine of equivalents. 

1851. Alvotech has knowledge of and is aware of the ’792 patent, including due to AbbVie’s August 10, 2021 letter providing a
supplemental patent list pursuant to 42 U.S.C. § 262(l)(7); AbbVie’s service of Plaintiffs’ Initial Infringement Contentions on September 10, 2021; and the filing of this Complaint. 

1852. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’792 patent. 
 1853. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or
importation of the Alvotech aBLA Product will infringe the ’792 patent. 

  
 311 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 312 of 323 PageID #:22568 

 

 1854. AbbVie seeks an injunction preventing Alvotech from the commercial manufacture, use,
sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT CXIX. 

INFRINGEMENT OF U.S. PATENT NO. 11,167,030 

1855. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1856. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1857. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1858. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1859. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1860. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1861. Based on confidential information disclosed to AbbVie
by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’030 patent is an act of infringement of one or more claims of the ’030 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 

  
 312 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 313 of 323 PageID #:22568 

 

 1862. Alvotech has provided information to AbbVie pursuant to 42 U.S.C.
§ 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use, sale, offer
for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or contribute to the
infringement by others of at least claims 15-18 of the ’030 patent under at least 35 U.S.C. § 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie has provided to Alvotech claim-by-claim infringement contentions for claims 15-18 of the ’030 patent. 

1863. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the formulation of the Alvotech
aBLA Product directly infringes at least one claim of the ’030 patent, either literally or under the doctrine of equivalents. 
 1864.
On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 15-18 of the ’030 patent, either literally or
under the doctrine of equivalents. 
 1865. Alvotech has knowledge of and is aware of the ’030 patent, including due to AbbVie’s
service of Plaintiffs’ Initial Infringement Contentions on September 10, 2021; AbbVie’s November 9, 2021 letter providing a supplemental patent list pursuant to 42 U.S.C. § 262(l)(7); and the filing of this Complaint.

 1866. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the
claims of the ’030 patent. 

  
 313 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 314 of 323 PageID #:22568 

 

 1867. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B)
preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT CXX. 
 DECLARATORY
JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 11,167,030 
 1868. AbbVie incorporates by reference each of the preceding paragraphs as if
fully set forth herein. 
 1869. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

 1870. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1871. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1872. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1873. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1874. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

  
 314 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 315 of 323 PageID #:22568 

 

 1875. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C.
§ 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’030
patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’030 patent, literally or under the
doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A judicial determination
of infringement is necessary and appropriate to resolve this controversy. 
 1876. Alvotech has provided information to AbbVie pursuant to
42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial manufacture, use,
sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by others, or
contribute to the infringement by others of at least claims 15-18 of the ’030 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. AbbVie
has provided to Alvotech claim-by-claim infringement contentions for claims 15-18 of the ’030 patent. 

1877. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the formulation of the Alvotech
aBLA Product directly infringes at least one claim of the ’030 patent, either literally or under the doctrine of equivalents. 
 1878.
On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement of at least claims 15-18 of the ’030 patent, either literally or
under the doctrine of equivalents. 

  
 315 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 316 of 323 PageID #:22568 

 

 1879. Alvotech has knowledge of and is aware of the ’030 patent, including due to
AbbVie’s service of Plaintiffs’ Initial Infringement Contentions on September 10, 2021; AbbVie’s November 9, 2021 letter providing a supplemental patent list pursuant to 42 U.S.C. § 262(l)(7); and the filing of
this Complaint. 
 1880. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from
infringing the claims of the ’030 patent. 
 1881. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale,
offer for sale, and/or importation of the Alvotech aBLA Product will infringe the ’030 patent. 
 1882. AbbVie seeks an injunction
preventing Alvotech from the commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 

COUNT CXXI. 

INFRINGEMENT OF U.S. PATENT NO. 11,191,834 

1883. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1884. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1885. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 
 1886. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

  
 316 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 317 of 323 PageID #:22568 

 

 1887. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing
pursuant to 42 U.S.C. § 262(l)(8)(A). 
 1888. On information and belief, Alvotech intends to engage in the commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 

1889. Based on confidential information disclosed to AbbVie by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s
submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the expiration of the ’1834 patent is an act of infringement of one or more
claims of the ’1834 patent under 35 U.S.C. § 271(e)(2), either literally or under the doctrine of equivalents. 
 1890.
Alvotech has provided information to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential
information, Alvotech’s commercial manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will
infringe, actively induce infringement by others, or contribute to the infringement by others of at least claims 13 and 14 of the ’1834 patent under at least 35 U.S.C. § 271(a)-(c), either literally or under the doctrine of
equivalents. 
 1891. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind to the fact that the
formulation of the Alvotech aBLA Product directly infringes at least one claim of the ’1834 patent, either literally or under the doctrine of equivalents. 

  
 317 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 318 of 323 PageID #:22568 

 

 1892. On information and belief, Alvotech will knowingly or with willful blindness induce or
contribute to another’s direct infringement of at least claims 13 and 14 of the ’1834 patent, either literally or under the doctrine of equivalents. 

1893. Alvotech has knowledge of and is aware of the ’1834 patent, including due to AbbVie’s December 7, 2021 letter providing a
supplemental patent list pursuant to 42 U.S.C. § 262(l)(7) and the filing of this Complaint. 
 1894. AbbVie will suffer
irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims of the ’1834 patent. 

1895. AbbVie seeks an injunction pursuant to at least 35 U.S.C. § 271(e)(4)(B) preventing Alvotech from the commercial manufacture,
use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT CXXII. 

DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 11,191,834 

1896. AbbVie incorporates by reference each of the preceding paragraphs as if fully set forth herein. 

1897. AbbVie’s claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. 

1898. On information and belief, in late August or early September 2020, Alvotech submitted an aBLA to the FDA seeking approval for the
commercial manufacture, use, offer for sale, sale, and/or importation of the Alvotech aBLA Product, a biosimilar version of adalimumab. The reference product for adalimumab is BLA No. 125057. AbbVie Inc. is the holder of BLA No. 125057.

 1899. Alvotech represents that the FDA accepted Alvotech’s aBLA for the Alvotech aBLA Product for review on or before
November 5, 2020. 

  
 318 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 319 of 323 PageID #:22568 

 

 1900. On November 5, 2020, Alvotech provided AbbVie with a copy of its aBLA. 

1901. On May 11, 2021, Alvotech provided AbbVie a notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A).

 1902. On information and belief, Alvotech intends to engage in the commercial manufacture, use, sale, offer for sale, and/or importation
of the Alvotech aBLA Product promptly upon receiving FDA approval to do so. 
 1903. Based on confidential information disclosed to AbbVie
by Alvotech pursuant to 42 U.S.C. § 262(l)(2), Alvotech’s submission of its aBLA to obtain approval to engage in the commercial manufacture, use, sale, offer to sell, and/or importation of the Alvotech aBLA Product prior to the
expiration of the ’1834 patent and Alvotech’s notice of commercial marketing, create an actual, immediate, and real controversy within the Declaratory Judgment Act that Alvotech will infringe one or more of the claims of ’1834 patent,
literally or under the doctrine of equivalent equivalents. This declaratory judgment action is also authorized by the BPCIA due to Alvotech’s provision of a notice of commercial marketing. See 42 U.S.C. § 262(l)(9)(A). A
judicial determination of infringement is necessary and appropriate to resolve this controversy. 
 1904. Alvotech has provided information
to AbbVie pursuant to 42 U.S.C. § 262(l)(2)(A) relating to the manufacture, indications, dosage, and methods of use and administration for the Alvotech aBLA Product. Based on this confidential information, Alvotech’s commercial
manufacture, use, sale, offer for sale, and/or importation of the Alvotech aBLA Product (either directly or through any affiliates, subsidiaries, and/or agents), once the aBLA is approved by the FDA, will infringe, actively induce infringement by
others, or contribute to the infringement by others of at least claims 13 and 14 of the ’1834 patent under at least 35 U.S.C. §§ 271(a)-(c), either literally or under the doctrine of equivalents. 

  
 319 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 320 of 323 PageID #:22568 

 

 1905. On information and belief, Alvotech is aware, has knowledge, and/or is willfully blind
to the fact that the formulation of the Alvotech aBLA Product directly infringes at least one claim of the ’1834 patent, either literally or under the doctrine of equivalents. 

1906. On information and belief, Alvotech will knowingly or with willful blindness induce or contribute to another’s direct infringement
of at least claims 13 and 14 of the ’1834 patent, either literally or under the doctrine of equivalents. 
 1907. Alvotech has
knowledge of and is aware of the ’1834 patent, including due to AbbVie’s December 7, 2021 letter providing a supplemental patent list pursuant to 42 U.S.C. § 262(l)(7) and the filing of this Complaint. 

1908. AbbVie will suffer irreparable injury for which damages are an inadequate remedy unless Alvotech is enjoined from infringing the claims
of the ’1834 patent. 
 1909. AbbVie seeks a declaratory judgment that future commercial manufacture, use, sale, offer for sale, and/or
importation of the Alvotech aBLA Product will infringe the ’1834 patent. 
 AbbVie seeks an injunction preventing Alvotech from the
commercial manufacture, use, sale, offer for sale within and/or importation into the United States of the Alvotech aBLA Product. 
 COUNT
CXXIII. 
 WILLFUL INFRINGEMENT 

1910. Alvotech is on notice of each of the patents and acts of infringement set forth in Counts
I-CXXII. It has nonetheless expressed its intention to begin commercial marketing without awaiting a judicial decision on infringement or validity. Alvotech’s infringement under each of the above counts
is willful under 35 U.S.C. § 284. 

  
 320 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 321 of 323 PageID #:22568 

 

 PRAYER FOR RELIEF 

WHEREFORE, Plaintiffs respectfully request that this Court enter judgment in their favor against Defendant and grant the following relief:

 a. a judgment that Alvotech has infringed, induced infringement, or contributed to infringement of one or more claims of the AbbVie
Patents under 35 U.S.C. § 271(e)(2)(C); 
 b. a judgment and declaration that Alvotech has or will infringe or has or will induce
or contribute to infringement of one or more claims of the AbbVie Patents by engaging in the manufacture, import, offer for sale, sale, or use within the United States of the Alvotech aBLA Product before the expirations of the AbbVie Patents; 

c. a judgment and declaration that Alvotech’s infringement is willful under 35 U.S.C. § 284; 

d. preliminary and/or permanent equitable relief, including but not limited to a preliminary and permanent injunction that enjoins Alvotech,
its officers, partners, agents, servants, employees, parents, subsidiaries, affiliate corporations, other related business entities, and all other persons acting in concert, participation, or in privity with them and/or their successors or assigns
from infringing the AbbVie Patents, or contributing to or inducing anyone to do the same, by acts including the manufacture, use, offer to sell, sale, or distribution within the United States, or importation into the United States, of any current or
future versions of the Alvotech aBLA Product, the use or manufacturing of which infringes the AbbVie Patents; 
 e. a declaration that this
is an exceptional case and an award to Plaintiffs of their attorneys’ fees, costs, and expenses pursuant to 35 U.S.C. § 271(e)(4) and 35 U.S.C. § 285; 

f. any available damages pursuant to 35 U.S.C. § 284; and 

g. such other relief as this Court may deem just and proper. 

  
 321 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 322 of 323 PageID #:22568 

 

			
	Dated: December 21, 2021	  	 /s/ Sean M. Berkowitz

Sean M. Berkowitz (ARDC No. 6209701)
 Brenda Danek (ARDC
No. 6315056)
 sean.berkowitz@lw.com

brenda.danek@lw.com
 LATHAM & WATKINS LLP

330 North Wabash Avenue, Suite 2800
 Chicago, Illinois 60611

Telephone: (312) 876-7700

Facsimile: (312) 993-9767

Michael A. Morin (ARDC No. 6229902)
 David P. Frazier (pro
hac vice)
 Tara D. Elliott (pro hac vice)
 Ashley M.
Fry (pro hac vice)
 michael.morin@lw.com

david.frazier@lw.com
 tara.elliott@lw.com

ashley.fry@lw.com
 LATHAM & WATKINS LLP

555 Eleventh Street, N.W., Suite 1000
 Washington, D.C.
20004-1304
 Telephone: (202) 637-2200

  
 322 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 323 of 323 PageID #:22568 

 

			
		  	 Facsimile: (202) 637-2201

Arlene Chow (pro hac vice)
 Herman Yue (pro hac
vice)
 arlene.chow@lw.com
 herman.yue@lw.com

LATHAM & WATKINS LLP
 1271 Avenue of the Americas

New York, NY 10020
 Telephone: (212) 906-1200
 Facsimile: (212) 751-4864

Michael Seringhaus (pro hac vice)

michael.seringhaus@lw.com
 LATHAM & WATKINS LLP

140 Scott Drive
 Menlo Park, CA 94025

 
 Telephone: (650) 328-4600

Facsimile: (650) 463-2600

Gabrielle LaHatte (pro hac vice)

gabrielle.lahatte@lw.com
 LATHAM & WATKINS
LLP

  
 323 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 324 of 323 PageID #:22568 

 

			
		  	 505 Montgomery Street
 Suite 2000

San Francisco, CA 94111
 Telephone: (415) 391-0600
 Facsimile: (415) 395-8095

William B. Raich (pro hac vice)
 Charles T. Collins-Chase
(pro hac vice)
 Cecilia Sanabria (pro hac vice)

Kassandra M. Officer (pro hac vice)

william.raich@finnegan.com
 charles.collins-chase@finnegan.com

cecilia.sanabria@finnegan.com
 kassandra.officer@finnegan.com

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP
 901
New York Ave., N.W.
 Washington, D.C. 20001
 Telephone: (202) 408-4000
 Facsimile: (202) 408-4400

Oulu Wang (pro hac vice)
 lulu.wang@finnegan.com

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP

  
 324 

 Case: 1:21-cv-02899 Document #: 130 Filed: 12/21/21 Page 325 of 323 PageID #:22568 

 

			
		  	 2 Seaport Lane
 Boston, MA 02210

Telephone: (617) 646-1600

Facsimile: (617) 646-1666

Counsel for Plaintiffs AbbVie Inc.
 and AbbVie
Biotechnology Ltd

  

  
 325 

 Execution Version 

FRE 408 / Confidential 
  

 Exhibit D 

IN THE UNITED STATES DISTRICT COURT 

FOR THE NORTHERN DISTRICT OF ILLINOIS 
  

			
	  

ABBVIE INC. and ABBVIE
 BIOTECHNOLOGY LTD

 
 Plaintiffs,
  

v.
  

ALVOTECH HF.
  

Defendant.
  
	  	  
 Civil Action No. 1:21-cv-2258
 Civil Action No.
1:21-cv-2899
  

Honorable John Z. Lee
  

Magistrate Judge M. David Weisman

 JOINT STIPULATION OF DISMISSAL 

IT IS HEREBY STIPULATED AND AGREED, by and between the parties, through their undersigned counsel of record, that: 

1. All claims, affirmative defenses, and counterclaims, in these actions are hereby dismissed without prejudice. 

2. Each party will bear its own attorneys’ fees and costs. 

 Execution Version 

FRE 408 / Confidential 
  

 Exhibit E – Appellate Dismissal 

No. 21-3052 
  

 
  

United States Court of Appeals 

for the Seventh Circuit 
  

 
 ABBVIE INC. and
ABBVIE BIOTECHNOLOGY LTD, 

                        
                Plaintiffs-Appellants, 
 v. 

ALVOTECH HF., 

                        
                        Defendant-Appellee. 

 
  

Appeal from the United States District Court 

for the Northern District of Illinois 

Case No. 1:21-cv-01530 

The Honorable Harry D. Leinenweber 
  

 
 JOINT MOTION
TO DISMISS APPEAL 
  
  

 
  
  

 

 Execution Version 

FRE 408 / Confidential 
  

 Pursuant to Rule 42 of the Federal Rules of Appellate Procedures, the parties, by joint
motion and agreement, request that this Court dismiss the above-captioned appeal, with prejudice, and with each party to bear its own costs and fees. 

 Execution Version 

FRE 408 / Confidential 
  

 Exhibit [F] – Teva Undertaking to be Bound 

WHEREAS, on August 20, 2020, Alvotech hf. and Teva Pharmaceuticals International GmbH entered into an agreement under which Teva
Pharmaceuticals International GmbH and its Affiliates, including Teva Pharmaceuticals USA, Inc. (collectively, “Teva”) would be responsible for selling and offering to sell in the United States any adalimumab biosimilar
developed by Alvotech hf.; 
 WHEREAS, Alvotech hf. has entered into a settlement and license agreement dated _______, 2022 with AbbVie Inc.
and its Affiliates (“US SLA”) to obtain a license to AbbVie’s patents related to adalimumab in the United States; 

WHEREAS, under the US SLA, AbbVie granted to Alvotech a license to make, use, import, offer for sale and sell Alvotech’s biosimilar
adalimumab product; and 
 [***] 

NOW, THEREFORE, in consideration of the sublicense, Teva hereby undertakes as follows: 

1. [***] 
 2. [***] 

3. [***] 
 [signature block on next page] 

 Execution Version 

FRE 408 / Confidential 
  

			
	Teva Pharmaceuticals International GmBH	  	Teva Pharmaceuticals USA, Inc.
		
	By:
                                         
                                       	  	By:
                                         
                                       
	Name:
                                         
                                   	  	Name:
                                         
                                   
	Title:
                                         
                                     	  	Title:
                                         
                                     
	Date:	  	Date:
		
	Teva Pharmaceuticals International GmBH	  	Teva Pharmaceuticals USA, Inc.
		
	By:
                                         
                                       	  	By:
                                         
                                       
	Name:
                                         
                                   	  	Name:
                                         
                                   
	Title:
                                         
                                     	  	Title:
                                         
                                     
	Date:	  	Date:

 Execution Version 

FRE 408 / Confidential 
  

 Exhibit G – JOINT MOTION TO DISMISS ITC ACTION 

UNITED STATES INTERNATIONAL TRADE COMMISSION 

WASHINGTON, D.C. 
 Before
the Honorable Monica Bhattacharyya 
 Administrative Law Judge 

 

			
	 In the Matter
of
  
 CERTAIN ADALIMUMAB, PROCESSES FOR MANUFACTURING OR RELATING TO SAME, AND
PRODUCTS CONTAINING SAME
	  	Investigation No. 337-TA-1296

 JOINT MOTION TO TERMINATE 

THE INVESTIGATION BASED ON SETTLEMENT 

Pursuant to 19 U.S.C. § 1337(c) and 19 C.F.R. § 210.21(b), Complainants AbbVie Inc., AbbVie Biotechnology Ltd, and AbbVie Operations
Singapore Pte. Ltd. (collectively, “Complainants”) and Respondents Alvotech hf., Alvotech Germany GmbH (“Alvotech Germany”), Alvotech Swiss AG (“Alvotech Swiss”), Alvotech USA Inc. (“Alvotech USA”)
(collectively, “Alvotech”), Ivers-Lee AG (“Ivers-Lee”), Teva Pharmaceutical Industries Ltd. (“Teva Ltd.”), and Teva Pharmaceuticals USA
Inc. (“Teva USA”) (collectively, “Teva”) (“Respondents”), jointly move to terminate the investigation based on the Settlement Agreement between Complainants and Alvotech attached as Exhibit A (public) and Exhibit B
(confidential).4 
 Counsel for Complainant and Respondents submit that the Settlement
Agreement satisfies the requirements of Rule 210.21(b) and that termination is in the public interest. The parties state that there are no other agreements, written or oral, express or implied, relating to the subject matter of this Investigation.

  
  

	4	 In accordance with Commission Rule 210.21(b) the settlement agreement contains confidential business
information within the meaning of § 201.6(a). 

 Execution Version 

FRE 408 / Confidential 
  

 Accordingly, Complainant and Respondents request that the Administrative Law Judge issue an
initial determination terminating this investigation on the basis of settlement pursuant to 19 C.F.R. § 210.21(b). 
 [[insert
signature blocks]]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]